Clinical trial NCT02873702
Conditions: Erosive Esophagitis
Keywords: Drug therapy
Sponsor: Takeda
Start date: 2016-12-21; Completion date: 2017-11-06
Enrollment: 37 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
The purpose of this study is to determine the efficacy of dexlansoprazole compared to lansoprazole in healing erosive esophagitis (EE) in Chinese participants.

Detailed description:
The drug being tested in this study is called dexlansoprazole. Dexlansoprazole is being tested to treat people who have EE. This study will look at erosive esophageal healing in people who take dexlansoprazole.

The study will enroll approximately 450 participants. Participants will be randomly assigned to one of the two treatment groups with 1:1 ratio-which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need):

* Dexlansoprazole 60 mg
* Lansoprazole 30 mg

After 8 weeks of treatment, participants will be evaluated to assess esophageal healing. If the EE is healed participants will be randomly assigned to one of two different treatment groups with 1:1 ratio:

* Dexlansoprazole 30 mg
* Placebo (dummy inactive pill) - this is a capsule that looks like the study drug but has no active ingredient.

All participants will be asked to take one capsule at the same time each day throughout the study.

This multi-center trial will be conducted in China. The overall time to participate in this study is up to 39 weeks. Participants will make 7 visits to the clinic, and will be contacted by telephone 5 to 10 days after last dose of study drug for a follow-up assessment.

Arms: arm 1: Dexlansoprazole 60 milligram (mg), delayed-release capsules, orally, once daily for up to 8 weeks in the Healing Period. arm 2: Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks in the Healing Period. arm 3: Participants who will be healed at Week 8 will be randomized to receive dexlansoprazole 30 mg, delayed-release capsules, orally, once daily for up to 6 months in the Maintenance period. arm 4: Participants who will be healed at Week 8 will be randomized to receive dexlansoprazole placebo-matching capsules, orally, once daily for up to 6 months in the Maintenance period.
Interventions: intervention 1: Dexlansoprazole intervention 2: Lansoprazole intervention 3: Placebo
Intervention descriptions: intervention 1: Dexlansoprazole delayed-release capsules. intervention 2: Lansoprazole capsules. intervention 3: Dexlansoprazole placebo-matching capsules.

Protocol documents:
Prot_000.pdf: 
This may include, but is not limited to, redaction of the following: 


•
Title: A Phase 3 Study to Evaluate the Efficacy and Safety of Dexlansoprazole (60 mg QD) and an 
Active Comparator, Lansoprazole (30 mg QD) on Healing of Erosive Esophagitis, and 
Maintenance of Healing in Subjects With Healed Erosive Esophagitis With Dexlansoprazole (30 
mg QD) and Placebo
NCT Number: NCT02873702
Protocol Approve Date: 20 February 2017
Certain information within this protocol has been redacted (ie, specific content is masked 
irreversibly from view with a black/blue bar) to protect either personally identifiable 
information or company confidential information. 
Named persons or organizations associated with the study.
Proprietary information, such as scales or coding systems, which are considered confidential 
information under prior agreements with license holder.
Other information as needed to protect confidentiality of Takeda or partners, personal
information, or to otherwise protect the integrity of the clinical study.


TITLE PAGE
PROTOCOL AMENDMENT
A Phase 3 Study to Evaluate the Efficacy and Safety of Dexlansoprazole (60 mg QD) and an 
Active Comparator, Lansoprazole (30 mg QD) on Healing of Erosive Esophagitis, and 
Maintenance of Healing in Subjects With Healed Erosive Esophagitis With Dexlansoprazole 
(30 mg QD) and Placebo
Sponsor:
Takeda Development Center Asia, Pte. Ltd.
21 Biopolis Road, Nucleos North Tower, Level 4, Singapore 138567
Study Number:
TAK-390MR_301
IND Number:
Not Applicable
EudraCT Number:
Not Applicable 
Compound:
TAK-390MR Dexlansoprazole Capsules
Date:
20 February 2017
Amendment Number:
03
Amendment History: 
Date
Amendment Number
Amendment Type
Region
05 August 2011
Initial Protocol
Not applicable
China
16 December 2015
01
Substantial
China
09 June 2016
02
Nonsubstantial
China
20 February 2017
03
Nonsubstantial
China
CONFIDENTIAL PROPERTY OF TAKEDA
This document is a confidential communication of Takeda. Acceptance of this document constitutes the agreement by 
the recipient that no information contained herein will be published or disclosed without written authorization from 
Takeda except to the extent necessary to obtain informed consent from those persons to whom the drug may be 
administered. Furthermore, the information is only meant for review and compliance by the recipient, his or her staff, 
and applicable institutional review committee and regulatory agencies to enable conduct of the study.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 2 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
1.0
ADMINISTRATIVE INFORMATION
1.1
Contacts
A separate contact information list will be provided to each site.
TDC Asia sponsored Asia Pacific investigators will be provided with emergency medical contact 
information cards to be carried by each subject.
General advice on protocol procedures should be obtained through the monitor assigned to the 
study site. Information on service providers is given in Section 3.1 and relevant guidelines 
provided to the site.
Issue
Asia Pacific Contact
Serious adverse event, pregnancy, and special interest 
adverse event reporting
Medical Monitor
(medical advice on protocol, compound, and medical 
management of subjects)
Responsible Medical Officer 
(carries overall responsibility for the conduct of the study)
PPD


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 3 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
1.2
Approval
REPRESENTATIVES OF TAKEDA
This study will be conducted with the highest respect for the individual participants in accordance 
with the requirements of this clinical study protocol and also in accordance with the following:
!
The ethical principles that have their origin in the Declaration of Helsinki.
!
International Conference on Harmonisation E6 Good Clinical Practice: Consolidated 
Guideline.
!
All applicable laws and regulations, including, without limitation, data privacy laws, clinical 
trial disclosure laws, and regulations.
SIGNATURES
The signature of the responsible Takeda medical officer (and other signatories, as applicable) can 
be found on the signature page.
Electronic Signatures are provided on the last page of this document.
Date
Date
Date
PPD
PPD
PPD


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 4 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
INVESTIGATOR AGREEMENT 
I confirm that I have read and that I understand this protocol, the Investigator’s Brochure, and any 
other product information provided by the sponsor. I agree to conduct this study in accordance 
with the requirements of this protocol and also protect the rights, safety, privacy, and well-being of 
study subjects in accordance with the following:

The ethical principles that have their origin in the Declaration of Helsinki.

International Conference on Harmonisation, E6 Good Clinical Practice: Consolidated 
Guideline.

All applicable laws and regulations, including, without limitation, data privacy laws and 
regulations.

Regulatory requirements for reporting serious adverse events defined in Section 10.2 of this 
protocol.

Terms outlined in the Clinical Study Site Agreement.

Responsibilities of the Investigator (Appendix B).
I further authorize that my personal information may be processed and transferred in accordance 
with the uses contemplated in Appendix D of this protocol.
Signature of Investigator
Date
Investigator Name (print or type)
Investigator’s Title
Location of Facility (City, State/Province)
Location of Facility (Country)


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 5 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
1.3
Protocol Amendment 03 Summary of Main Changes
This section describes the changes in reference to the protocol incorporating Amendment No. 03.
The primary reason for this amendment is to clarify acceptable windows for some screening 
procedures. Minor grammatical, editorial, and formatting changes are included for clarification 
purposes only.
For specific descriptions of the changes listed below and where these changes are located, see
Appendix I.
Changes in Amendment 3
1. Update contract research organization (CRO) contact information.
2. Change the appropriate contact for confirming available brands of rescue medication.
3. Gastrin levels will be blinded to both investigators and medical monitors during the study
period.
4. Clarify acceptable windows for screening labs and endoscopy.
5. Update one of the definitions of an SAE.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 6 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
TABLE OF CONTENTS
1.0
ADMINISTRATIVE INFORMATION ...........................................................................2
1.1
Contacts.....................................................................................................................2
1.2
Approval....................................................................................................................3
1.3
Protocol Amendment 03 Summary of Main Changes.................................................5
2.0
STUDY SUMMARY ....................................................................................................11
3.0
STUDY REFERENCE INFORMATION ......................................................................14
3.1
Study-Related Responsibilities.................................................................................14
3.2
Coordinating Investigator.........................................................................................14
3.3
List of Abbreviations ...............................................................................................15
3.4
Corporate Identification...........................................................................................17
4.0
INTRODUCTION.........................................................................................................18
4.1
Background .............................................................................................................18
4.2
Rationale for the Proposed Study.............................................................................21
5.0
STUDY OBJECTIVES AND ENDPOINTS..................................................................22
5.1
Objectives................................................................................................................22
5.1.1
Primary Objective ..............................................................................................22
5.1.2
Secondary Objective ..........................................................................................22
5.1.3
Additional Objective..........................................................................................22
5.2
Endpoints.................................................................................................................22
5.2.1
Primary Endpoint...............................................................................................22
5.2.2
Secondary Endpoint ...........................................................................................22
5.2.3
Additional Endpoints .........................................................................................22
6.0
STUDY DESIGN AND DESCRIPTION.......................................................................24
6.1
Study Design ...........................................................................................................24
6.2
Justification for Study Design, Dose, and Endpoints ................................................26
6.3
Premature Termination or Suspension of Study or Investigational Site.....................27
6.3.1
Criteria for Premature Termination or Suspension of the Study..........................27
6.3.2
Criteria for Premature Termination or Suspension of Investigational Sites .........27
6.3.3
Procedures for Premature Termination or Suspension of the Study or the 
Participation of Investigational Site(s)................................................................27
7.0
SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS..............28
7.1
Inclusion Criteria .....................................................................................................28
7.2
Exclusion Criteria ....................................................................................................28
7.3
Excluded Medications and Treatments.....................................................................30


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 7 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
7.4
Diet, Fluid, Activity Control ....................................................................................31
7.5
Criteria for Discontinuation or Withdrawal of a Subject...........................................32
7.6
Procedures for Discontinuation or Withdrawal of a Subject......................................34
8.0
CLINICAL TRIAL MATERIAL MANAGEMENT ......................................................35
8.1
Study Medication and Materials...............................................................................35
8.1.1
Dosage Form, Manufacturing, Packaging, and Labeling.....................................35
8.1.2
Storage...............................................................................................................37
8.1.3
Dose and Regimen .............................................................................................37
8.1.4
Overdose............................................................................................................38
8.2
Investigational Drug Assignment and Dispensing Procedures ..................................39
8.3
Randomization Code Creation and Storage..............................................................39
8.4
Investigational Drug Blind Maintenance ..................................................................39
8.5
Unblinding Procedure..............................................................................................39
8.6
Accountability and Destruction of Sponsor-Supplied Drugs.....................................40
9.0
STUDY PLAN ..............................................................................................................42
9.1
Study Procedures.....................................................................................................42
9.1.1
Informed Consent Procedure..............................................................................42
9.1.2
Demographics, Medical History, and Medication History Procedure..................42
9.1.3
Physical Examination Procedure ........................................................................42
9.1.4
Weight, Height...................................................................................................43
9.1.5
Vital Sign Procedure..........................................................................................43
9.1.6
GERD Symptoms Investigator Assessment ........................................................43
9.1.7
Daily Diary........................................................................................................44
9.1.8
Documentation of Concomitant Medications......................................................44
9.1.9
Documentation of Concurrent Medical Conditions.............................................44
9.1.10 Procedures for Clinical Laboratory Samples.......................................................44
9.1.11 Contraception and Pregnancy Avoidance Procedure...........................................46
9.1.12 Pregnancy ..........................................................................................................47
9.1.13 ECG Procedure..................................................................................................48
9.1.14 Documentation of Screen Failure .......................................................................48
9.1.15 Documentation of Study Randomization ............................................................49
9.1.16 Endoscopy .........................................................................................................49
9.2
Monitoring Subject Treatment Compliance..............................................................50
9.3
Schedule of Observations and Procedures................................................................50
9.3.1
Screening...........................................................................................................51


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 8 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
9.3.2
Study Randomization.........................................................................................52
9.3.3
Healing Period ...................................................................................................52
9.3.4
Maintenance Period............................................................................................54
9.3.5
Final Visit or Early Termination.........................................................................55
9.3.6
Unscheduled Visit..............................................................................................56
9.3.7
Follow-up ..........................................................................................................57
9.3.8
Post Study Care..................................................................................................57
10.0
PRETREATMENT EVENTS AND ADVERSE EVENTS ............................................58
10.1
Definitions...............................................................................................................58
10.1.1 Pretreatment Events ...........................................................................................58
10.1.2 AEs....................................................................................................................58
10.1.3 Additional Points to Consider for PTEs and AEs................................................58
10.1.4 SAEs..................................................................................................................60
10.1.5 Severity of PTEs and AEs..................................................................................61
10.1.6 Causality of AEs ................................................................................................61
10.1.7 Relationship to Study Procedures.......................................................................61
10.1.8 Start Date...........................................................................................................62
10.1.9 Stop Date...........................................................................................................62
10.1.10
Frequency.....................................................................................................62
10.1.11
Action Concerning Study Medication ...........................................................62
10.1.12
Outcome .......................................................................................................62
10.2
Procedures...............................................................................................................63
10.2.1 Collection and Reporting of AEs........................................................................63
10.2.2 Collection and Reporting of SAEs......................................................................64
10.2.3 Reporting of Abnormal Liver Function Tests .....................................................65
10.3
Follow-up of SAEs ..................................................................................................65
10.3.1 Safety Reporting to Investigators, IRBs or IECs, and Regulatory Authorities.....65
11.0
STUDY-SPECIFIC COMMITTEES .............................................................................66
12.0
DATA HANDLING AND RECORDKEEPING............................................................67
12.1
eCRF .......................................................................................................................67
12.2
Record Retention .....................................................................................................67
13.0
STATISTICAL METHODS..........................................................................................69
13.1
Statistical and Analytical Plans ................................................................................69
13.1.1 Analysis Sets......................................................................................................69
13.1.2 Analysis of Demographics and Other Baseline Characteristics ...........................69


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 9 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
13.1.3 Efficacy Analysis...............................................................................................69
13.1.4 Safety Analysis ..................................................................................................70
13.2
Determination of Sample Size..................................................................................70
14.0
QUALITY CONTROL AND QUALITY ASSURANCE...............................................72
14.1
Study-Site Monitoring Visits ...................................................................................72
14.2
Protocol Deviations..................................................................................................72
14.3
Quality Assurance Audits and Regulatory Agency Inspections ................................72
15.0
ETHICAL ASPECTS OF THE STUDY........................................................................73
15.1
IRB and/or IEC Approval ........................................................................................73
15.2
Subject Information, Informed Consent, and Subject Authorization .........................74
15.3
Subject Confidentiality ............................................................................................75
15.4
Publication, Disclosure, and Clinical Trial Registration Policy.................................75
15.4.1 Publication and Disclosure.................................................................................75
15.4.2 Clinical Trial Registration..................................................................................76
15.4.3 Clinical Trial Results Disclosure ........................................................................76
15.5
Insurance and Compensation for Injury....................................................................76
16.0
REFERENCES..............................................................................................................77
LIST OF IN-TEXT TABLES
Table 7.a
Excluded Medications........................................................................................31
Table 8.a
Study Drugs.......................................................................................................35
Table 8.b
Rescue Medications ...........................................................................................36
Table 8.c
Study Medication Dispensed at Each Visit .........................................................38
Table 8.d
Study Medication Supplies.................................................................................38
Table 9.a
Clinical Laboratory Tests...................................................................................45
Table 10.a
Takeda Medically Significant AE List................................................................61
LIST OF IN-TEXT FIGURES
Figure 6.a
Schematic of Study Design ................................................................................26
LIST OF APPENDICES
Appendix A
Schedule of Study Procedures............................................................................79
Appendix B
Responsibilities of the Investigator.....................................................................82


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 10 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
Appendix C
Elements of the Subject Informed Consent.........................................................84
Appendix D
Investigator Consent to Use of Personal Information..........................................87
Appendix E
LA Classification of Esophagitis Grading System ..............................................88
Appendix F
GERD Symptoms Investigator Assessments.......................................................89
Appendix G
Definition of Heartburn Severity (Daytime/Nighttime).......................................90
Appendix H
Diary..................................................................................................................91
Appendix I
Detailed Description of Amendments to Text.....................................................92


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 11 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
2.0
STUDY SUMMARY
Name of Sponsor(s):
Takeda Development Center Asia, Pte. Ltd.
Compound: 
Dexlansoprazole
Title of Protocol: A Phase 3 Study to Evaluate the Efficacy 
and Safety of Dexlansoprazole (60 mg QD) and an Active 
Comparator, Lansoprazole (30 mg QD) on Healing of 
Erosive Esophagitis, and Maintenance of Healing in 
Subjects With Healed Erosive Esophagitis With 
Dexlansoprazole (30 mg QD) and Placebo
IND No.: Not applicable
EudraCT No.:
Not applicable
Study Number: TAK-390MR_301
Phase: 3b
Study Design:
This is a phase 3, randomized, double-blind, multicenter, active-controlled, 2-arm study with an initial 8-week Healing 
Period, followed by a randomized, double-blind, placebo-controlled 6-month Maintenance Period. The study is 
designed to evaluate healing of erosive esophagitis (EE), maintenance of healed EE and the effect of therapy on 
relieving gastroesophageal reflux disease (GERD) related symptoms
Primary Objectives:
The primary objective is to determine the efficacy of dexlansoprazole capsules (60 mg once daily [QD]) compared 
with lansoprazole capsules (30 mg QD) in healing EE over 8 weeks of treatment in Chinese subjects with 
endoscopically-proven EE.
Secondary Objectives:
The secondary objective is to confirm the efficacy and safety of dexlansoprazole capsules (30 mg QD) compared with
placebo in the maintenance of healing of EE over 6 months of treatment in Chinese subjects with healed EE.
Subject Population: Subjects 18 years or older, inclusive, with EE.
Number of Subjects:
Estimated total: approximately 450
EE Healing (8 Weeks):

Approximately 225 subjects/ dexlansoprazole 60 mg capsules.

Approximately 225 subjects/ lansoprazole 30 mg capsules.
Maintenance (6 Months):

Approximately 150 subjects/dexlansoprazole 30 mg capsules.

Approximately 150 subjects/placebo.
Number of Sites:
Estimated total: 25 sites in China
Dose Level(s):
Healing Period:
Dexlansoprazole 60 mg capsules QD
Lansoprazole 30 mg capsules QD
Maintenance Period:
Dexlansoprazole 30 mg capsules QD
Placebo QD
Route of Administration:
Oral
Duration of Treatment:
32 Weeks
Period of Evaluation:
39 Weeks


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 12 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
Main Criteria for Inclusion:
The subject is capable of understanding and complying with protocol requirements. The subject or, when applicable, 
the subject’s legally acceptable representative signs and dates a written, informed consent form (ICF) prior to the 
initiation of any study procedures. The subject is a man or woman and aged at least 18 years. Must have 
endoscopically-confirmed EE as defined by the Los Angeles (LA) Classification Grading System (A-D). All women 
of childbearing potential, or men subjects with women partners who are sexually active, agree to use adequate 
contraception from signing of ICF throughout the duration of the study and for 30 days after the last dose of study 
medication.
Main Criteria for Exclusion:
The subject has a history or clinical manifestations of serious neurologic, cardiovascular, pulmonary, hepatic, renal, 
metabolic, gastrointestinal, urological, endocrine, hematologic, dermatologic, immunologic, psychiatric disorders, or 
other abnormality which may impact the ability of the subjects to participate or potentially confound the study results. 
The subject is required to take excluded medications, or it is anticipated that the subject will require treatment with at 
least 1 of the disallowed concomitant medications during the study evaluation period, as specified in the excluded 
medication section (Section 7.3).
Within 30 days prior to the Screening Visit, the subject has received any investigational drug or participate another 
clinical study (other than study TAK-390MR_302) or has a hypersensitivity to any proton pump inhibitor (PPI) 
(including, but not limited to, lansoprazole, omeprazole, rabeprazole, pantoprazole, esomeprazole or ilaprazole), any 
component of dexlansoprazole, or antacid (eg, magnesium trisilicate or similar antacid). The subject has a history of 
malignancy or was treated for malignancy within 5 years before the start of the Screening Visit (the subject may be 
included in the study if he/she has cured cutaneous basal cell carcinoma). The subject has a known history or any 
suspicious Barrett’s esophagus with dysplastic changes seen during screening endoscopy. The subject developed acute 
upper gastrointestinal bleeding, gastric ulcer (a mucosal defect with white coating) or duodenal ulcer (a mucosal 
defect with white coating) within 30 days before the start of the Screening Visit (with the possible inclusion of those 
with gastric or duodenal erosion). 
The subject requires chronic use (>12 doses per month) of nonsteroidal anti-inflammatory drugs (NSAIDs) including 
cyclooxygenase-2 (COX-2) NSAIDs within 30 days prior to the Screening Period and throughout the study. The 
subject has comorbidities that could affect the esophagus (eosinophilic esophagitis, esophageal varices, scleroderma, 
viral or fungal infection, esophageal strictures); a history of radiotherapy or cryotherapy of the esophagus; and a 
history of corrosive or physiochemical injury (with the possible inclusion in the study of those with Schatzki’s ring).
The subject has a history of surgical procedures that may affect the esophagus (eg, fundoplication and mechanical 
dilatation for esophageal strictures) or a history of gastric or duodenal surgery other than endoscopic removal of 
benign polyps. The subject has any abnormal screening laboratory value that suggests a clinically significant 
underlying disease or condition that may prevent the subject from entering the study, based on the medical judgment 
of the investigator; or the subject has: creatinine >1.5 mg/dL or alanine aminotransferase (ALT) and/or aspartate 
aminotransferase (AST) >2.5 times the upper limit of normal (×ULN) or total bilirubin >2.0 mg/dL. 
The subject is known to have acquired immunodeficiency syndrome (AIDS) or hepatitis, including hepatitis virus 
carriers: hepatitis B surface antigen (HBsAg) positive or hepatitis C virus (HCV)-antibody positive. The subject has 
current Zollinger-Ellison syndrome or a history of gastric acid hypersecretion. The subject is scheduled for surgery 
that requires hospitalization or requires surgical treatment during his/her participation in the study. The subject has 
donated or lost >300 mL blood volume, undergone plasmapheresis, or has had a transfusion of any blood product 
within 90 days prior to the first dose of study drug. The subject has a history of alcohol or drug abuse (defined as any 
illicit drug use), or drug addiction in the 12 months prior to Screening. If the subject is a pregnant or lactating woman; 
is intending to become pregnant before, during, or within 1 month after participating in this study; is intending to 
donate ova during this time period; or is a man who is intending to donate sperm. Any subject who, in the opinion of 
the investigator, is unable to comply with the requirements of the study or is unsuitable for any reason. The subject 
with positive serology result of Helicobacter pylori (H. pylori) that need eradication therapy during the study 
participation period as anticipated by the investigator. The subject is an immediate family member, study site 
employee, is in a dependent relationship with a study site employee who is involved in conduct of this study (eg, 
spouse, parent, child, sibling), or may consent under duress.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 13 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
Main Criteria for Evaluation and Analyses:
Primary endpoint: The percentage of subjects who have complete healing of EE over 8 weeks as assessed by 
endoscopy. 
Secondary endpoint: The percentage of subjects who maintain complete healing of EE over 6 months as assessed by 
endoscopy.
Additional endpoints: 

The percentage of days with neither daytime nor nighttime heartburn over the 8 weeks of the Healing Period as 
assessed by the daily paper diary.

The percentage of days with neither daytime nor nighttime heartburn over the 6 months of the Maintenance 
Period as assessed by the daily diary among the subjects who were healed at Week 8.

The percentage of days without rescue medication use over the 8 weeks of the Healing Period as assessed by the 
daily diary.

The percentage of days without rescue medication use over the 6 months of the Maintenance Period as assessed 
by the daily diary among the subjects who were healed at Week 8.

The severity of GERD symptoms at Weeks 4 and 8 as assessed by the investigator during the Healing Period.

The severity of GERD symptoms at Months 1, 3, and 6 as assessed by the investigator during the Maintenance 
Period. 
Safety will be assessed by summarizing the incidence of adverse events (AEs), clinical laboratory values, gastrin 
levels and vital signs.
Statistical Considerations:
Efficacy Assessments
The primary efficacy variable will be the percentage of subjects who have complete healing of EE over 8 weeks as 
assessed by endoscopy. The treatment difference of healing rate between dexlansoprazole and lansoprazole will be 
calculated and the lower bound of 95% confidence interval will be compared with -10%. Noninferiority to 
lansoprazole will be declared if the lower bound is greater than -10%.
The secondary efficacy variable will be the percentage of subjects who maintained complete healing of EE over 
6 months as assessed by endoscopy. A comparison between dexlansoprazole and placebo will be made using 
Cochran-Mantel-Haenszel (CMH) test using stratification factor of baseline grade. 
Safety Assessments
Safety will be assessed by summarizing the incidence of AEs, clinical laboratory values, gastrin levels, physical 
exams, electrocardiograms (ECG) and vital signs.
Sample Size Justification:
A total of 450 subjects with EE documented during Screening are planned to be enrolled into this study. 
Approximately 300 subjects are expected to enter the Maintenance Period. 
Assuming a 10% dropout rate during the Healing Period and an 85% healing rate at Week 8 for both lansoprazole and 
dexlansoprazole, 225 subjects per arm will provide at least 80% power at the 1-sided 0.025 level of significance to 
meet the noninferiority criteria between lansoprazole and dexlansoprazole. Noninferiority to lansoprazole will be 
declared if the lower bound of the confidence interval for the difference in healing rates is greater than -10%.
Assuming a 33% dropout rate during the Maintenance Period and that maintenance rates are 14% and 66% for placebo 
and dexlansoprazole 30 mg, respectively, 150 subjects per arm will have at least 99% power at the 2-sided 0.05 level 
of significance to detect a difference between the treatment groups.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 14 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
3.0
STUDY REFERENCE INFORMATION
3.1
Study-Related Responsibilities 
The sponsor will perform all study-related activities with the exception of those identified in the 
Study-Related Responsibilities template. The vendors identified in the template for specific 
study-related activities will perform these activities in full or in partnership with the sponsor.
3.2
Coordinating Investigator
TDC Asia will select a signatory coordinating investigator (CI) from the investigators who 
participate in the study and enroll at least 1 subject. Selection criteria for this investigator will 
include significant knowledge of the study protocol, the study medication, their expertise in the 
therapeutic area and the conduct of clinical research as well as study participation. The signatory 
CI will be required to review and sign the clinical study report and, by doing so, agrees that it 
accurately describes the results of the study.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 15 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
3.3
List of Abbreviations
AE
adverse event
AIDS
acquired immunodeficiency syndrome
ALP
alkaline phosphatase
ALT
alanine aminotransferase 
AST
aspartate aminotransferase 
AUC
area under the plasma concentration-time curve
BID
twice daily
BMI
body mass index
BUN
blood urea nitrogen
CI
coordinating investigator
Cmax
maximum observed plasma concentration
CMH
Cochran-Mantel-Haenszel
CNS
central nervous system
COX-2
cyclooxygenase-2
CRO
contract research organization 
CYP
cytochrome P450
ECG
electrocardiogram
ECL
enterochromaffin-like
eCRF
electronic case report form
EE
erosive esophagitis
FAS
full analysis set
FAS - H
full analysis set for the Healing Period 
FAS - M
full analysis set for the Maintenance Period
FDA
Food and Drug Administration
FSH
follicle-stimulating hormone
GCP
Good Clinical Practice
GERD
gastroesophageal reflux disease
GI
gastrointestinal
GGT
γ-glutamyl transferase
(H+, K+)-ATPase
hydrogen, potassium adenosine triphosphatase
H2RA
histamine2-receptor antagonist
HBsAg
hepatitis B surface antigen
hCG
human chorionic gonadotropin
HCV
hepatitis C virus
H. pylori
Helicobacter pylori
HRQOL
health-related quality of life
ICF
informed consent form
ICH
International Conference on Harmonisation 
ID
identification


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 16 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
IEC
independent ethics committee
INR
international normalized ratio
IRB
institutional review board
IUD
intrauterine device
IWRS
interactive web response system
LA
Los Angeles
LDH
lactate dehydrogenase
MedDRA
Medical Dictionary for Regulatory Activities
MHRA
Medicines and Healthcare products Regulatory Agency
MR
modified release 
NSAID
nonsteroidal anti-inflammatory drug
OE
overencapsulated
PK
pharmacokinetic
PMDA
Pharmaceuticals and Medical Devices Agency of Japan
PPI
proton pump inhibitor
PTE
pretreatment event
QD
once daily
QOL
quality of life
SAE
serious adverse event
SAP
statistical analysis plan
SUSAR
suspected unexpected serious adverse reaction
TCM
traditional Chinese medicines
TEAE
treatment-emergent adverse event
tmax
time to reach Cmax
Total CO2
bicarbonate
TRAE
treatment-related adverse event
ULN
upper limit of normal
WHODRUG
World Health Organization Drug Dictionary


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 17 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
3.4
Corporate Identification 
Takeda
TDC Japan, TDC Asia, TDC Europe and/or TDC Americas, as applicable
TCH
Takeda (China) Holdings Co., LTD
TDC Japan
Takeda Development Center Japan
TDC Asia
Takeda Development Center Asia, Pte Ltd
TDC Europe
Takeda Development Centre Europe Ltd.
TDC Americas
Takeda Development Center Americas, Inc.
TPC
Takeda Pharmaceutical Company Limited


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 18 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
4.0
INTRODUCTION
4.1
Background
Gastroesophageal reflux disease (GERD) is a common recurring medical problem in the adult 
population with a prevalence between 10% to 20% in the Western world and less than 5% in Asia 
[1]. Prevalence of GERD-related symptoms ranges from at least one a month in approximately 
40%, once a week in 20%, to daily in 14% of patients [1,2]. A number of risk factors, such as 
advancing age, obesity, smoking, and alcohol and caffeine consumption have all been associated 
with the development of GERD [1]. Gastroesophageal reflux disease affects men and women in 
nearly equal proportions; however, males develop erosive esophagitis (EE) and Barrett’s 
esophagus more often than females [1], and females develop nonerosive GERD more often than 
males [3]. GERD results in substantial morbidity due to the occurrence of serious complications 
[4,5] and its adverse impact on quality of life (QOL) [6].
Gastroesophageal reflux disease comprises a spectrum of acid-related disorders, including 
nonerosive GERD and EE. Erosive esophagitis is defined as the presence of superficial esophageal 
erosions in patients with or without typical GERD symptoms. EE is diagnosed during endoscopy 
in up to 50% of patients with GERD symptoms [7]. The severity of these symptoms is associated 
with the extent and duration of gastric acid exposure in the esophagus [8,9]. Patients who do not 
receive treatment, or in whom acid reflux is not effectively controlled, are at risk of developing 
significant complications, such as bleeding, strictures, and the premalignant condition of Barrett’s 
esophagus [4,5].
Therapy for GERD is largely focused on the prevention of reflux of gastric acid into the 
esophagus, either by pharmacological or surgical means, with surgery usually reserved for 
intractable cases. Pharmacological management of GERD includes treatment with antacids, 
histamine2-receptor antagonists (H2RA), prokinetic agents, and proton pump inhibitors (PPIs). 
PPIs, which are labeled for once daily (QD) dosing, are the most effective medications for 
relieving GERD symptoms, healing the injured mucosa, maintaining a healed mucosa, and 
preventing the development of complications [10]. 
However, significant challenges remain in the treatment of patients with endoscopically negative 
GERD, moderate to severe esophageal erosions (Los Angeles [LA] Classification Grades C 
and D) [11] or ulcers, and other GERD-related conditions. This is reflected by the high number of 
prescriptions written for twice daily (BID) dosing of currently available PPIs [12]. BID dosing 
with PPIs in itself represents a current challenge in treatment, because a dosing frequency for a PPI 
greater than QD has been shown to increase the probability of discontinuation of treatment and to 
reduce the rate of adherence to therapy [13]. In addition, concomitant antacid use has been 
reported by 37% of patients receiving PPIs [14]. This concomitant antacid use among some PPI 
users suggests that currently available PPIs may not achieve sufficient acid control when used as 
monotherapy for symptom relief. In addition, 79% of individuals with weekly heartburn also 
report nighttime heartburn. Approximately 60% of individuals with nighttime symptoms 
experience interference with sleep, which may affect daytime activities and quality-of-life [15]. 


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 19 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
The validated LA Classification System is used to grade the severity of EE based on the extent of 
visible mucosal breaks seen in the esophagus [11]. Patients with more severe disease (Grades C 
and D) constitute a more difficult to treat population, as evidenced by lower EE healing rates and 
higher incidence of relapse and complications [16,17]. Approximately 25% of patients with EE 
present with baseline Grades C or D [18-20], and use of once-daily PPI therapy in these patients 
results in lower healing rates than those with Grades A and B [18-20]. Therefore, improvement in 
acid suppression therapy may reduce the risk for development of serious complications and 
enhance quality of life in these patients.
Erosive esophagitis is among the gastric acid-related disorders in which gastric acid reflux to the 
esophagus leads to problems in affected individuals. In 1994, the concept of a “mucosal break,” 
defined as “an area of slough or an area of erythema with a discrete lined demarcation from the 
adjacent or normal looking mucosa,” was introduced in the LA classification for diagnosis and 
grading of erosive esophagitis. Erosive esophagitis is graded by severity into 4 grades (A-D) based 
on the extent of mucosal breaks. Acid reflux induces prolonged, unpleasant subjective symptoms, 
such as heartburn or gastric acid reflux, in symptomatic patients with erosive esophagitis, often 
aggravating their health-related quality of life (HRQoL). 
The PPIs, such as lansoprazole, represent the drugs of first choice for erosive esophagitis, and are 
being widely used all over the world. 
The PPIs inhibit the hydrogen, potassium adenosine triphosphatase ([H+, K+]-ATPase) enzyme 
(proton pump) which represents the final step in acid secretion by the parietal cells in the gastric 
mucosa, and produce potent antisecretory efficacy for acid-related disorders. 
Dexlansoprazole is the R-enantiomer of lansoprazole. To further enhance the potential for 
dexlansoprazole capsules to demonstrate clinical benefit, especially in treating patients with unmet 
medical needs, Takeda Global Research & Development Center, Inc. now known as Takeda 
Development Center Americas, Inc. (TDC Americas) developed a dual delayed-release 
formulation of dexlansoprazole, also known as TAK-390MR and dexlansoprazole modified 
release (MR). This novel formulation consists of 2 types of granules contained within a single 
capsule. Each type of granule has a different pH-dependent release profile. The first peak occurs 
1 to 2 hours after administration, followed by a second peak within 4 to 5 hours. This dual 
delayed-release formulation is designed to extend the duration of drug exposure and maintain 
pharmacologically active levels of drug over a longer time period. As a result, the pharmacokinetic 
(PK) profile of dexlansoprazole following the administration of dexlansoprazole is characterized 
by a concentration-time profile with 2 distinct peaks. In order to achieve this 2-peak, prolonged PK 
profile, dexlansoprazole MR releases drug substance over a longer period of time, thus requiring 
higher daily doses and consequently higher area under the plasma concentration-time curves 
(AUCs), without a commensurate increase in maximum observed plasma concentration (Cmax), 
compared with that following administration of the conventional lansoprazole formulation. 
Dexlansoprazole 30 mg capsules are approved for use in adults in over 30 countries for treatment 
of heartburn associated with symptomatic nonerosive GERD, and maintenance of healed EE, and 
60 mg capsules are approved for healing of EE. 


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 20 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
In the United States (US) registration trials, dexlansoprazole capsules were evaluated in 
5072 subjects in many phase 1 studies and in the phase 3 healing of EE, maintenance of healed EE, 
symptomatic nonerosive GERD, and long-term safety studies. A total of 282 subjects were 
exposed to doses of either 60 or 90 mg for ≥52 weeks, 382 subjects were exposed to doses of either 
60 or 90 mg for ≥48 weeks and 863 subjects to doses of 30, 60, or 90 mg for 6 months (≥24 weeks). 
No safety concerns were noted in phase 1 studies of dexlansoprazole capsules in healthy 
volunteers and selected patient groups. No prolongation of QT interval was observed using doses 
up to 300 mg (T-P104-092). Five separate drug-drug interaction studies using dexlansoprazole 
capsule 60 or 90 mg (in which no PK interactions were seen with diazepam, phenytoin, 
theophylline, or warfarin and no pharmacodynamic interactions were seen with warfarin or 
clopidogrel) revealed no trends in adverse events (AEs) (T-P105-134, T-P105-133, T-P105-132, 
T-P105-139, and TAK-390MR_101). As expected with PPI therapy, mean serum gastrin levels 
increased 1- to 2-fold during the first 3 months of receiving dexlansoprazole capsules in 2 6-month 
maintenance studies (T-EE04-086 and T-EE05-135) and a long-term (12-month) safety study 
(T-GI04-088), and then generally stabilized for the remainder of treatment. These increases in 
gastrin levels were not dependent on the dose of dexlansoprazole capsules. In a phase 1 study in 
healthy volunteers, gastrin levels returned to Baseline within 7 days of last dose of 
dexlansoprazole [21]. In the maintenance of healed EE studies, and in the long-term safety study, 
no clinically important differences in gastric biopsy results were observed between any of the 
dexlansoprazole capsule treatment groups and placebo. In the long-term safety study, chronic 
gastritis (in either antral or fundic tissue) was the most commonly reported abnormality in 31% 
and 36% of patients in the dexlansoprazole 60 and 90 mg groups respectively. There were no 
reports of enterochromaffin cell-like (ECL) hyperplasia in the phase 3 studies of 6 months to 1 
year duration.
Gender had no effect on either the rate (time to reach Cmax [tmax]) or extent (Cmax and AUC) of 
dexlansoprazole absorption following the administration of dexlansoprazole capsules 
(T-P105-119) Although mean tmax values were approximately 2 hours shorter in subjects 18 to 
40 years of age compared with subjects 65 to 80 years of age, the extent of absorption as measured 
by Cmax and AUC was not statistically significantly different between young and elderly subjects 
(T-P105-119). While hepatic impairment had no effect on the rate of absorption, dexlansoprazole 
Cmax and AUC values in subjects with moderate hepatic impairment were approximately 2 times 
higher compared with those in subjects who have normal hepatic function, likely due to decreased 
clearance (T-P105-115).
Dexlansoprazole is extensively metabolized in the liver to inactive metabolites by oxidation, 
reduction, and subsequent formation of sulfate, glucuronide, and glutathione conjugates. 
Oxidative metabolites are formed by the cytochrome P450 (CYP) enzyme system, including 
hydroxylation mainly by CYP2C19 and oxidation by CYP3A4. Following the administration of a 
[14C]dexlansoprazole dose, the major circulating component in plasma was dexlansoprazole 
regardless of CYP2C19 metabolizer status, and no single metabolite accounted for more than 10% 
of the plasma total radioactivity through 6 hours postdose (T-P106-141). Although 51% of the 
administered [14C]dexlansoprazole dose was excreted in the urine, no unchanged dexlansoprazole 
was present in the urine. The remaining 48% of the radioactive dose was recovered in the feces.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 21 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
All dexlansoprazole capsule doses were well tolerated and demonstrated an acceptable safety 
profile similar to that of lansoprazole 30 mg.
4.2
Rationale for the Proposed Study
Phase 3 studies performed in the United States, Canada, Europe, Russia, India, Australia, New 
Zealand, South Africa, and South America have demonstrated positive results using 
dexlansoprazole for healing of EE and maintenance of healed EE. This study will be the first to 
examine the effectiveness and safety of dexlansoprazole capsules in Chinese subjects with EE. 
Efficacy and safety of dexlansoprazole capsules has been demonstrated in the phase 3 clinical 
program for the indications of symptomatic nonerosive GERD, healing of EE and maintenance of 
healed EE. All tested dexlansoprazole doses were highly effective in controlling and preventing 
the return of heartburn and other GERD symptoms, healing EE, preventing relapse of erosive 
esophagitis and maintaining QOL.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 22 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
5.0
STUDY OBJECTIVES AND ENDPOINTS
5.1
Objectives
5.1.1
Primary Objective 
The primary objective is to compare the efficacy of dexlansoprazole capsules (60 mg QD) and 
lansoprazole capsules (30 mg QD) in healing EE over 8 weeks of treatment in Chinese subjects 
with endoscopic evidence of EE; the primary comparison will be to determine whether 
dexlansoprazole is noninferior to lansoprazole.
5.1.2
Secondary Objective
The secondary objective is to compare the efficacy of dexlansoprazole capsules (30 mg QD) and 
placebo in the maintenance of healing in Chinese subjects with healed EE; the primary comparison 
will be to determine whether dexlansoprazole is superior to placebo.
5.1.3
Additional Objective 
5.2
Endpoints
5.2.1
Primary Endpoint 
The primary endpoint is the percentage of subjects who have complete healing of EE over 8 weeks 
as assessed by endoscopy.
5.2.2
Secondary Endpoint 
The secondary endpoint is the percentage of subjects who maintain complete healing of EE over 
6 months as assessed by endoscopy.
5.2.3
Additional Endpoints
Additional endpoints include:
!
The percentage of days with neither daytime nor nighttime heartburn over the 8 weeks of the 
Healing Period as assessed by the daily paper diary.
!
The percentage of days with neither daytime nor nighttime heartburn over the 6 months of the 
Maintenance Period as assessed by the daily diary among the subjects who were healed at 
Week 8.
!
The percentage of days without rescue medication use over the 8 weeks of the Healing Period 
as assessed by the daily diary.
CCI


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 23 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL

The percentage of days without rescue medication use over the 6 months of the Maintenance 
Period as assessed by the daily diary among the subjects who were healed at Week 8.

The severity of GERD symptoms at Weeks 4 and 8 as assessed by the investigator during the 
Healing Period.

The severity of GERD symptoms at Months 1, 3, and 6 as assessed by the investigator during 
the Maintenance Period. 
Safety will be assessed by summarizing the incidence of AEs, clinical laboratory values, gastrin 
levels, physical examinations, electrocardiograms (ECGs), and vital signs.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 24 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
6.0
STUDY DESIGN AND DESCRIPTION
6.1
Study Design
This is a phase 3, randomized, double-blind, multicenter, active-controlled, 2-arm study with an 
initial 8-week healing period with noninferiority design, followed by a randomized, 
placebo-controlled 6-month maintenance period. The study is designed to evaluate healing, 
maintenance of healed EE and the effect of therapy on relieving GERD-related symptoms. 
Approximately 450 subjects will be enrolled at an estimated 25 sites across China.
The study consists of 3 periods; a Screening Period (maximum 21 days), a Healing Period, which 
will last 8 weeks, and a Maintenance Period of up to 6 months. After signing an informed consent 
form (ICF) subjects will undergo a screening evaluation within 21 days prior to the first dose of 
study drug (Study Day 1). Subjects will be instructed that lifestyle or behavior modifications 
designed to treat their symptoms of GERD should not be altered throughout the study. Subjects 
will be given a diary on the first day of the Screening Period. Throughout the Screening Period, 
subjects will record the presence and maximum severity of daytime and nighttime heartburn 
symptoms each day in their diary. 
During the Screening Period, subjects will undergo various procedures to determine eligibility for 
the Healing Period. Screening evaluations will include the following: demographics, medical and 
social history, physical examination including vital signs, height and weight, ECG, endoscopy, 
clinical laboratory evaluations including tests for serum and urine pregnancy (all women of 
childbearing potential) and hepatitis panel, and concomitant medication assessment. The screening 
clinical laboratory tests, hepatitis panel, and endoscopy must be performed within 14 days prior to 
randomization. Endoscopy data will be collected to identify subjects with EE, and only those 
subjects with endoscopically-confirmed EE Grades A-D as defined by the LA Classification 
Grading System (Appendix E), will be eligible for this study. Endoscopic pictures will be taken by 
the study site and kept in the site’s source document files according to the site’s practice.
Subjects who satisfy the screening evaluation and selection criteria, and have EE confirmed by 
endoscopy, may be entered into the study. Subjects having an esophageal stricture will be 
excluded from the study. The endoscope must pass freely into the stomach during the endoscopy.
All subjects will return to the investigative site on Day -1 which will be deemed as the Baseline. 
Subjects who have completed all of the Screening procedures and met all eligibility requirements 
and none of the exclusion criteria will have routine fasting laboratory evaluations, including 
fasting serum gastrin, a urine pregnancy test (all women of childbearing potential), physical 
examination, and vital signs measurements to assure continued eligibility. Subjects will be 
dispensed study drug on Study Day -1 according to an interactive web response system (IWRS) 
and will begin taking study drug on the following day (Study Day 1). In addition, subjects will be 
assessed for GERD symptoms such as heartburn, acid regurgitation, dysphagia, belching, and 
epigastric pain by the investigator.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 25 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL

Subjects will be assigned in a 1:1 ratio to one of the following 2 treatment groups during the 
8-week Healing Period; the randomization will be stratified by baseline endoscopic findings 
(grades A/B or C/D).
–
Group I:
dexlansoprazole capsules (60 mg QD)
–
Group II:
lansoprazole capsules (30 mg QD)
During the 8-week Healing Period, study drug will be self-administered orally QD before 
breakfast in the morning. Subjects will document the presence and maximum severity of daytime 
and nighttime heartburn symptoms using a diary. Subjects will also record the use of rescue 
medication. Subject visits will be conducted at Weeks 4 and 8 of the Healing Period to collect 
and/or dispense study drug, assess GERD symptoms, review concomitant medication use, and 
assess AEs. 
At the Week 4 Visit, the subject will undergo a physical examination including vital signs, 
laboratory evaluations, and urine pregnancy test (all women of childbearing potential). 
At the Week 8 Visit, all subjects will undergo a physical examination including vital signs, 
laboratory evaluations, fasting serum gastrin, serum and urine pregnancy test (all women of 
childbearing potential), ECG and an endoscopy. In addition, study drug will be collected, a review 
of concomitant medication use will be performed, and an assessment of AEs will be conducted. If 
the subject’s EE has healed completely as determined by endoscopy, the subject will have 
completed the Healing Period of the study, and will continue in the Maintenance Period. If the 
subject’s EE has not completely healed after 8 weeks of treatment, all Final Visit procedures will 
be performed and the subject will not be eligible to continue into the Maintenance Period. 
For subjects who prematurely discontinue during the Healing Period, efforts should be made to 
perform all procedures scheduled for the Week 8 / Early Termination Visit no later than 5 days 
after the last dose of study drug.
At the start of the 6-Month Maintenance Period, subjects with healed EE will be randomized in a 
1:1 ratio to one of the following 2 groups; the randomization will be stratified by baseline 
endoscopic findings (grades A/B or C/D).
–
Group I:
dexlansoprazole capsules (30 mg QD)
–
Group II:
placebo (QD)
During the 6-month Maintenance Period, study drug will be self-administered orally, QD in the 
morning before breakfast. Subjects will continue to document the presence and maximum severity 
of daytime and nighttime heartburn symptoms using a diary. Subjects will also record the use of 
rescue medication. Subject visits will be conducted at Months 1, 3 and 6, of the Maintenance 
Period to collect and/or dispense study drug, assess GERD symptoms, review concomitant 
medication use, and assess AEs. Endoscopies will be performed at Months 1 and 6/Final Visit to 
evaluate maintenance of healed EE. Subjects with endoscopic evidence of relapsed EE will be 
discontinued from the study.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 26 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
At the Month 1 Visit, the subject will undergo a physical examination including vital signs, 
laboratory evaluations, endoscopy, and urine pregnancy test (all women of childbearing potential). 
At the Month 3 Visit, the subject will undergo a physical examination including vital signs, 
laboratory evaluations and urine pregnancy test (all women of childbearing potential). An optional 
endoscopy may be performed based on investigator’s discretion if the subject presents with GERD 
symptoms at any time point during the Maintenance Period. 
At the Month 6 Visit, all subjects will undergo a physical examination including vital signs, 
laboratory evaluations, fasting serum gastrin, serum and urine pregnancy test (all women of 
childbearing potential), endoscopy, and ECG. In addition, study drug will be collected, a review of 
concomitant medication use will be performed, and an assessment of AEs will be conducted. 
For subjects who prematurely discontinue during the Maintenance Period, efforts should be made 
to perform all procedures (including endoscopy) scheduled for the Month 6 / Early Termination 
Visit no later than 5 days after the last dose of study drug.
A schematic of the study design is included as Figure 6.a. A schedule of assessments is listed in 
Appendix A.
Figure 6.a
Schematic of Study Design
dexlansoprazole (60 mg QD)
dexlansoprazole (30 mg QD)
Screening Period 
OR
Randomization
OR
lansoprazole (30 mg QD)
placebo (QD)
Healing Period
Maintenance Period
Day -1
Day 1
Week 4
Week 8/Final Visit
Day 1
Mo 1
Mo 3
Mo 6/Final Visit
Randomize
1st Dose
Healing Period
Randomize
1st Dose
Maintenance 
Period
Mo=month.
6.2
Justification for Study Design, Dose, and Endpoints
This EE Healing Period of the study will compare dexlansoprazole 60 mg capsules QD with 
lansoprazole 30 mg capsules QD during the Healing Period. 
Dexlansoprazole 60 mg capsules are approved in over 30 countries and lansoprazole 30 mg 
capsules are approved in China for healing of EE over an 8-week treatment period. Subjects with 
endoscopically-proven healing of EE after 8 weeks of treatment will continue into the 
Maintenance Period of the study. During this period all subjects with healed EE will receive either 
dexlansoprazole 30 mg capsules QD or placebo QD for 6 months. The study design, endpoints and 
dose of dexlansoprazole capsules for healing of EE (60 mg QD) and maintenance of healed EE 


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 27 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
(30 mg QD) have been selected based on completed, multicenter, controlled phase 3 registration 
studies.
The efficacy and safety measurements and the clinical and routine laboratory procedures used in 
this study are considered standard and generally accepted. 
6.3
Premature Termination or Suspension of Study or Investigational Site
6.3.1
Criteria for Premature Termination or Suspension of the Study
The study will be completed as planned unless one or more of the following criteria are satisfied 
that require temporary suspension or early termination of the study:

New information or other evaluation regarding the safety or efficacy of the study medication 
that indicates a change in the known benefit:risk profile for the compound, such that the 
risk/benefit is no longer acceptable for subjects participating in the study.

Significant violation of Good Clinical Practice (GCP) that compromises the ability to achieve 
the primary study objectives or compromises subject safety.
6.3.2
Criteria for Premature Termination or Suspension of Investigational Sites
A study site may be terminated prematurely or suspended if the site (including the investigator) is 
found in significant violation of GCP, protocol, or contractual agreement, is unable to ensure 
adequate performance of the study, or as otherwise permitted by the contractual agreement.
6.3.3
Procedures for Premature Termination or Suspension of the Study or the 
Participation of Investigational Site(s)
In the event that the sponsor, an institutional review board (IRB)/independent ethics committee 
(IEC) or regulatory authority elects to terminate or suspend the study or the participation of an 
investigational site, a study-specific procedure for early termination or suspension will be 
provided by the sponsor; the procedure will be followed by applicable investigational sites during 
the course of termination or study suspension.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 28 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
7.0
SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS
All entry criteria, including test results, need to be confirmed prior to randomization. 
7.1
Inclusion Criteria
Subject eligibility is determined according to the following criteria: 
1. In the opinion of the investigator, the subject is capable of understanding and complying with 
protocol requirements.
2. The subject or, when applicable, the subject’s legally acceptable representative signs and dates 
a written, informed consent form prior to the initiation of any study procedures. 
3. The subject is a man or woman and aged at least 18 years. 
4. The subject must have endoscopically confirmed EE as defined by the LA Classification 
Grading System (A-D).
5. All women of childbearing potential who are sexually active agree to routinely use adequate 
contraception from signing of the informed consent throughout the duration of the study and 
for 30 days after the last dose of study medication.
6. All male subjects who are nonsterilized* and sexually active with women of childbearing 
potential* agree to use adequate contraception* from signing of informed consent throughout 
the duration of the study and for 30 days after the last dose of study medication.
*Definitions and acceptable methods of contraception are defined in 
Section 9.1.11 Contraception and Pregnancy Avoidance Procedure and 
reporting responsibilities are defined in Section 9.1.12 Pregnancy.
7.2
Exclusion Criteria
Any subject who meets any of the following criteria will not qualify for entry into the study: 
1. The subject has a history or clinical manifestations of serious neurologic, cardiovascular, 
pulmonary, hepatic, renal, metabolic, gastrointestinal, urological, endocrine, hematologic, 
dermatologic, immunologic, psychiatric disorders, or other abnormality which may impact the 
ability of the subjects to participate or potentially confound the study results.
2. The subject is required to take excluded medications, or it is anticipated that the subject will 
require treatment with at least 1 of the disallowed concomitant medications during the study 
evaluation period as specified in the excluded medication section (Section 7.3).
3. The subject has received any investigational drug or participated in another clinical study 
(other than study TAK-390MR_302) within 30 days prior to the Screening Visit. 
4. The subject has a hypersensitivity to any PPI (including, but not limited to, lansoprazole, 
omeprazole, rabeprazole, pantoprazole, esomeprazole or ilaprazole), any component of 
dexlansoprazole, or antacid (eg, magnesium trisilicate or similar antacid).


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 29 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
5. The subject had a history of cancer, (except basal cell carcinoma of the skin), that has not been 
in remission for at least 5 years prior to Screening. 
6. The subject has a known history or any suspicious Barrett’s esophagus with dysplastic changes 
seen during screening endoscopy. 
7. The subject developed acute upper gastrointestinal bleeding, gastric ulcer (a mucosal defect 
with white coating) or duodenal ulcer (a mucosal defect with white coating), within 30 days 
before the start of the Screening Visit (with the possible inclusion of those with gastric or 
duodenal erosion). The subject requires chronic use (>12 doses per month) of nonsteroidal 
anti-inflammatory drugs (NSAIDs) including cyclooxygenase-2 (COX-2) NSAIDs within 
30 days prior to the Screening Period and throughout the study.
8. The subject has comorbidities that could affect the esophagus (eosinophilic esophagitis, 
esophageal varices, scleroderma, viral or fungal infection, esophageal strictures); a history of 
radiotherapy or cryotherapy of the esophagus; and a history of corrosive or physiochemical 
injury (with the possible inclusion in the study of those with Schatzki’s ring).
9. The subject has a history of surgical procedures that may affect the esophagus (eg, 
fundoplication and mechanical dilatation for esophageal strictures) or a history of gastric or 
duodenal surgery other than endoscopic removal of benign polyps.
10. The subject has any abnormal screening or Day-1, laboratory value that suggests a clinically 
significant underlying disease or condition that may prevent the subject from entering the 
study, based on the medical judgment of the investigator; or the subject has: 
a) Creatinine >1.5 mg/dL or
b) Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) >2.5 times the 
upper limit of normal (×ULN) or
c) Total bilirubin >2.0 mg/dL.
11. The subject is known to have the acquired immunodeficiency syndrome (AIDS) or hepatitis, 
including hepatitis virus carriers (ie, hepatitis B surface antigen HBs-antigen (HBsAg) positive 
or hepatitis C virus (HCV)-antibody positive).
12. The subject has current Zollinger-Ellison syndrome (gastric acid hypersecretion) or a history 
of gastric acid hypersecretion.
13. The subject is scheduled for surgery that requires hospitalization or requires surgical treatment 
during his/her participation in the study.
14. The subject has donated or lost >300 mL blood volume, undergone plasmapheresis, or has had 
a transfusion of any blood product within 90 days prior to the first dose of study drug.
15. The subject has a history of alcohol or drug abuse (defined as any illicit drug use), or drug 
addiction in the 12 months prior to Screening.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 30 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
16. If the subject is a pregnant or lactating woman; is intending to become pregnant before, during, 
or within 30 days after participating in this study; is intending to donate ova during this time 
period; or is a man who is intending to donate sperm.
17. Any subject who, in the opinion of the investigator, is unable to comply with the requirements 
of the study or is unsuitable for any reason.
18. The subject with positive serology result of Helicobacter pylori (H. pylori) that needs 
eradication therapy during the study participation period as anticipated by the investigator. 
19. The subject is an immediate family member, study site employee, is in a dependent 
relationship with a study site employee who is involved in conduct of this study (eg, spouse, 
parent, child, sibling), or may consent under duress.
7.3
Excluded Medications and Treatments
Excluded medications and periods of exclusion are listed in Table 7.a. Subjects must be instructed 
not to take any medications, including over-the-counter products or traditional Chinese medicines 
(TCM) without first consulting with the investigator.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 31 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
Table 7.a
Excluded Medications
Excluded Medications
Period of Exclusion
Prescription or nonprescription H2RA
During Screening and throughout the study.
Antacids (except the rescue medication or similar 
antacid)
During Screening and throughout the study. 
PPIs (except study-supplied dexlansoprazole or 
lansoprazole)
During Screening and throughout the study.
NSAIDs, chronic use (>12 doses/month) including 
COX-2 NSAIDs 
Within 30 days prior to Screening and throughout the study. 
Drugs with significant anticholinergic effects such as 
tricyclic antidepressants or drugs with CNS effects 
that could mask perception of symptoms (eg, SSRI, 
benzodiazepines). 
During Screening and throughout the study. However, subjects 
who have remained on a stable regimen and dose of these 
medications for 30 days prior to Day -1 and who agree to 
maintain the same regimen and dose during the trial including 
the screening and treatment period will qualify. Also, 
short-term use of anticholinergics for trial-related procedures is 
not exclusionary.
Misoprostol
During Screening and throughout the study.
Prokinetics (including metoclopramide, cisapride, 
tegaserod)
During Screening and throughout the study.
Anticoagulant or antiplatelet therapy
During Screening and throughout the study
Medications with pH-dependent absorption*
During Screening and throughout the study
Methotrexate**
During Screening and throughout the study
Other: bethanechol
During Screening and throughout the study
H2RA=histamine 2-receptor antagonist, SSRI=selective serotonin reuptake inhibitor.
*Consideration of coadministration is based on clinically meaningful differences in efficacy or safety of medication 
due to pH dependent absorption.
** The investigator or designee should discuss methotrexate use with the medical monitor on a case by case basis if 
methotrexate treatment is necessary throughout the study. 
7.4
Diet, Fluid, Activity Control 
The principal investigator, the coinvestigators, and the study collaborators are to explain, and give 
instructions on, the following before the start of the study or during the study, as well as to check to 
see if the subjects keep to the instructions at the time of their scheduled visits.

Every subject should keep to the scheduled visits, seek medical consultation, and undergo 
predetermined laboratory.

The subject should ensure that all study medications are swallowed with approximately 
240 mL water according to the administration, and dosing schedule. Subjects should be 
instructed according to Section 8.1.3.1 (Missed Doses) and 9.2 (Compliance). Details of any 
missed or forgotten doses should be reported to the Investigator or designee at the subsequent 
study visit.

The subject should store all medications in a cool, dry, safe place which is out of reach of
children and to bring all study supplies (empty / used / unused drug packets and diaries alike) 
to each study visit.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 32 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL

The subject should record his/her nighttime (during sleep) subjective symptoms and the 
previous daytime subjective symptoms in his/her subject diary upon rising in the morning on a
daily basis. The subject should also record the use of rescue medication since the start of the 
Screening Period as well as his/her study medication compliance status during the Treatment 
Phase. 

The subject will be required to fast for at least 8 hours before each visit at which fasted blood 
tests will be drawn and/or endoscopy will be performed, after the ICF is signed. Fasting is 
defined as no food or nutritional drinks for 8 hours before the blood draw. Water is allowed. 
Any medication that needs to be taken with food and any study medications should be held 
until after the fasting blood has been drawn and/or the endoscopy has been performed. 
Medication that does not need to be taken with food should be continued. The investigator 
must instruct the subject accordingly prior to visits in which serum gastrin is measured and 
endoscopy is performed.

After the first dose of study drug during the Healing Period and the Maintenance Period, the 
subject should present to the clinic in the morning as scheduled.

The subject should consult with the study investigator or designee prior to being treated by 
physicians other than the study investigator. All other medications such as over-the-counter 
drugs beyond those prescribed for the study should be reported at the next study visit.

The subject should report on all subjective or objective symptoms experienced (ie, including 
details of day of onset, severity, outcome, and day of outcome) at every visit. In case of 
emergency such as occurrence of a serious adverse event (SAE), the subject, family, or legal 
designee should contact the principal investigator as soon as possible.

The subject should use contraception without fail. A woman of childbearing potential will 
agree to use contraception from signing of informed consent throughout the duration of the 
study and 30 days after the final dose of the study medication. Pregnancy in a woman subject, 
if found, should be reported immediately.

The subject should not donate blood during the study.

The subject should refrain from excessive drinking and eating, and any extreme diet change 
(eg, change to an extremely high-fat diet) or excessive exercise throughout the study. Subjects 
will be instructed to maintain usual food intake, sleep habits, consistent activity, and caffeine 
intake throughout the study.
7.5
Criteria for Discontinuation or Withdrawal of a Subject
The primary reason for discontinuation or withdrawal of the subject from the study or study drug 
should be recorded in the electronic case report form (eCRF) using the following categories. For 
screen failure subjects, refer to Section 9.1.13.
1. Pretreatment event (PTE) or adverse event (AE). The subject has experienced a PTE or AE that 
requires early termination because continued participation imposes an unacceptable risk to the 
subject’s health or the subject is unwilling to continue because of the PTE or AE.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 33 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL

Liver Function Test Abnormalities
–
Study medication should be discontinued immediately with appropriate clinical 
follow-up (including repeat laboratory tests, until a subject’s laboratory profile has 
returned to normal/baseline status, see Section 9.1.10), if the following circumstances 
occur at any time during study medication treatment:
–
ALT or AST >8×ULN, or
–
ALT or AST >5×ULN and persists for more than 2 weeks, or
–
ALT or AST >3×ULN in conjunction with elevated total bilirubin >2×ULN or 
international normalized ratio (INR) >1.5, or
–
ALT or AST >3×ULN with appearance of fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%).
2. Significant protocol deviation. The discovery post-randomization that the subject failed to 
meet protocol entry criteria or did not adhere to protocol requirements, and continued 
participation poses an unacceptable risk to the subject’s health.
3. Relapse of EE during the Maintenance Period.
4. Lost to follow-up. The subject did not return to the clinic and attempts to contact the subject 
were unsuccessful. Attempts to contact the subject must be documented in the subject’s source 
documents.
5. Voluntary withdrawal. The subject (or subject’s legally acceptable representative) wishes to 
withdraw from the study. The reason for withdrawal, if provided, should be recorded in the 
eCRF.
Note: All attempts should be made to determine the underlying reason for the withdrawal and, 
where possible, the primary underlying reason should be recorded (ie, withdrawal due to an 
AE or lack of efficacy should not be recorded in the “voluntary withdrawal” category).
6. Study termination. The sponsor, IRB, IEC, or regulatory agency terminates the study.
7. Pregnancy. The subject is found to be pregnant.
Note: If the subject is found to be pregnant, the subject must be withdrawn immediately. The 
procedure is described in Section 9.1.12.
8. Lack of efficacy. The investigator has determined that the subject is not benefiting from 
investigational treatment and continued participation would pose an unacceptable risk to the 
subject. 
9. Other.
Note: The specific reasons should be recorded in the “specify” field of the eCRF, for example: 
noncompliance.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 34 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
7.6
Procedures for Discontinuation or Withdrawal of a Subject
The investigator may terminate a subject’s study participation at any time during the study when 
the subject meets the study termination criteria described in Section 7.5. In addition, a subject may 
discontinue his or her participation without giving a reason at any time during the study. Should a 
subject’s participation be discontinued, the primary criterion for termination must be recorded. In 
addition, efforts should be made to perform all procedures scheduled for the Early Termination 
Visit. Discontinued or withdrawn subjects will not be replaced. 


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 35 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
8.0
CLINICAL TRIAL MATERIAL MANAGEMENT
This section contains information regarding all medication and materials provided directly by the 
sponsor, and/or sourced by other means, that are required by the study protocol, including 
important sections describing the management of clinical trial material.
8.1
Study Medication and Materials
Once a subject meets all eligibility criteria, the site will randomize the subject via the IWRS, which 
will assign a unique study drug identification number. The subject will be randomized into the 
Healing Period in a 1:1 ratio into 1 of 2 treatment groups:

Dexlansoprazole 60 mg capsules.

Lansoprazole 30 mg capsules.
At Week 8 of the Treatment Period, if the subject is healed per the endoscopy, the subject will be 
randomized into the Maintenance Period in a 1:1 ratio to 1 of 2 treatment groups:

Dexlansoprazole 30 mg capsules.

Placebo capsules.
Randomization will be stratified by baseline endoscopic findings (grades A/B or C/D) for both the 
Healing and Maintenance Periods.
8.1.1
Dosage Form, Manufacturing, Packaging, and Labeling
In this protocol, the term study medication refers to all or any of the drugs defined below.
During the 8-week Healing Period and for the 6-month Maintenance Period, blinded study drug 
will be provided according to Table 8.a.
Table 8.a
Study Drugs
Study Drugs
Dosage Strength/Dosage Form
Manufacturer
Dexlansoprazole
30 and 60 mg capsules
Takeda Pharmaceutical Company Ltd.
Lansoprazole 
30 mg capsules
Tianjin Takeda Pharmaceuticals Company Ltd.
Placebo
capsules (dose is not applicable)
Fisher Clinical Services
The study sites will be supplied with study medication that is blinded via overencapsulation (OE) 
of dexlansoprazole 60 mg capsules and lansoprazole 30 mg capsules for subjects in the 8-week 
Healing Period. Sites enrolling subjects in the Maintenance Period will also be supplied with OE 
dexlansoprazole 30 mg and placebo. The study drugs will be foil/foil blistered and packaged in 
7-day child resistant blister cards containing 7 capsules. Each card will have a single-panel 
multilingual label that will contain, but will not be limited to: protocol number, medication 
identification (ID) number, name and strength of the product, quantity of dosage unit, directions 
for use, storage conditions, country specific regulatory caution statement, and name and address of 
the sponsor. The matching placebo capsules will be manufactured by Fisher Clinical Services. The 


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 36 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
study medication is overencapsulated, foil/foil blistered, packaged, labeled and distributed by 
Fisher Clinical Services.
8.1.1.1
Investigational Drug
The investigational drugs are manufactured as follows: dexlansoprazole capsules (30 and 60 mg) 
are manufactured by Takeda Pharmaceutical Company Limited, Osaka, Japan; lansoprazole (30 
mg) is manufactured by Tianjin Takeda Pharmaceuticals Co., Ltd., Tianjin, China; the placebo is 
manufactured by Fisher Clinical Services. The active capsule contains drug substance and 
excipients. The placebo capsules contain excipients only. The study medication is 
overencapsulated, foil/foil blistered, packaged, labeled, and distributed by Fisher Clinical 
Services.

OE dexlansoprazole 60 mg capsules.

OE lansoprazole 30 mg capsules.

OE dexlansoprazole 30 mg capsules.

Placebo.
8.1.1.2
Rescue Medication
During the study, including the during Screening Period, over-the-counter medications such as 
Talcid chewable tablets (hydrotalcite) or Gaviscon tablets can be used as rescue medication if the 
symptoms caused by acid reflux cannot be tolerated by the subjects. The investigator or designee 
will give medical instructions to the subject regarding the use of rescue medication during the 
dispensing visits. Subjects shall be instructed to refrain from using rescue medication unless 
necessary to manage symptoms. Proper documentation of use is required. Subjects shall contact 
the investigators if they would like to take the rescue medication at a dose higher than approved in 
the local package insert.
The use of rescue medication shall be recorded in the subject daily diary.
The institution or its designee will help to source the rescue medication for the subjects as 
necessary, or alternatively, subject may buy the rescue medication from the pharmacy and be 
reimbursed.
Rescue medications include those listed in Table 8.b:
Table 8.b
Rescue Medications
Rescue Medication 
(Active Ingredients in Each Tablet)
Dosage Strength
Manufacturer
Talcid chewable tablets (hydrotalcite)
500 mg
Bayer China Ltd.
Gaviscon Tablets
aluminum hydroxide 0.05g 
magnesium trisilicate 0.0125g
alginic acid 0.25g
Local China domestic companies


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 37 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
If the listed rescue medications are not available, the subject should contact the subject’s 
responsible investigator for confirmation of available brand. During the rescue medication 
administration, the following should be noted:
1. The administration of rescue medication shall be in accordance with the local package insert;
2. For aluminum based medications, an interval of at least 2 hours must be maintained between 
administration of study medication (dexlansoprazole, lansoprazole, or placebo) and rescue 
medication;
3. When rescue medication has been taken for more than 7 consecutive days, or more than 25% of 
the days in whole study period, the investigator should discuss with CRO/sponsor and decide 
whether to withdraw the subject.
8.1.1.3
Sponsor-Supplied Drug

OE dexlansoprazole 60 mg capsules.

OE lansoprazole 30 mg capsules.

OE dexlansoprazole 30 mg capsules.

Placebo capsules. 
8.1.2
Storage
All clinical trial material must be kept in an appropriate, limited-access, secure location until it is 
used or returned to the sponsor or designee for destruction. All sponsor-supplied drugs must be 
stored under the conditions specified on the label, and remain in the original container until 
dispensed.
All study medication supplied for the study must be stored as follows:
Store at: 20°C to 25°C; excursions allowed between 15°C and 30°C.
A daily temperature log of the drug storage area must be maintained every working day.
Temperature excursions must be reported to the sponsor or designee.
The investigator should ensure that study drug is used only in accordance with the approved 
protocol. Study drug shall be dispensed only to subjects enrolled in the study.
8.1.3
Dose and Regimen
All subjects with EE confirmed by endoscopy at Screening will be assigned to 60 mg 
dexlansoprazole or 30 mg lansoprazole capsules QD for 8 weeks of treatment. At the Week 8 
Visit, all EE subjects will have an endoscopy. EE subjects who have healed will be randomized to 
dexlansoprazole 30 mg capsules or placebo for 6 months to assess maintenance of healed EE. 


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 38 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
The number of cards subjects will receive at each visit is outlined in Table 8.c.
Table 8.c
Study Medication Dispensed at Each Visit
Study Visits
Number of 7-Day Cards Dispensed at #Each Visit
Day -1/Visit 2
5 cards of Dexlansoprazole 60 mg or Lansoprazole 30 mg capsules
Week 4/Visit 3
5 cards of Dexlansoprazole 60 mg or Lansoprazole 30 mg capsules
Week 8/Visit 4
5 cards of Dexlansoprazole 30 mg capsules or Placebo capsules
Month 1/Visit 5
9 cards of Dexlansoprazole 30 mg capsules or Placebo capsules
Month 3/Visit 6
13 cards of Dexlansoprazole 30 mg capsules or Placebo capsules
All subjects will self-administer 1 capsule of blinded study medication QD at approximately the 
same time each morning. The last dose of study medication is taken with a sip of water on the 
morning of their visit (Visits 3, 4, 5, 6 and 7). 
Table 8.d
Study Medication Supplies
Investigational 
Product
Formulation
Dosage
Mode of 
Administration
Manufacturer and Location
Dexlansoprazole
30 mg capsule
30 mg QD AM
Oral
Takeda Pharmaceutical 
Company Ltd
Dexlansoprazole
60 mg capsule
60 mg QD AM
Oral
Takeda Pharmaceutical 
Company Ltd
Lansoprazole
30 mg capsule
30 mg QD AM
Oral
Tianjin Takeda Pharmaceuticals 
Company Ltd
Placebo
0 mg capsule
0 mg QD AM
Oral
Fisher Clinical Services
8.1.3.1
Missed Doses
Subjects should be instructed that all doses of study medication (dexlansoprazole or lansoprazole) 
should be taken on time. Subjects should also be instructed that if any dose is missed inadvertently 
it is acceptable for that dose to be taken within 12 hours of the time that it was due. If more than 
12 hours have passed since the dose was due, it should not be taken, but instead subjects should be 
instructed to report the missed dose to the investigator or designee during the next visit.
8.1.4
Overdose
An overdose is defined as a known deliberate or accidental administration of investigational drug, 
to or by a study subject, at a dose above that which is assigned to that individual subject according 
to the study protocol. 
All cases of overdose (with or without associated AEs) will be documented on an overdose page of 
the eCRF, in order to capture this important safety information consistently in the database. AEs 
associated with an overdose will be documented on AE eCRF(s) according to Section 10.0, 
Pretreatment Events and Adverse Event.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 39 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
Serious adverse events (SAEs) of overdose should be reported according to the procedure outlined 
in Section 10.2.2, Collection and Reporting of SAEs.
In the event of drug overdose, the subject should be treated symptomatically by the investigator.
8.2
Investigational Drug Assignment and Dispensing Procedures
An IWRS will be used for both the Healing and Maintenance Periods.
The investigator or investigator’s designee will access the IWRS at Screening to obtain the subject 
identification number. The investigator or the investigator’s designee will utilize the IWRS to 
enroll the subject into the study. During this contact, the investigator or designee will provide the 
necessary subject-identifying information, including the subject number assigned at Screening. 
The medication ID number of the investigational drug to be dispensed will then be provided by the 
IWRS. If sponsor-supplied drug is lost or damaged, the site can request a replacement from IWRS. 
(Refer to IWRS manual provided separately.) At subsequent drug-dispensing visits, the 
investigator or designee will again contact the IWRS to request additional investigational drug for 
a subject. 
8.3
Randomization Code Creation and Storage 
Randomization personnel of the sponsor or designee will generate the randomization schedules for 
both the Healing Period and for the Maintenance Period prior to the start of the study.
Once a subject meets all admission criteria, the site will randomize the subject via the IWRS, 
which will assign a study drug kit number for the Healing Period. The study drug kit number will 
encode the subject’s randomization to 1 of the 2 arms (dexlansoprazole 60 mg QD or lansoprazole 
30 mg QD) at a ratio of 1:1, according to the randomization schedules generated prior to study 
start.
Subjects with healed EE at the end of the Healing Period will be randomized again via the IWRS 
for the subsequent Maintenance Period. A study drug kit number will be assigned by IWRS and 
encode the subject’s randomization to 1 of the 2 arms (dexlansoprazole 30 mg QD, or placebo QD) 
at a ratio of 1:1, according to the randomization schedules generated prior to study start.
Randomization will be stratified by baseline endoscopic findings (grades A/B or C/D) for both the 
Healing and Maintenance Periods.
All randomization information will be stored in a secured area, accessible only by authorized 
personnel.
8.4
Investigational Drug Blind Maintenance 
The investigational drug blind will be maintained using the IWRS.
8.5
Unblinding Procedure 
The investigational drug blind shall not be broken by the investigator unless information 
concerning the investigational drug is necessary for the medical treatment of the subject. In the 


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 40 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
event of a medical emergency, if possible, the medical monitor should be contacted before the 
investigational drug blind is broken to discuss the need for unblinding.
For unblinding a subject, the investigational drug blind can be obtained by the investigator by 
accessing the IWRS.
The sponsor must be notified as soon as possible if the investigational drug blind is broken. The 
date, time, and reason the blind is broken must be recorded in the source documents and the same 
information (except the time) must also be recorded on the eCRF.
If any site personnel are unblinded during the Healing or Maintenance Periods, investigational 
drug must be stopped immediately and the subject must be withdrawn from the study. 
8.6
Accountability and Destruction of Sponsor-Supplied Drugs
Drug supplies will be counted and reconciled at the site before being returned to the sponsor or 
designee.
The investigator or designee must ensure that the sponsor-supplied drug is used in accordance with 
the approved protocol and is dispensed only to subjects enrolled in the study. To document 
appropriate use of sponsor-supplied drug (dexlansoprazole 60 mg, lansoprazole 30 mg, 
dexlansoprazole 30 mg, placebo), the investigator must maintain records of all sponsor-supplied 
drug delivery to the site, site inventory, dispensation and use by each subject, and return to the 
sponsor or designee.
Upon receipt of sponsor-supplied drug, the investigator or designee must verify the contents of the 
shipments against the packing list. The verifier should ensure that the quantity is correct; the 
medication is received within the labeled storage conditions, and is in good condition. If quantity 
and conditions are acceptable, investigator or designee should acknowledge the receipt of the 
shipment by recording in IWRS. If there are any discrepancies between the packing list versus the 
actual product received, Takeda must be contacted to resolve the issue. The packing list should be 
filed in the investigator’s essential document file. 
The investigator must maintain 100% accountability for all sponsor-supplied drugs received and 
dispensed during his or her entire participation in the study. Proper drug accountability includes, 
but is not limited to:

Frequently verifying that actual inventory matches documented inventory.

Verifying that the log is completed for the drug lot (or medication ID number) used to prepare 
each dose.

Verifying that all containers used and unused are documented accurately on the log.

Verifying that required fields are completed accurately and legibly.
If any dispensing errors or discrepancies are discovered, the sponsor must be notified immediately.
The investigator must record the current inventory of all sponsor-supplied drugs (dexlansoprazole 
30 and 60 mg, lansoprazole 30 mg, placebo) on a sponsor-approved drug accountability log. The 


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 41 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
following information will be recorded at a minimum: protocol number and title, name of 
investigator, site identifier and number, description of sponsor-supplied drugs, date and amount 
dispensed including initials of the person dispensing the drug, and the date and amount returned to 
the site by the subject, including the initials of the person receiving the sponsor-supplied drug. The 
log should include all required information as a separate entry for each subject to whom 
sponsor-supplied drug is dispensed.
Prior to site closure or at appropriate intervals, a representative from the sponsor or its designee 
will perform clinical study material accountability and reconciliation before clinical study 
materials are returned to the sponsor or its designee for destruction. The investigator will retain the 
original documentation regarding clinical study material accountability and return, copies (as 
required) will be sent to the sponsor or designee.
The investigator will be notified of any expiry date or retest date extension of clinical study 
material during the study conduct. On expiry date notification from the sponsor or designee, the 
site must complete all instructions outlined in the notification, including segregation of expired 
clinical study material for return to the sponsor or its designee for destruction.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 42 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
9.0
STUDY PLAN
9.1
Study Procedures
The following sections describe the study procedures and data to be collected. For each procedure, 
subjects are to be assessed by the same investigator or site personnel whenever possible. The 
Schedule of Study Procedures is located in Appendix A.
9.1.1
Informed Consent Procedure
The requirements of the informed consent are described in Section 15.2.
Informed consent must be obtained prior to the subject entering into the study, and before any 
protocol-directed procedures are performed.
A unique subject identification number (subject number) will be assigned to each subject at the 
time that informed consent is obtained this subject number will be used throughout the study.
9.1.2
Demographics, Medical History, and Medication History Procedure
Demographic information to be obtained will include: date of birth, sex, race as described by the 
subject, smoking status, history of use of alcohol and caffeine-containing drinks, history of 
H. pylori eradication therapy (eg, triple therapy with PPI + amoxicillin + clarithromycin), and date 
of completion of such therapy (within the past 1 year/more than 1 year) of the subject at Screening 
Period. 
Medical history to be obtained will include determining whether the subject has any significant 
conditions or diseases relevant to the disease under study that stopped at or prior to signing of 
informed consent. Ongoing conditions are considered concurrent medical conditions 
(see Section 9.1.9). Medical history will include the following:

EE.

Other upper gastrointestinal (GI) diseases including gastric ulcer, duodenal ulcer, nonerosive 
GERD, or procedures.
Medication history information to be obtained includes any medication relevant to eligibility 
criteria and efficacy/safety evaluation stopped at or within 90 days prior to signing of the informed 
consent form. Medication history will include the following:

PPIs.

H2RA.
9.1.3
Physical Examination Procedure
A baseline physical examination (defined as the pretreatment assessment immediately prior to the 
start of investigational drug) will consist of the following body systems: (1) eyes; (2) ears, nose, 
throat; (3) cardiovascular system; (4) respiratory system; (5) gastrointestinal system; 
(6) dermatologic system; (7) extremities; (8) musculoskeletal system; (9) nervous system; 


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 43 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
(10) lymph nodes; (11) other. All subsequent physical examinations should assess clinically 
significant changes from the baseline examination.
9.1.4
Weight, Height
A subject should have weight and height measured while wearing indoor clothing and with shoes 
off. Body mass index (BMI) is calculated by sponsor or its designee using metric units with the 
formula provided below. 
BMI = weight (kg)/height (m)2
9.1.5
Vital Sign Procedure
Vital sign measurements including body temperature (oral, tympanic or infra-axillary, in 
Centigrade), blood pressure (systolic and diastolic) and pulse (beats per minute) will be collected. 
Blood pressure and pulse will be measured while the subjects are in a sitting position after they 
have been seated for at least 5 minutes. Vital signs will be assessed at all time points specified in 
the Schedule of Study Procedures (Appendix A).
When vital signs are scheduled at the same time as blood draws, the blood draw will take priority 
and vital signs will be obtained within 0.5 hour before or after the scheduled blood withdrawal.
9.1.6
GERD Symptoms Investigator Assessment
Subjects will have a GERD symptom assessment performed by the investigator during the 
Screening Period (on Day -1), Weeks 4, and 8/Final Visit of the Healing Period and Months 1, 3, 
and 6/Final Visit of the Maintenance Period. The maximum severity of the GERD symptoms of 
heartburn, acid regurgitation, dysphagia, belching, and epigastric pain will be assessed by 
appropriate site personnel as either none, mild, moderate, severe, or very severe as defined below, 
during the 7 days prior to the subject’s study visit and recorded on the appropriate eCRF. The 
definitions for the symptoms being assessed are:

Heartburn: A burning feeling in the mid epigastric area and/or chest area.

Acid regurgitation: Flow of sour or bitter fluid into the mouth.

Dysphagia: Difficulty in swallowing.

Belching: The voiding of gas from the stomach through the mouth, which may be associated 
with acid regurgitation.

Epigastric pain: Central upper abdominal pain.

None: No symptoms.

Mild: Symptom does not last long and is easily tolerated.

Moderate: Symptom causes discomfort and/or interrupts usual activities (including sleep).

Severe: Symptom causes great interference with usual activities and may be incapacitating 
(including sleep).


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 44 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL

Very Severe: Symptom causes intense and constant discomfort and/or marked interference 
with usual activities (including sleep).
9.1.7
Daily Diary
Subjects will be given paper diaries on the first day of the Screening Period. Throughout the 
Screening Period, Healing Period, and Maintenance Period, subjects will document the presence 
and maximum severity of daytime and nighttime heartburn symptoms each day in their daily diary. 
Subjects will also record the use of rescue medication. If the subject experiences no heartburn on 
any given day, they should also provide this information. The daily diary should be completed 
every morning upon waking and every evening before bedtime. The last entry for the Healing 
Period is in the morning prior to their Week 8/Final Visit site visit. The last entry for the 
Maintenance Period is in the morning prior to the subject’s Month 6/Final Visit site visit.
The paper diaries will be collected and reviewed at subsequent visits. Subjects must return their 
daily dairies at every visit. The severity of heartburn will be graded by the subject according to the 
definitions outlined in Appendix G. Should paper diaries be lost or destroyed, the subject should 
contact the site immediately to receive additional diary pages to insure continuity of symptom 
reporting.
9.1.8
Documentation of Concomitant Medications
Concomitant medication is any drug given in addition to the study medication. These may be 
prescribed by a physician or obtained by the subject over the counter. Concomitant medication is 
not provided by Takeda. At each study visit, subjects will be asked whether they have taken any 
medication other than the study medication (used from signing of informed consent through the 
end of the study), and all medication including vitamin supplements, over-the-counter 
medications, and oral herbal preparations, must be recorded in the eCRF.
9.1.9
Documentation of Concurrent Medical Conditions
Concurrent medical conditions are those significant ongoing conditions or diseases that are present 
at signing of informed consent. This includes clinically significant laboratory, ECG, or physical 
examination abnormalities noted at screening/baseline examination. The condition (ie, diagnosis) 
should be described and assessed during subsequent site visits where physical examination is 
required.
9.1.10 Procedures for Clinical Laboratory Samples
All samples will be collected in accordance with acceptable laboratory procedures. The maximum 
volume of blood at any single visit is approximately 20 mL, and the approximate total volume of 
blood for the study is 140 mL. Details of these procedures and required safety monitoring will be 
given in the laboratory manual.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 45 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
Table 9.a
Clinical Laboratory Tests
Hematology
Serum Chemistry
Urinalysis
RBCs
WBCs with differential
Hemoglobin
Hematocrit
Platelets
ALT
AST
Alkaline phosphatase (ALP)
Albumin
Glucose (a)
Gastrin (a,b)
Total bilirubin
Total protein
Creatinine
Blood urea nitrogen (BUN)
Creatine kinase
γ-glutamyl transferase (GGT)
Lactate dehydrogenase (LDH)
Potassium
Sodium
Bicarbonate
Magnesium (c)
Calcium 
Phosphorus
Chloride
Serum iron
Uric acid
Total cholesterol
Triglycerides (a)
Vitamin B12
Specific gravity
pH
Protein
Ketones
Glucose
Bilirubin
RBC 
WBC
Other: H. Pylori serology screening visit only
Serum
Urine
hCG (if child-bearing potential)
FSH (if menopausal)
Hepatitis panel including: HBsAg, HCV-antibody (d)
Urine Pregnancy test (if child-bearing potential)
FSH=follicle-stimulating hormone, hCG=human chorionic gonadotropin, RBC=red blood cell, WBC=white blood 
cell.
(a) To be measured under fasting conditions except the Screening Visit (Day -21 to -2).
(b) Gastrin levels to be measured under fasting conditions. Gastrin levels will be blinded to both investigators and the 
medical monitor during the study period.
(c) If, at any time after enrollment into the study, a subject’s serum magnesium is less than or equal to 1.1 mEq/L 
(≤0.55 mmol/L), a 24-hour urine sample for magnesium will be collected to verify the serum chemistry result.
(d) To be measured either at the central laboratory or the local laboratory, depending on the site capability. 


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 46 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
The central laboratory will perform laboratory tests for hematology, serum chemistries, and 
urinalysis. The results of laboratory tests will be returned to the investigator, who is responsible for 
reviewing and filing these results.
The investigator is responsible for transcribing laboratory results which were conducted locally to 
the eCRF. The investigator will maintain a copy of the laboratory accreditation and the reference 
ranges for the laboratory used.
If subjects experience ALT or AST >3 ×ULN, follow-up laboratory tests (at a minimum, serum 
alkaline phosphatase, ALT, AST, total bilirubin, GGT, and INR) should be performed within a 
maximum of 7 days and preferably within 48 to 72 hours after the abnormality was found. (Please 
refer to Section 7.5 for discontinuation criteria, and Section 10.2.3 for the appropriate guidance on 
reporting of abnormal liver function tests in relation to ALT or AST >3 ×ULN in conjunction with 
total bilirubin >2 ×ULN.)
If the ALT or AST remains elevated >3 ×ULN on these 2 consecutive occasions the investigator 
must contact the Medical Monitor for consideration of additional testing, close monitoring, 
possible discontinuation of study medication, discussion of the relevant subject details and 
possible alternative etiologies. The abnormality should be recorded as an AE (please refer to 
Section 10.2.3 Reporting of Abnormal Liver Function Tests for reporting requirements).
Given the possibility that the use of dexlansoprazole or lansoprazole may be associated with 
increases in serum gastrin, the subjects will be examined for gastrin to investigate the magnitude of 
these increases during the Treatment Phase. Gastrin levels will be blinded to both investigators and 
the medical monitor during the study period.
The screening clinical laboratory, including hepatitis panel, must be performed within 14 days 
prior to randomization. 
Screening laboratory results from the TAK-390MR_302 study performed in the same institution 
can be accepted as screening laboratory results in TAK-390MR_301 study, on a case-by-case 
basis, given the burden of frequent blood draws in a short period of time. The investigator must 
contact the medical monitor for a discussion of the relevant subject details before subject's 
randomization.
9.1.11 Contraception and Pregnancy Avoidance Procedure
From signing of the ICF throughout the duration of the study and for 30 days after last dose of 
study drug, nonsterilized** male subjects who are sexually active with women of childbearing 
potential* must use double-barrier contraception (eg, condom with spermicidal cream or jelly). In 
addition, they must be advised not to donate sperm during this period.
From the signing of the informed consent, throughout the duration of the study, and for 30 days 
after last dose of study medication, women of childbearing potential* who are sexually active with 
nonsterilized men** must use adequate contraception. In addition they must be advised not to 
donate ova during this period.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 47 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
*Women NOT of childbearing potential are defined as those who have been surgically sterilized 
(hysterectomy, bilateral oophorectomy, or tubal ligation) or who are postmenopausal (eg, defined 
as at least 1 year since last regular menses with an FSH>40 IU/L or at least 5 years since last 
regular menses, confirmed before any study medication is implemented).
**Sterilized men should be at least 1 year postvasectomy and have confirmed that they have 
obtained documentation of the absence of sperm in the ejaculate.
An acceptable method of contraception is defined as one that has no higher than a 1% failure rate. 
In this study, where medications and devices containing hormones are included, the only 
acceptable methods of contraception are:
Barrier methods (each time the 
subject has intercourse) where 
applicable*:
Intrauterine devices 
(IUDs):
Hormonal contraceptives:

Cap (plus spermicidal cream or 
jelly) PLUS male condom and 
spermicide.

Diaphragm (plus spermicidal 
cream or jelly) PLUS male 
condom and spermicide.

Copper T PLUS condom 
or spermicide.

Progesterone T PLUS 
condom or spermicide.

Implants.

Hormone shot/injection.

Combined pill.

Minipill.

Patch.

Vaginal ring PLUS male 
condom and spermicide.
*Barrier methods is only applicable in countries where spermicide is commercially available.
Subjects will be provided with information on acceptable methods of contraception as part of the 
subject informed consent process and will be asked to sign a consent form stating that they 
understand the requirements for avoidance of pregnancy, donation of ova, and sperm donation 
during the course of the study.
During the course of the study, regular hCG pregnancy tests will be performed only for women of 
childbearing potential and subjects will receive continued guidance with respect to the avoidance 
of pregnancy and sperm donation as part of the study procedures (Appendix A). In addition to a 
negative serum and urine hCG pregnancy test at Screening, subjects also must have a negative 
serum and urine hCG pregnancy test at Day -1.
9.1.12 Pregnancy
If any subject is found to be pregnant during the study she should be withdrawn and any 
sponsor-supplied drug (dexlansoprazole 30, 60 mg, lansoprazole 30 mg, and matching placebo) 
should be discontinued immediately. In addition, any pregnancies in the partner of a male subject 
during the study or for 30 days after the last dose should be recorded following authorization from 
the subject’s partner. 


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 48 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
If the pregnancy occurs during administration of active study medication, eg, after Visit 2 or within 
30 days of the last dose of active study medication, the pregnancy should be reported immediately, 
using a pregnancy notification form, to the contact listed in Section 1.0.
Should the pregnancy occur during or after administration of blinded drug, the investigator must 
inform the subject of their right to receive treatment. If the subject chooses to receive unblinded 
treatment information, the individual blind should be broken by the investigator. Subjects 
randomized to placebo need not be followed.
If the woman subject and/or woman partner of a man who is a subject agrees to the primary care 
physician being informed, the investigator should notify the primary care physician that the 
subject/woman partner of the subject was participating in a clinical study at the time she became 
pregnant and provide details of treatment the subject received (blinded or unblinded, as 
applicable).
All reported pregnancies will be followed up to final outcome using the pregnancy form. The 
outcome, including any premature termination, must be reported to the sponsor. An evaluation 
after the birth of the child will also be conducted.
9.1.13 ECG Procedure
A standard 12-lead ECG will be recorded. The investigator (or a qualified observer at the 
investigational site) will interpret the ECG using 1 of the following categories: within normal 
limits, abnormal but not clinically significant, or abnormal and clinically significant. 
The time that the ECG was performed will be recorded. The following parameters will be recorded 
on the eCRF from the subject’s ECG tracing: heart rate, RR interval, PR interval, QT interval, and 
QRS interval. 
As ECG tracings on thermal paper fade over time, any such tracings should be completely 
photocopied and both the original tracing and the counter-signed copy should be filed in the 
subject’s medical record. 
9.1.14 Documentation of Screen Failure
Investigators must account for all subjects who sign informed consent. If the subject is found to be 
not eligible at this visit, the investigator should complete the eCRF. 
The IWRS should be contacted as a notification of screen failure.
The primary reason for screen failure is recorded in the eCRF using the following categories:

Pretreatment event/AE.

Did not meet inclusion criteria or did meet exclusion criteria.

Significant protocol deviation.

Lost to follow-up.

Voluntary withdrawal.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 49 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL

Study termination.

Other.
Subject numbers assigned to subjects who fail screening should not be reused.
9.1.15 Documentation of Study Randomization
Only subjects who meet all of the inclusion criteria and none of the exclusion criteria are eligible 
for randomization into the Healing Period.
If the subject is found to be not eligible for randomization, the investigator should record the 
primary reason for failure on the applicable eCRF.
All screening procedures and test must be reviewed prior to randomization. Subjects who meet all 
the inclusion and none of the exclusion criteria will be randomized into the Healing Period via 
IWRS.
Subject with healed EE at the end of the Healing Period will be randomized again via the IWRS for 
the subsequent Maintenance Period.
Instructions on accessing and using the IWRS will be provided in a separate manual. Blinded 
details of subject treatment allocation (medication ID numbers) provided via the IWRS should be 
documented in the subject’s medical record and/or eCRF.
9.1.16 Endoscopy
Endoscopy should be performed while subjects are fasted and according to the usual practice of the 
institution (ie, with regard to premedications or concomitant therapies, as long as they are not 
prohibited in Section 7.3 of this protocol).
The investigator (or designee) will record the results of endoscopy (including results of the LA 
classification and other gradings) performed promptly in the subject’s medical record. 
To ensure the accuracy of the EE evaluation according to LA grading, a 2nd review process of the 
endoscopic images will be established at each site. The 1st reviewer, ie, the endoscopist should take 
sufficient images or videotape the process at each endoscopic examination. The 2nd reviewer will 
evaluate the EE LA grading according to the endoscopic images. 

Preferably, the principal investigator performs as the 2nd reviewer and conducts the 2nd 
review in a timely manner after the endoscopy is performed by the 1st reviewer who is a 
subinvestigator in this study. 

In cases where the principal investigator is the 1st reviewer, a subinvestigator at the same site 
can be delegated as the 2nd reviewer and conducts the 2nd review in a timely manner.

Only investigators (either principal investigators or subinvestigators) can be delegated as the 
2nd reviewer. 


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 50 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
If the LA grading by the 2 reviewers are consistent, this result becomes the final report. If not, the 
2 reviewers will discuss their findings and reach a consensus which will then become the final 
report.
During Screening and at Week 8/Final Visit of the Healing Period, an endoscopy will be 
performed on all subjects to document the presence/absence of EE. Erosive esophagitis will be 
graded according to the LA Classification of Esophagitis Grading System (Appendix E). 
The screening endoscopy must be performed within 14 days prior to randomization. Any reliable, 
documented results available from an endoscopy performed in a routine clinical setting (before 
signing of informed consent) within 14 days prior to randomization in the same institution will be 
accepted instead, given the invasive nature of the procedure.
Any Barrett’s esophagus seen during screening endoscopy will exclude the subject from study. 
These endoscopic assessments will be recorded on the eCRF and a copy of the results should be 
kept with the subject’s notes.
If a subject has endoscopically confirmed healing of EE at Week 8, they will be randomized into 
the Maintenance Period. During the Maintenance Period, endoscopies will be performed at 
Months 1 and 6/Final Visit to evaluate maintenance of healed EE. Subjects with endoscopic 
evidence of relapsed EE will be discontinued from the study.
Subjects who prematurely discontinue the study during the Maintenance Period should undergo 
Month 6 / Early Termination procedures no later than 5 days after the last dose of study drug, 
including the endoscopy.
Digital images of the current esophageal erosions should be captured and stored at the 
investigational site; images may be accessed by Takeda as necessary for quality assurance 
purpose. 
9.2
Monitoring Subject Treatment Compliance
Subjects will be required to bring study medication containers and unused medications to each 
dispensing site visit and final visit. Investigators or designee should perform subject treatment 
compliance checks by reviewing the subject’s diary and returned medications.
If a subject is persistently noncompliant with the study medication [dexlansoprazole 30, 60 mg, 
lansoprazole 30 mg, or placebo] (eg, at more than 2 consecutive compliance checks to have taken 
less than 80% or more than 120% of the study medication). The subject should be withdrawn from 
the study. At each applicable study visit it should be documented in the subject’s medical record 
that study medication was dispensed or collected, and/or checked for compliance. All subjects 
should be reinstructed about the dosing requirement during study contacts. The authorized study 
personnel conducting the re-education must document the process in the subject source records.
9.3
Schedule of Observations and Procedures
The schedule for all study-related procedures for all evaluations is shown in Appendix A.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 51 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
9.3.1
Screening 
Subjects will be screened within 21 days prior to randomization. Subjects will be screened in 
accordance with predefined inclusion and exclusion criteria as described in Section 7.0. See 
Section 9.1.14 for procedures for documenting screening failures.
The screening clinical laboratory tests, hepatitis panel, and endoscopy must be performed within 
14 days prior to randomization.
Any reliable, documented results available from an endoscopy performed in a routine clinical 
setting (before signing of informed consent) in the same institution will be accepted instead, given 
the invasive nature of the procedure.
Screening laboratory results from the TAK-390MR_302 study performed in the same institution 
can be accepted as a screening laboratory results in TAK-390MR_301 study, on a case-by-case 
basis, given the burden of frequent blood draws in a short period of time. The investigator must 
contact the medical monitor for a discussion of the relevant subject details before subject's 
randomization.
Procedures to be Completed During the Screening Period (Days -21 to -2) include:

Informed consent.

Demographics, medical, and social history.

Medication history.

Physical examination.

Vital signs.

Weight and height.

Concomitant medication(s).

Concurrent medical condition(s).

Pretreatment events assessment.

Prescribe rescue medication and give the medical instruction, as necessary.

Screening clinical laboratory tests and hematology (to be performed within 14 days prior to 
randomization).

Urinalysis.

Serum and urine hCG (women of childbearing potential only).

FSH (only performed if menopause is suspected).

Guidance on the avoidance of pregnancy.

Instructions on how to make entries in the subject diary, provision of the diary, and 
commencement of diary entry.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 52 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL

ECG.

Hepatitis panel including HBsAg and HCV-antibody (to be performed within 14 days prior to 
randomization).

Endoscopy (to be performed within 14 days prior to randomization).
9.3.2
Study Randomization 
Study randomization will take place on Day -1. The following procedures will be performed and 
documented during study randomization:

Physical exam.

Vitals signs.

Weight.

Clinical laboratory tests (subjects should be fasting for a minimum of 8 hours prior to all labs) 
to include:
–
Urine and serum hCG (baseline serum pregnancy test will not be needed if the screening 
pregnancy test is within 14 days of baseline).
–
Fasting gastrin.

GERD symptoms investigator assessment.

Daily diary review/dispense new diary pages.

Concomitant medication(s).

Pretreatment events assessment.

IWRS randomization.

Dispense study medication via IWRS.
If the subject has satisfied all of the inclusion criteria and none of the exclusion criteria for 
randomization, the subject should be randomized using the IWRS system, as described in 
Section 8.2. Subjects will be instructed on when to take the first dose of investigational drug as 
described in Section 6.1. The procedure for documenting Screening failures is provided in 
Section 9.1.14.
9.3.3
Healing Period
9.3.3.1
Day 1

Begin study medication.

Complete daily diary.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 53 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
9.3.3.2
Week 4 Visit (±3Days)
Procedures to be completed at Week 4 Visit include:

Physical examination.

GERD symptoms investigator assessment.

Vital signs.

Weight.

AE assessment.

Concomitant medication(s).

Clinical laboratory tests (subjects should be fasting for a minimum of 8 hours prior to all labs) 
to include:
–
Chemistry panel and hematology.
–
Urine hCG.
–
Urinalysis.

Daily diary review/dispense new diary pages.

Dispense study medication via IWRS.

Return of study medication.

Study drug compliance and accountability.
9.3.3.3
Week 8/Final Visit (±3Days)
Procedures to be completed at Week 8/Final Visit include:

Physical examination.

GERD symptoms investigator assessment.

Vital signs.

Weight.

AE assessment.

Concomitant medication(s).

Clinical laboratory tests (subjects should be fasting for a minimum of 8 hours prior to all labs) 
to include:
–
Chemistry panel and hematology.
–
Serum and urine hCG.
–
Urinalysis.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 54 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
–
Fasting gastrin.

Daily diary review.

Return of all study medication for healing period and instruct the subject NOT to take them 
anymore if the medication is not returned for any special reason(s).

Study drug compliance and accountability.

ECG.

Endoscopy.
9.3.4
Maintenance Period
Subjects at Week 8 of the Healing Period who have endoscopically confirmed healing of EE will 
be randomized into the Maintenance Period. Week 8 Visit procedures will be considered Day -1 
assessments for the Maintenance Period.
9.3.4.1
Day -1

IWRS randomization.

Dispense study medication via IWRS.

Dispense daily diary.
9.3.4.2
Day 1

Begin study medication for Maintenance Period.

Complete daily diary.
9.3.4.3
Month 1 (±7Days)
Procedures to be completed at Month 1 Visit include:

Physical examination.

GERD symptoms investigator assessment.

Vital signs.

Weight.

AE assessment.

Concomitant medication(s).

Clinical laboratory tests (subjects should be fasting for a minimum of 8 hours prior to all labs) 
to include:
–
Chemistry panel and hematology.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 55 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
–
Urine hCG.
–
Urinalysis.

Daily diary review/dispense.

Dispense study medication via IWRS.

Return of study medication.

Study drug compliance and accountability.

Endoscopy.
9.3.4.4
Month 3 (±7Days)
Procedures to be completed at Month 3 Visit include:

Physical examination.

GERD symptoms investigator assessment.

Vital signs.

Weight.

AE assessment.

Concomitant medication(s).

Clinical laboratory tests (subjects should be fasting for a minimum of 8 hours prior to all labs) 
to include:
–
Chemistry panel and hematology.
–
Urine hCG.
–
Urinalysis.

Daily diary review/dispense new diary pages.

Dispense study medication via IWRS.

Return of study medication.

Study drug compliance and accountability.

An optional endoscopy may be performed based on investigator discretion if subject presents 
with GERD symptoms.
9.3.5
Final Visit or Early Termination
The Final Visit will be performed at the 6 Month Visit. The following procedures will be 
performed and documented:

Physical examination.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 56 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL

GERD symptoms investigator assessment.

Vital signs.

Weight.

AE assessment. 

Concomitant medication(s).

Clinical laboratory tests (subjects should be fasting for a minimum of 8 hours prior to all labs) 
to include:
–
Chemistry panel and hematology.
–
Serum and urine hCG.
–
Urinalysis.
–
Fasting gastrin.

Daily diary review.

Return of study medication.

Study drug compliance and accountability.

Endoscopy.
For all subjects receiving study medication, the investigator must complete the End of Study eCRF 
page.
9.3.6
Unscheduled Visit
An unscheduled visit may occur when the subject returns to the clinic at any time during the 
Healing or Maintenance Period of the study for the evaluation of symptoms or side effects.
At minimum, the following procedures are to be completed with additional procedures at the 
investigator’s discretion:

Physical examination.

GERD symptoms investigator assessment.

Vital signs.

Weight.

AE assessment.

Concomitant medication(s).

Fasting gastrin.

Endoscopy.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 57 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
9.3.7
Follow-up
The study center staff will follow up with a phone call 5 to 10 days post-treatment and any new 
AEs will be recorded in the eCRFs and subject’s source documents. Follow-up will begin the first 
day after the Final Visit/Early Termination and will continue until 10 days post treatment.
9.3.8
Post Study Care
The study medication will not be available upon completion of the subject’s participation in the 
study. The subject should be returned to the care of a physician and standard therapies as required.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 58 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
10.0
PRETREATMENT EVENTS AND ADVERSE EVENTS 
10.1
Definitions
10.1.1 Pretreatment Events
A PTE is defined as any untoward medical occurrence in a clinical investigation subject who has 
signed informed consent to participate in a study but prior to administration of any study 
medication; it does not necessarily have to have a causal relationship with study participation.
10.1.2 AEs
An AE is defined as any untoward medical occurrence in a clinical investigation subject 
administered a drug; it does not necessarily have to have a causal relationship with this treatment.
An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal 
laboratory finding), symptom, or disease temporally associated with the use of a drug whether or 
not it is considered related to the drug.
10.1.3 Additional Points to Consider for PTEs and AEs
An untoward finding generally may:

Indicate a new diagnosis or unexpected worsening of a pre-existing condition. (Intermittent 
events for pre existing conditions underlying disease should not be considered PTEs or AEs.)

Necessitate therapeutic intervention.

Require an invasive diagnostic procedure.

Require discontinuation or a change in dose of study medication or a concomitant medication.

Be considered unfavorable by the investigator for any reason.

PTEs/AEs caused by a study procedure (eg, a bruise after blood draw) should be recorded as a 
PTE/AE.
Diagnoses vs signs and symptoms:

Each event should be recorded to represent a single diagnosis. Accompanying signs (including 
abnormal laboratory values or ECG findings) or symptoms should NOT be recorded as 
additional AEs. If a diagnosis is unknown, sign(s) or symptom(s) should be recorded 
appropriately as a PTE(s) or as an AE(s).
Laboratory values and ECG findings:

Changes in laboratory values or ECG parameters are only considered to be PTEs or AEs if they 
are judged to be clinically significant (ie, if some action or intervention is required or if the 
investigator judges the change to be beyond the range of normal physiologic fluctuation). A 
laboratory retest and/or continued monitoring of an abnormal value are not considered an 


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 59 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
intervention. In addition, repeated or additional noninvasive testing for verification, evaluation 
or monitoring of an abnormality is not considered an intervention.

If abnormal laboratory values or ECG findings are the result of pathology for which there is an 
overall diagnosis (eg, increased creatinine in renal failure), the diagnosis only should be 
reported appropriately as a PTE or as an AE.
Pre-existing conditions:

Pre-existing conditions (present at the time of signing of informed consent) are considered 
concurrent medical conditions and should NOT be recorded as PTEs or AEs. Baseline 
evaluations (eg, laboratory tests, ECG, X-rays) should NOT be recorded as PTEs unless 
related to study procedures. However, if the subject experiences a worsening or complication 
of such a concurrent condition, the worsening or complication should be recorded 
appropriately as a PTE (worsening or complication occurs before start of study medication) or 
an AE (worsening or complication occurs after start of study medication). Investigators should 
ensure that the event term recorded captures the change in the condition (eg, “worsening 
of…”).

If a subject has a pre-existing episodic condition (eg, asthma, epilepsy) any occurrence of an 
episode should only be captured as a PTE/AE if the episodes become more frequent, serious or 
severe in nature, that is, investigators should ensure that the AE term recorded captures the 
change in the condition from Baseline (eg, “worsening of…”).

If a subject has a degenerative concurrent condition (eg, cataracts, rheumatoid arthritis),
worsening of the condition should only be captured as a PTE/AE if occurring to a greater 
extent to that which would be expected. Again, investigators should ensure that the AE term 
recorded captures the change in the condition (eg, “worsening of…”).
Worsening of PTEs or AEs:

If the subject experiences a worsening or complication of a PTE after starting administration of 
the study medication, the worsening or complication should be recorded appropriately as an 
AE. Investigators should ensure that the AE term recorded captures the change in the condition 
(eg, “worsening of…”).

If the subject experiences a worsening or complication of an AE after any change in study 
medication, the worsening or complication should be recorded as a new AE. Investigators 
should ensure that the AE term recorded captures the change in the condition (eg, “worsening 
of…”).
Changes in severity of AEs/PTEs:

If the subject experiences changes in severity of AEs/PTE, the event should be captured once 
with the maximum severity recorded.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 60 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
Preplanned surgeries or procedures:

Preplanned procedures (surgeries or therapies) that were scheduled prior to signing of 
informed consent are not considered PTEs or AEs. However, if a preplanned procedure is 
performed early (eg, as an emergency) due to a worsening of the pre-existing condition, the 
worsening of the condition should be captured appropriately as a PTE or an AE. Complications 
resulting from any planned surgery should be reported as AEs.
Elective surgeries or procedures:

Elective procedures performed where there is no change in the subject’s medical condition 
should not be recorded as PTEs or AEs, but should be documented in the subject’s source 
documents. Complications resulting from an elective surgery should be reported as AEs.
Insufficient clinical response (lack of efficacy):

Insufficient clinical response, efficacy, or pharmacologic action, should NOT be recorded as 
an AE. The principal investigator must make the distinction between exacerbation of 
pre-existing illness and lack of therapeutic efficacy.
Overdose:

Cases of overdose with any medication without manifested side effects are NOT considered 
PTEs or AEs, but instead will be documented on an Overdose page of the eCRF. Any 
manifested side effects will be considered PTEs or AEs and will be recorded on the AE page of 
the eCRF.
10.1.4 SAEs
An SAE is defined as any untoward medical occurrence that at any dose:
1. Results in death.
2. Is LIFE THREATENING.

The term “life threatening” refers to an event in which the subject was at risk of death at the 
time of the event; it does not refer to an event that hypothetically might have caused death 
if it were more severe.
3. Requires inpatient HOSPITALIZATION or prolongation of existing hospitalization.
4. Results in persistent or significant DISABILITY/INCAPACITY.
5. Is a CONGENITAL ANOMALY/BIRTH DEFECT.
6. Is an IMPORTANT MEDICAL EVENT that satisfies any of the following:

May require intervention to prevent items 1 through 5 above.

May expose the subject to danger, even though the event is not immediately life 
threatening or fatal or does not result in hospitalization.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 61 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL

Includes any event or synonym described in the Takeda Medically Significant AE List 
(Table 10.a).
Table 10.a
Takeda Medically Significant AE List 
Term
Acute respiratory failure/acute respiratory distress 
syndrome
Hepatic necrosis
Torsade de pointes / ventricular fibrillation / ventricular 
tachycardia
Acute liver failure
Anaphylactic shock
Malignant hypertension
Acute renal failure
Convulsive seizures
Pulmonary hypertension
Agranulocytosis
Pulmonary fibrosis
Aplastic anemia
Confirmed or suspected endotoxin shock
Toxic epidermal necrolysis/Stevens-Johnson syndrome Confirmed or suspected transmission of infectious agent by a 
medicinal product
Neuroleptic malignant syndrome / malignant hyperthermia
Spontaneous abortion / stillbirth and fetal death
PTEs that fulfill 1 or more of the serious criteria above are also to be considered SAEs and should 
be reported and followed up in the same manner (see Sections 10.2.2 and 10.3).
10.1.5 Severity of PTEs and AEs
The different categories of intensity (severity) are characterized as follows:
Mild:
The event is transient and easily tolerated by the subject.
Moderate:
The event causes the subject discomfort and interrupts the subject’s usual activities.
Severe:
The event causes considerable interference with the subject’s usual activities.
10.1.6 Causality of AEs
The relationship of each AE to study medication(s) will be assessed using the following 
categories:
Related:
An AE that follows a reasonable temporal sequence from administration of a drug (including the 
course after withdrawal of the drug), or for which possible involvement of the drug can be 
argued, although factors other than the drug, such as underlying diseases, complications, 
concomitant drugs and concurrent treatments, may also be responsible.
Not related:
An AE that does not follow a reasonable temporal sequence from administration of a drug and/or 
that can reasonably be explained by other factors, such as underlying diseases, complications, 
concomitant drugs and concurrent treatments.
10.1.7 Relationship to Study Procedures
Relationship (causality) to study procedures should be determined for all PTEs and AEs.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 62 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
The relationship should be assessed as “Related” if the investigator considers that there is 
reasonable possibility that an event is due to a study procedure. Otherwise, the relationship should 
be assessed as “Not related.”
10.1.8 Start Date 
The start date of the AE/PTE is the date that the first signs/symptoms were noted by the subject 
and/or physician.
10.1.9
Stop Date 
The stop date of the AE/ PTE is the date at which the subject recovered, the event resolved but with 
sequelae or the subject died.
10.1.10
Frequency 
Episodic AEs/ PTE (eg, vomiting) or those which occur repeatedly over a period of consecutive 
days are intermittent. All other events are continuous.
10.1.11
Action Concerning Study Medication 

Drug withdrawn – a study medication is stopped due to the particular AE.

Dose not changed – the particular AE did not require stopping a study medication.

Unknown – only to be used if it has not been possible to determine what action has been taken.

Not applicable – a study medication was stopped for a reason other than the particular AE eg, 
the study has been terminated, the subject died, dosing with study medication was already 
stopped before the onset of the AE.

Dose reduced – the dose was reduced due to the particular AE

Dose Interrupted - The study medication was temporarily interrupted (discontinued) (including 
voluntary drug interruption by the subject) due to the particular AE, and resumed at a later 
date.
10.1.12
Outcome 

Recovered/resolved – Subject returned to first assessment status with respect to the AEs/PTE.

Recovering/resolving – the intensity is lowered by one or more stages: the diagnosis or 
signs/symptoms has almost disappeared; the abnormal laboratory value improved, but has not 
returned to the normal range or to Baseline; the subject died from a cause other than the 
particular AEs/PTE with the condition remaining “recovering/resolving.”

Not recovered/not resolved – there is no change in the diagnosis, signs or symptoms; the 
intensity of the diagnosis, signs/ symptoms or laboratory value on the last day of the observed 
study period has got worse than when it started; is an irreversible congenital anomaly; the 


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 63 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
subject died from another cause with the particular AEs/PTE state remaining “Not 
recovered/not resolved.”

Resolved with sequelae – the subject recovered from an acute AEs/PTE but was left with 
permanent/significant impairment (eg, recovered from a cardiovascular accident but with 
some persisting paresis.

Fatal – the AEs/PTEs which are considered as the cause of death.

Unknown – the course of the AEs/PTE cannot be followed up due to hospital change or 
residence change at the end of the subject’s participation in the study.
10.2
Procedures
10.2.1 Collection and Reporting of AEs
10.2.1.1 PTE and AE Collection Period
Collection of PTEs will commence from the time the subject signs the informed consent to 
participate in the study and continue until the subject is first administered study medication or until 
screen failure. For subjects who discontinue prior to study medication administration, PTEs are 
collected until the subject discontinues study participation.
Collection of AEs will commence from the time that the subject is first administered study 
medication. Routine collection of AEs will continue until the Final Visit or Early Termination. A 
follow-up phone call will be made to each subject 5 to 10 days following the last dose of study 
drug to collect any AEs that may have occurred.
The stop date of the AEs/PTE is the date at which the subject recovered, the event resolved but 
with sequelae or the subject died.
10.2.1.2 PTE and AE Reporting
At each study visit, the investigator will assess whether any subjective AEs have occurred. A 
neutral question, such as “How have you been feeling since your last visit?” may be asked. 
Subjects may report AEs occurring at any other time during the study. Subjects experiencing a 
PTE must be monitored until the symptoms subside and any clinically relevant changes in 
laboratory values have returned to Baseline or there is a satisfactory explanation for the change. 
Nonserious PTEs, related or unrelated to the study procedure, need not to be followed-up for the 
purposes of the protocol.
All subjects experiencing AEs, whether considered associated with the use of the study medication 
or not, must be monitored until the symptoms subside and any clinically relevant changes in 
laboratory values have returned to Baseline or until there is a satisfactory explanation for the 
changes observed. All clinically significant laboratory abnormality that has been verified by 
retesting will be followed until the abnormality returns to an acceptable level or a satisfactory 
explanation has been obtained. All PTEs and AEs will be documented in the PTE/AE page of the 


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 64 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
eCRF, whether or not the investigator concludes that the event is related to the drug treatment. The 
following information will be documented for each event:

Event term.

Start and stop date and time.

Severity.

Investigator’s opinion of the causal relationship between the event and administration of study 
medication(s) (related or not related) (not completed for PTEs).

Investigator’s opinion of the causal relationship to study procedure(s), including the details of 
the suspected procedure.

Action concerning study medication (not applicable for PTEs).

Outcome of event.

Seriousness.
Subject diary and questionnaire will not be used as a primary means to collect AEs. However, 
should the investigator become aware of a potential AE through the information collected with this 
instrument, proper follow-up with the patient for medical evaluation should be undertaken. 
Through this follow-up if it is determined that an AE not previously reported has been identified, 
normal reporting requirements should be applied.
10.2.2 Collection and Reporting of SAEs
When an SAE occurs through the AE collection period it should be reported according to the 
following procedure:
A Takeda SAE form must be completed, in English, and signed by the investigator immediately or 
within 24 hours of first onset or notification of the event. The information should be completed as 
fully as possible but contain, at a minimum:

A short description of the event and the reason why the event is categorized as serious.

Subject identification number.

Investigator’s name.

Name of the study medication(s).

Causality assessment.
The SAE form should be transmitted within 24 hours to the attention of the contact listed in 
Section 1.1.
Any SAE spontaneously reported to the investigator following the AE collection period should be 
reported to the sponsor if considered related to study participation.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 65 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
Also, investigators should report any SAE in appropriate format (ie, locally required form) to 
related authorities, IRB/IECs in accordance with local GCP and/or local regulations.
Reporting of Serious PTEs will follow the procedure described for SAEs.
10.2.3 Reporting of Abnormal Liver Function Tests 
If a subject is noted to have ALT or AST elevated >3 ×ULN on 2 consecutive occasions, the 
abnormality should be recorded as an AE. In addition, an LFT Increases eCRF must be completed 
providing additional information on relevant recent history, risk factors, clinical signs and 
symptoms and results of any additional diagnostic tests performed.
If during the treatment or follow up period a subject is noted to have ALT or AST >3 ×ULN and
total bilirubin >2 ×ULN for which an alternative etiology has not been identified, the event should 
be recorded as an SAE and reported as per Section 10.2.2. The investigator must contact the 
Medical Monitor for discussion of the relevant subject details and possible alternative etiologies, 
such as acute viral hepatitis A or B or other acute liver disease. Follow-up laboratory tests as 
described in Section 9.1.10 must also be performed. In addition, an LFT Increases eCRF must be 
completed and transmitted with the Takeda SAE form (as per Section 10.2.2).
10.3
Follow-up of SAEs
If information not available at the time of the first report becomes available at a later date, the 
investigator should complete a follow-up SAE form or provide other written documentation and 
fax it immediately within 24 hours of receipt. Copies of any relevant data from the hospital notes 
(eg, ECGs, laboratory tests, discharge summary, postmortem results) should be sent to the 
addressee, if requested.
All SAEs should be followed up until resolution or permanent outcome of the event. The timelines 
and procedure for follow-up reports are the same as those for the initial report.
10.3.1 Safety Reporting to Investigators, IRBs or IECs, and Regulatory Authorities
The sponsor will be responsible for reporting all suspected unexpected serious adverse reactions 
(SUSARs) and any other applicable SAEs to regulatory authorities, investigators and IRBs or 
IECs, as applicable, in accordance with national regulations in the countries where the study is 
conducted. Relative to the first awareness of the event by/or further provision to the sponsor or 
sponsor’s designee, SUSARs will be submitted within 7 days for fatal and life-threatening events 
and 15 days for other serious events, unless otherwise required by national regulations. The 
sponsor will also prepare an expedited report for other safety issues where these might materially 
alter the current benefit-risk assessment of an investigational medicinal product or that would be 
sufficient to consider changes in the investigational medicinal products administration or in the 
overall conduct of the trial. The investigational site also will forward a copy of all expedited 
reports to his or her IRB or IEC in accordance with national regulations.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 66 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
11.0
STUDY-SPECIFIC COMMITTEES
No steering committee, data safety monitoring committee, or clinical endpoint committee will be 
used in this study.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 67 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
12.0
DATA HANDLING AND RECORDKEEPING
The full details of procedures for data handling will be documented in the Data Management Plan. 
AEs, PTEs, medical history, and concurrent conditions will be coded using the Medical Dictionary 
for Regulatory Activities (MedDRA). Drugs will be coded using the World Health Organization 
Drug Dictionary (WHODRUG).
12.1
eCRF 
Completed eCRFs are required for each subject who signs an informed consent.
The sponsor or its designee will supply investigative sites with access to eCRFs. The sponsor will 
make arrangements to train appropriate site staff in the use of the eCRF. These forms are used to 
transmit the information collected in the performance of this study to the sponsor and regulatory 
authorities. eCRFs must be completed in English. Data are entered directly onto eCRFs.
After completion of the entry process, computer logic checks will be run to identify items, such as 
inconsistent dates, missing data, and questionable values. Queries may be issued by Takeda 
personnel (or designees) and will be answered by the site. 
Corrections are recorded in an audit trail that captures the old information, the new information, 
identification of the person making the correction, the date of the correction was made and the 
reason for change. Reasons for significant corrections should additionally be included. 
The principal investigator must review the eCRFs for completeness and accuracy and must sign 
and date the appropriate eCRFs as indicated. Furthermore, the investigator must retain full 
responsibility for the accuracy and authenticity of all data entered on the eCRFs.
eCRFs will be reviewed for completeness and acceptability at the study site during periodic visits 
by study monitors. The sponsor or its designee will be permitted to review the subject’s medical 
and hospital records pertinent to the study to ensure accuracy of the eCRFs. The completed eCRFs 
are the sole property of the sponsor and should not be made available in any form to third parties, 
except for authorized representatives of appropriate governmental health or regulatory authorities, 
without written permission of the sponsor. 
12.2
Record Retention
The investigator agrees to keep the records stipulated in Section 12.1 and those documents that 
include (but are not limited to) the study-specific documents, the identification log of all 
participating subjects, medical records, temporary media such as thermal sensitive paper should be 
copied and certified, source worksheets, all original signed and dated informed consent forms, 
subject authorization forms regarding the use of personal health information (if separate from the 
informed consent forms), electronic copy of eCRFs, including the audit trail, and detailed records 
of drug disposition to enable evaluations or audits from regulatory authorities, the sponsor or its 
designees. Furthermore, International Conference on Harmonisation (ICH) E6 Section 4.9.5 
requires the investigator to retain essential documents specified in ICH E6 (Section 8) until at least 
2 years after the last approval of a marketing application for a specified drug indication being 
investigated or, if an application is not approved, until at least 2 years after the investigation is 


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 68 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
discontinued and regulatory authorities are notified. In addition, ICH E6 Section 4.9.5 states that 
the study records should be retained until an amount of time specified by applicable regulatory 
requirements or for a time specified in the Clinical Study Site Agreement between the investigator 
and sponsor.
Refer to the Clinical Study Site Agreement for the sponsor’s requirements on record retention. The 
investigator should contact and receive written approval from the sponsor before disposing of any 
such documents.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 69 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
13.0
STATISTICAL METHODS
13.1
Statistical and Analytical Plans
A statistical analysis plan (SAP) will be prepared and finalized prior to unblinding of subject’s 
treatment assignment. This document will provide further details regarding the definition of 
analysis variables and analysis methodology to address all study objectives. 
A blinded data review will be conducted prior to unblinding of subject’s treatment assignment. 
This review will assess the accuracy and completeness of the study database, subject evaluability, 
and appropriateness of the planned statistical methods.
13.1.1 Analysis Sets
The full analysis set (FAS) will be defined separately for the Healing and Maintenance Periods. 
The full analysis set for the Healing Period (FAS – H) will include all randomized subjects who 
have documented EE at screening and receive at least 1 dose of study drug during the first 8 weeks 
of treatment. The full analysis set for the Maintenance Period (FAS – M) will include all subjects 
with healed EE by week 8 who are randomized and receive at least 1 dose of study drug during 
6 months of maintenance treatment.
The safety analysis set will be defined separately for the healing period and for the Maintenance 
Period. The safety analysis set for the Healing Period (Safety Set – H) will include all subjects who 
receive at least 1 dose of study drug during Healing Period. The safety analysis set for the 
Maintenance Period (Safety Set – M) will include all subjects with healed EE by Week 8 who are 
randomized and receive at least 1 dose of study drug during 6 months of maintenance treatment.
13.1.2 Analysis of Demographics and Other Baseline Characteristics
Demographic and baseline variables will be summarized using the safety analysis set and analyzed 
to assess the comparability of the treatment groups provided by randomization. Summary statistics 
(N, mean, median, SD, and range) will be generated for continuous variables (eg, age and weight). 
The numbers and percentages of subjects will be presented for categorical variables (eg, gender, 
race).
13.1.3 Efficacy Analysis
The primary efficacy variable will be the percentage of subjects who have complete healing of EE 
over 8 weeks as assessed by endoscopy. The treatment difference of healing rate between 
dexlansoprazole and lansoprazole will be calculated and the lower bound of 95% confidence 
interval will be compared with -10%. Noninferiority to lansoprazole will be declared if the lower 
bound is greater than -10%. Subjects who do not have endoscopically documented healing and 
who prematurely discontinue will be considered as not healed.
The secondary efficacy variable will be the percentage of subjects who maintained complete 
healing of EE over 6 months as assessed by endoscopy. A comparison between dexlansoprazole 
capsules and placebo will be made using Cochran-Mantel-Haenszel (CMH) test using 


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 70 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
stratification factor of baseline grade. Subjects who do not have endoscopically documented 
maintenance of healing and who prematurely discontinue will be considered to have relapsed.
An additional efficacy variable will be the severity of GERD symptoms at Weeks 4 and 8 as 
assessed by the investigator during the Healing Period. The severity of GERD will be compared 
between dexlansoprazole and lansoprazole capsules using a CMH test for ordered responses with 
baseline severity as the stratum. The number of subjects at each severity level for each GERD 
symptom at Months 1, 3, 6 will be also summarized by treatment group and baseline severity. At 
each visit, the severity will be compared between treatment groups using a CMH test for ordered 
responses (row mean score statistic with table scores of 0, 1, 2, 3, and 4) with baseline severity as 
the strata.
The percentage of days with neither daytime nor nighttime heartburn and the percentage of days 
without rescue medication use over the 8 weeks of the Healing Period and over the 6 months of the 
Maintenance Period as assessed by the daily diary will be summarized by treatment groups. 
Comparisons between treatment groups will be made using Wilcoxon rank-sum tests.
13.1.4 Safety Analysis
Safety will be assessed by summarizing the incidence of AEs, clinical laboratory values, gastrin 
levels, ECG, and vital signs.
Summary of AEs, ECG results, clinical laboratory values, gastrin levels, and vital signs will be 
provided separately for the Healing Period and for the Maintenance Period. For the Healing 
Period, baseline values will be the last available assessment before the first dose of study drug. The 
baseline values for the Maintenance Period will be the assessment performed at the Week 8 visit of 
the Healing Period. 
All AEs will be coded using MedDRA. Treatment-emergent adverse events (TEAE) will be 
summarized using preferred term and primary system organ class overall, by severity, and by 
relationship to study drug for each treatment group. Separate summaries will also be generated for 
treatment-related adverse events (TRAEs) overall and by severity. AEs that were reported more 
than once by a subject during the same period will be counted only once for that subject and period 
at the maximum severity.
Other safety assessments (ECG results, clinical laboratory values, gastrin levels, and vital signs) 
will be summarized by double-blind treatment group at all visits assessed using descriptive 
statistics. Values outside the reference ranges and markedly abnormal laboratory values will be 
flagged and tabulated.
13.2
Determination of Sample Size
A total of 450 subjects with EE documented during Screening are planned to be enrolled into this 
study. Approximately 300 subjects are expected to enter the Maintenance treatment period. 
Assuming a 10% dropout rate during the Healing Period and an 85% healing rate at Week 8 for 
both lansoprazole and dexlansoprazole, 225 subjects per arm will provide at least 80% power at 
the 1-sided 0.025 level of significance to meet the noninferiority criteria between lansoprazole and 


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 71 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
dexlansoprazole. Noninferiority to lansoprazole will be declared if the lower bound of the 
confidence interval for the difference in healing rates is greater than -10%.
The fixed noninferiority margin of -10% is based on a double-blind, parallel-group, comparative 
study that evaluated EE healing rates after an 8-week treatment period with lansoprazole 30 mg 
QD or placebo. In this study, the difference in response rate between the lansoprazole 30 mg dose 
group and the placebo group was 40.4%; the lower limit of the 2-sided 95% confidence interval 
was 25.9%. Hence, even with a conservative assumption of this lower bound as the treatment 
effect of lansoprazole 30 mg, a -10% noninferiority margin would assure that dexlansoprazole 
30 mg retains more than 60% of the treatment effect of lansoprazole 30 mg [22]. 
Assuming a 33% dropout rate during the Maintenance Period and that maintenance rates are 14% 
and 66% for placebo and dexlansoprazole 30 mg, respectively, 150 subjects per arm will have at 
least 99% power at the 2-sided 0.05 level of significance to detect a difference between the 
treatment groups.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 72 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
14.0
QUALITY CONTROL AND QUALITY ASSURANCE
14.1
Study-Site Monitoring Visits
Monitoring visits to the study site will be made periodically during the study to ensure that all 
aspects of the protocol are followed. Source documents will be reviewed for verification of data 
recorded on the eCRFs. Source documents are defined as original documents, data, and records. 
The investigator and institution guarantee access to source documents by the sponsor or its 
designee (CRO) and by the IRB or IEC.
All aspects of the study and its documentation will be subject to review by the sponsor or designee 
(as long as blinding is not jeopardized), including but not limited to the Investigator’s Binder, 
study medication, subject medical records, informed consent documentation, documentation of 
subject authorization to use personal health information (if separate from the informed consent 
forms), and review of eCRFs and associated source documents. It is important that the investigator 
and other study personnel are available during the monitoring visits and that sufficient time is 
devoted to the process.
14.2
Protocol Deviations
The investigator should not deviate from the protocol, except where necessary to eliminate an 
immediate hazard to study subjects. Should other unexpected circumstances arise that will require 
deviation from protocol-specified procedures, the investigator should consult with the medical 
monitor (and IRB or IEC, as required) to determine the appropriate course of action. There will be 
no exemptions (a prospective approved deviation) from the inclusion or exclusion criteria.
The site should document all protocol deviations in the subject’s source documents. In the event of 
a significant deviation, the site should notify the sponsor or its designee (and IRB or EC, as 
required). Significant deviations include, but are not limited to, those that involve fraud or 
misconduct, increase the health risk to the subject, or confound interpretation of primary study 
assessment. The Significant Protocol Deviation eCRF is to be completed for deviations that are 
identified as significant by the sponsor.
14.3
Quality Assurance Audits and Regulatory Agency Inspections
The study site also may be subject to quality assurance audits by the sponsor or designees. In this 
circumstance, the sponsor-designated auditor will contact the site in advance to arrange an 
auditing visit. The auditor may ask to visit the facilities where laboratory samples are collected, 
where the medication is stored and prepared, and any other facility used during the study. In 
addition, there is the possibility that this study may be inspected by regulatory agencies, including 
those of foreign governments (eg, the Food and Drug Administration [FDA], the United Kingdom 
Medicines and Healthcare products Regulatory Agency [MHRA], the Pharmaceuticals and 
Medical Devices Agency of Japan [PMDA]). If the study site is contacted for an inspection by a 
regulatory body, the sponsor should be notified immediately. The investigator and institution 
guarantee access for quality assurance auditors to all study documents as described in 
Section 14.1.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 73 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
15.0
ETHICAL ASPECTS OF THE STUDY
This study will be conducted with the highest respect for the individual participants (ie, subjects) 
according to the protocol, the ethical principles that have their origin in the Declaration of 
Helsinki, and the ICH Harmonised Tripartite Guideline for GCP. Each investigator will conduct 
the study according to applicable local or regional regulatory requirements and align his or her 
conduct in accordance with the “Responsibilities of the Investigator” that are listed in Appendix B. 
The principles of Helsinki are addressed through the protocol and through appendices containing 
requirements for informed consent and investigator responsibilities. 
15.1
IRB and/or IEC Approval
IRBs and IECs must be constituted according to the applicable state and federal/local requirements 
of each participating region. The sponsor or designee will require documentation noting all names 
and titles of members who make up the respective IRB or IEC. If any member of the IRB or IEC 
has direct participation in this study, written notification regarding his or her abstinence from 
voting must also be obtained. Those US sites unwilling to provide names and titles of all members 
due to privacy and conflict of interest concerns should instead provide a Federal Wide Assurance 
Number or comparable number assigned by the Department of Health and Human Services.
The sponsor or designee will supply relevant documents for submission to the respective IRB or 
IEC for the protocol’s review and approval. This protocol, the Investigator’s Brochure, a copy of 
the informed consent form, and, if applicable, subject recruitment materials and/or advertisements 
and other documents required by all applicable laws and regulations, must be submitted to a 
central or local IRB or IEC for approval. The IRB’s or IEC’s written approval of the protocol and 
subject informed consent must be obtained and submitted to the sponsor or designee before 
commencement of the study (ie, before shipment of the sponsor-supplied drug or study specific 
screening activity). The IRB or IEC approval must refer to the study by exact protocol title, 
number, and version date; identify versions of other documents (eg, informed consent form) 
reviewed; and state the approval date. The sponsor will [ship drug/notify site] once the sponsor has 
confirmed the adequacy of site regulatory documentation and, when applicable, the sponsor has 
received permission from competent authority to begin the trial. Until the site receives 
[drug/notification] no protocol activities, including screening may occur.
Sites must adhere to all requirements stipulated by their respective IRB or IEC. This may include 
notification to the IRB or IEC regarding protocol amendments, updates to the informed consent 
form, recruitment materials intended for viewing by subjects, local safety reporting requirements, 
reports and updates regarding the ongoing review of the study at intervals specified by the 
respective IRB or IEC, and submission of the investigator’s final status report to IRB or IEC. All 
IRB and IEC approvals and relevant documentation for these items must be provided to the 
sponsor or its designee.
Subject incentives should not exert undue influence for participation. Payments to subjects must 
be approved by the IRB or IEC and sponsor.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 74 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
15.2
Subject Information, Informed Consent, and Subject Authorization
Written consent documents will embody the elements of informed consent as described in the 
Declaration of Helsinki and the ICH Guidelines for GCP and will be in accordance with all 
applicable laws and regulations. The informed consent form, subject authorization form (if 
applicable), and subject information sheet (if applicable) describe the planned and permitted uses, 
transfers, and disclosures of the subject’s personal and personal health information for purposes of 
conducting the study. The informed consent form and the subject information sheet (if applicable) 
further explain the nature of the study, its objectives, and potential risks and benefits, as well as the 
date informed consent is given. The informed consent form will detail the requirements of the 
participant and the fact that he or she is free to withdraw at any time without giving a reason and 
without prejudice to his or her further medical care.
The investigator is responsible for the preparation, content, and IRB or IEC approval of the 
informed consent form and if applicable, the subject authorization form. The informed consent 
form, subject authorization form (if applicable), and subject information sheet (if applicable) must 
be approved by both the IRB or IEC and the sponsor prior to use.
The informed consent form, subject authorization form (if applicable), and subject information 
sheet (if applicable) must be written in a language fully comprehensible to the prospective subject. 
It is the responsibility of the investigator to explain the detailed elements of the informed consent 
form, subject authorization form (if applicable), and subject information sheet (if applicable) to the 
subject. Information should be given in both oral and written form whenever possible and in the 
manner deemed appropriate by the IRB or IEC. In the event the subject is not capable of rendering 
adequate written informed consent, then the subject’s legally acceptable representative may 
provide such consent for the subject in accordance with applicable laws and regulations.
The subject, or the subject’s legally acceptable representative, must be given ample opportunity to: 
(1) inquire about details of the study and (2) decide whether or not to participate in the study. If the 
subject, or the subject’s legally acceptable representative, determines he or she will participate in 
the study, then the informed consent form and subject authorization form (if applicable) must be 
signed and dated by the subject, or the subject’s legally acceptable representative, at the time of 
consent and prior to the subject entering into the study. The subject or the subject’s legally 
acceptable representative should be instructed to sign using their legal names, not nicknames, 
using blue or black ballpoint ink. The investigator must also sign and date the informed consent 
form and subject authorization (if applicable) at the time of consent and prior to subject entering 
into the study; however, the sponsor may allow a designee of the investigator to sign to the extent 
permitted by applicable law.
Once signed, the original informed consent form, subject authorization form (if applicable), and 
subject information sheet (if applicable) will be stored in the investigator’s site file. The 
investigator must document the date the subject signs the informed consent in the subject’s 
medical record. Copies of the signed informed consent form, the signed subject authorization form 
(if applicable), and subject information sheet (if applicable) shall be given to the subject.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 75 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
All revised informed consent forms must be reviewed and signed by relevant subjects or the 
relevant subject’s legally acceptable representative in the same manner as the original informed 
consent. The date the revised consent was obtained should be recorded in the subject’s medical 
record, and the subject should receive a copy of the revised informed consent form.
15.3
Subject Confidentiality
The sponsor and designees affirm and uphold the principle of the subject’s right to protection 
against invasion of privacy. Throughout this study, a subject’s source data will only be linked to 
the sponsor’s clinical study database or documentation via a unique identification number. As 
permitted by all applicable laws and regulations, limited subject attributes, such as sex, age, or date 
of birth, and subject initials may be used to verify the subject and accuracy of the subject’s unique 
identification number.
To comply with ICH Guidelines for GCP and to verify compliance with this protocol, the sponsor 
requires the investigator to permit its monitor or designee’s monitor, representatives from any 
regulatory authority (eg, FDA, Medicines and Healthcare products Regulatory Agency, 
Pharmaceuticals and Medical Devices Agency), the sponsor’s designated auditors, and the 
appropriate IRBs and IECs to review the subject’s original medical records (source data or 
documents), including, but not limited to, laboratory test result reports, ECG reports, admission 
and discharge summaries for hospital admissions occurring during a subject’s study participation, 
and autopsy reports. Access to a subject’s original medical records requires the specific 
authorization of the subject as part of the informed consent process (see Section 15.2).
Copies of any subject source documents that are provided to the sponsor must have certain 
personally identifiable information removed (ie, subject name, address, and other identifier fields 
not collected on the subject’s eCRF).
15.4
Publication, Disclosure, and Clinical Trial Registration Policy
15.4.1 Publication and Disclosure
The investigator is obliged to provide the sponsor with complete test results and all data derived by 
the investigator from the study. During the study, only the sponsor may make study information 
available to other study investigators or to regulatory agencies, except as required by law or 
regulation. Except as otherwise allowable in the clinical study site agreement, any public 
disclosure (including publicly accessible websites) related to the protocol or study results, other 
than study recruitment materials and/or advertisements, is the sole responsibility of the sponsor.
The sponsor may publish any data and information from the study (including data and information 
generated by the investigator) without the consent of the investigator. Manuscript authorship for 
any peer-reviewed publication will appropriately reflect contributions to the production and 
review of the document. All publications and presentations must be prepared in accordance with 
this section and the Clinical Study Site Agreement. In the event of any discrepancy between the 
protocol and the Clinical Study Site Agreement, the Clinical Study Site Agreement will prevail.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 76 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
15.4.2 Clinical Trial Registration
In order to ensure that information on clinical trials reaches the public in a timely manner and to 
comply with applicable law, regulation and guidance, Takeda will, at a minimum register all 
clinical trials conducted in patients that it sponsors anywhere in the world on ClinicalTrials.gov or 
other publicly accessible websites before trial initiation. Takeda contact information, along with 
investigator’s city, state (for US investigators), country, and recruiting status will be registered and 
available for public viewing. 
For some registries, Takeda will assist callers in locating trial sites closest to their homes by 
providing the investigator name, address, and phone number to the callers requesting trial 
information. Once subjects receive investigator contact information, they may call the site 
requesting enrollment into the trial. The investigative sites are encouraged to handle the trial 
inquiries according to their established subject screening process. If the caller asks additional 
questions beyond the topic of trial enrollment, they should be referred to the sponsor. 
Any investigator who objects to Takeda providing this information to callers must provide Takeda 
with a written notice requesting that their information not be listed on the registry site. 
15.4.3 Clinical Trial Results Disclosure
Takeda will post the results of this clinical trial, regardless of outcome, on ClinicalTrials.gov or 
other publicly accessible websites, as required by applicable laws and/or regulations.
15.5
Insurance and Compensation for Injury
Each subject in the study must be insured in accordance with the regulations applicable to the site 
where the subject is participating. If a local underwriter is required, then the sponsor or sponsor’s 
designee will obtain clinical study insurance against the risk of injury to clinical study subjects. 
Refer to the Clinical Study Site Agreement regarding the sponsor’s policy on subject 
compensation and treatment for injury. If the investigator has questions regarding this policy, he or 
she should contact the sponsor or sponsor’s designee.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 77 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
16.0
REFERENCES
1. Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux 
disease: a systematic review. Gut 2005;54(5):710-7.
2. Locke GR, 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ, 3rd. Prevalence and clinical 
spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. 
Gastroenterology 1997;112(5):1448-56.
3. Fass R. Erosive esophagitis and nonerosive reflux disease (NERD): comparison of 
epidemiologic, physiologic, and therapeutic characteristics. J Clin Gastroenterol 
2007;41(2):131-7.
4. Fennerty MB, Castell D, Fendrick AM, Halpern M, Johnson D, Kahrilas PJ, et al. The 
diagnosis and treatment of gastroesophageal reflux disease in a managed care environment. 
Suggested disease management guidelines. Arch Intern Med 1996;156(5):477-84.
5. Hillman LC, Chiragakis L, Shadbolt B, Kaye GL, Clarke AC. Proton-pump inhibitor therapy 
and the development of dysplasia in patients with Barrett's oesophagus. Med J Aust 
2004;180(8):387-91.
6. Revicki DA, Wood M, Maton PN, Sorensen S. The impact of gastroesophageal reflux disease 
on health-related quality of life. Am J Med 1998;104(3):252-8.
7. Fennerty MB. Medical treatment of gastroesophageal reflux disease in the managed care 
environment. Semin Gastrointest Dis 1997;8:90-9.
8. Orlando RC. The pathogenesis of gastroesophageal reflux disease: the relationship between 
epithelial defense, dysmotility, and acid exposure. (discussion 5S-7S). Am J Gastroenterol 
1997;92(4 Suppl):3S-5S.
9. Holloway RH, Dent J, Narielvala F, Mackinnon AM. Relation between oesophageal acid 
exposure and healing of oesophagitis with omeprazole in patients with severe reflux 
oesophagitis. Gut 1996;38(5):649-54.
10. Freston JW. Therapeutic choices in reflux disease: defining the criteria for selecting a proton 
pump inhibitor. Am J Med 2004;117(Suppl 5A):14S-22S.
11. Lundell LR, Dent J, Bennett JR, Blum AL, Armstrong D, Galmiche JP, et al. Endoscopic 
assessment of oesophagitis: clinical and functional correlates and further validation of the Los 
Angeles classification. Gut 1999;45(2):172-80.
12. Hunt RH. Review article: the unmet needs in delayed-release proton-pump inhibitor therapy in 
2005. Aliment Pharmacol Ther 2005;22(Suppl 3):10-9.
13. Van Soest EM, Siersema PD, Dieleman JP, Sturkenboom MCJM, Kuipers EJ. Persistence and 
adherence to proton pump inhibitors in daily clinical practice. Aliment Pharmacol Ther 
2006;24(2):377-85.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 78 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
14. Crawley JA, Schmitt CM. How satisfied are chronic heartburn sufferers with their prescription 
medications? Results of the Patient Unmet Needs Survey. J Clin Outcomes Manage 
2000;7(11):29-34.
15. Shaker R, Castell DO, Schoenfeld PS, Spechler SJ. Nighttime heartburn is an 
under-appreciated clinical problem that impacts sleep and daytime function: the results of a 
Gallup survey conducted on behalf of the American Gastroenterological Association. Am J 
Gastroenterol 2003;98(7):1487-93.
16. Donnellan C, Sharma N, Preston C, Moayyedi P. Medical treatments for the maintenance 
therapy of reflux oesophagitis and endoscopic negative reflux disease (Review). Cochrane 
Database Syst Rev 2005(2):CD003245.
17. Katz PO, Scheiman JM, Barkun AN. Review article: acid-related disease--what are the unmet 
clinical needs? Aliment Pharmacol Ther 2006;23 Suppl 2:9-22.
18. Richter JE, Kahrilas PJ, Johanson J, Maton P, Breiter JR, Hwang C, et al. Efficacy and safety 
of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a 
randomized controlled trial. Am J Gastroenterol 2001;96(3):656-65.
19. Castell DO, Kahrilas PJ, Richter JE, Vakil NB, Johnson DA, Zuckerman S, et al. 
Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive 
esophagitis. Am J Gastroenterol 2002;97(3):575-83.
20. Labenz J, Armstrong D, Lauritsen K, Katelaris P, Schmidt S, Schutze K, et al. A randomized 
comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive 
oesophagitis: the EXPO study. Aliment Pharmacol Ther 2005;21(6):739-46.
21. Zhang W, Wu J, Atkinson SN. Effects of dexlansoprazole MR, a novel dual delayed release 
formulation of a proton pump inhibitor, on plasma gastrin levels in healthy subjects. J Clin 
Pharmacol 2009;49(4):444-54.
22. Earnest DL, Dorsch E, Jones J, Jennings DE, Greski-Rose PA. A placebo-controlled 
dose-ranging study of lansoprazole in the management of reflux esophagitis. Am J 
Gastroenterol 1998;93(2):238-43.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 79 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
Appendix A
Schedule of Study Procedures
Screening Period
Healing Period
Maintenance Period
Screening
Study 
Day -1
Baseline
Study 
Day 1
Week 4 
(a)
Week 8 (a)/ 
Final Visit
Study 
Month 1
Study 
Month 3
Month 6 (b)
Final Visit
Unscheduled 
Visit
Follow-up 
Phone Call 
(c)
Study Day/Week/Month:
Day -21 to -2
Day -1
Day 1
Week 4
Week 8
Month 1 Month 3
Month 6
Last dose 
+5 to 10 
days
Visit Windows (Days):
±3
±3
±7
±7
±7
Visit Number:
1
2
3
4
5
6
7
8
Informed consent
X
Demographics/medical/social history
X
Medication history
X
Physical examination
X
X
X
X
X
X
X
X
Concurrent medical conditions
X
Vital signs, body weight and height 
X(d)
X
X
X
X
X
X
X
ECG
X
X 
X
X
Endoscopy 
X (e)
X
X (n)
X(o)
X (n)
X(o)
H. Pylori serology
X
Clinical laboratory tests (j) 
X (e)
X (f)
X (f)
X (f)
X (f)
X (f)
Hepatitis panel (j)
X (e)
Fasting serum gastrin (f)
X
X
X
X
Urine pregnancy test (k) 
X
X
X
X
X
X
X
Serum hCG (k)
X
X
X
X
Serum FSH
X(g)
Guidance on avoidance of pregnancy 
and ova and sperm donation
X
X
X
X
X
X
X
IWRS randomization
X
X (m)
Footnotes are on last table page.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 80 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
Appendix A
Schedule of Study Procedures (continued)
Screening Period
Healing Period
Maintenance Period
Screening
Study 
Day -1
Baseline
Study 
Day 1
Week 4 
(a)
Week 8 (a)/ 
Final Visit
Study 
Month 1
Study 
Month 3
Month 6 (b)
Final Visit
Unscheduled 
Visit
Follow-up 
Phone Call 
(c)
Study Day/Week/Month:
Day -21 to -2
Day -1
Day 1
Week 4
Week 8
Month 1 Month 3
Month 6
Last dose 
+5 to 10 
days
Visit Windows (Days):
±3
±3
±7
±7
±7
Visit Number:
1
2
3
4
5
6
7
8
First day of study drug
X (l)
X (m)
Concomitant medications
X
X
X
X
X
X
X
X
AEs assessment
X
X
X
X
X
X
X
X
X
GERD symptoms assessment (p)
X
X
X
X
X
X
X
Daily diary review/dispense (h) 
X
X
X
X
X
X
X
X
Dispense study drug via IWRS
X (i)
X
X (m)
X(q)
X(q)
Drug return/accountability
X
X
X
X
X
Footnotes are on last table page.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 81 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
(a) Subjects who prematurely discontinue from the Healing Period should undergo Week 8 / Final Visit procedures no later than 5 days after the last dose of study 
drug.
(b) Subjects who prematurely discontinue from the Maintenance Period should undergo Month 6 / Final Visit procedures no later than 5 days after the last dose of 
study drug. 
(c) Follow-up phone call will occur for all subjects from 5 to 10 days after their last dose of study medication. 
(d) Height is measured only at Screening.
(e) The screening clinical laboratory tests, hepatitis panel, and endoscopy must be performed within 14 days prior to randomization. Any reliable, documented 
results available from an endoscopy performed in a routine clinical setting (before signing of informed consent) in the same institution will be accepted instead, 
given the invasive nature of the procedure.
(f) Except for Visit 1 (Screening Days -21 to -2), subjects should be fasting for a minimum of 8 hours prior to the specimen collection. During the study drug 
treatment period, subjects should be instructed to take their dose of study medication on the morning of their visit with a sip of water before specimen collection 
occurs. Breakfast should be eaten only after specimen collection. 
(g) Only if menopause is suspected.
(h) Subjects should complete the diary every morning (for nighttime symptoms) and every evening (for daytime symptoms). The diary will be dispensed at 
Screening and reviewed/dispensed at corresponding subsequent visits.
(i) Study drug dispensed on Study Day -1 of the Screening Period Visit after the subject has completed all of the Screening Period procedures and subject has met all 
admission criteria for the study. Study drug will be self-administered on a daily basis for 8 weeks (Healing Period) and then 6 months (Maintenance Period). 
(j) Clinical laboratory tests include chemistry, hematology, and urinalysis. Hepatitis panel including HBsAg and HCV-antibody can be done either at the central 
laboratory or the local laboratory, depending on the site capability.
(k) Women of childbearing potential only. Baseline serum pregnancy test will not be needed if the screening pregnancy test is within 14 days of baseline.
(l) Healing therapy (blinded dexlansoprazole 60 mg capsules QD or lansoprazole 30 mg capsules QD).
(m) Perform only if endoscopy confirms successful EE healing. Randomize to maintenance therapy, and dispense (blinded dexlansoprazole 30 mg capsules QD or 
matching placebo) accordingly. The first dose of maintenance therapy should be taken approximately 24 hours after last dose of healing therapy (ie, in the morning).
(n) If subject has endoscopically-proven EE, they should be terminated from the study and undergo Final Visit (Month 6) Procedures.
(o) Unscheduled Visit and Month 3 Visit endoscopies are optional, and may be warranted if subject presents with symptoms during EE Maintenance Period based 
on investigator’s discretion. If subject has endoscopically-proven EE, the subject should be terminated from the study and undergo Final Visit (Month 6) /Early 
Termination Visit Procedures.
(p) GERD symptoms should be assessed by an Investigator. If possible the same Investigator should perform these assessments for an individual subject throughout 
the study. 
(q) Dispense study drug if subject has not had endoscopically-proven relapse of EE.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 82 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
Appendix B
Responsibilities of the Investigator
Clinical research studies sponsored by the sponsor are subject to ICH GCP and all the applicable 
local laws and regulations. 
The investigator agrees to assume the following responsibilities:
1. Conduct the study in accordance with the protocol.
2. Personally conduct or supervise the staff who will assist in the protocol.
3. Ensure that study related procedures, including study specific (nonroutine/nonstandard panel) 
screening assessments, are NOT performed on potential subjects, prior to the receipt of written 
approval from relevant governing bodies/authorities.
4. Ensure that all colleagues and employees assisting in the conduct of the study are informed of 
these obligations.
5. Secure prior approval of the study and any changes by an appropriate IRB/IEC that conform to 
ICH, and local regulatory requirements.
6. Ensure that the IRB/IEC will be responsible for initial review, continuing review, and approval 
of the protocol. Promptly report to the IRB/IEC all changes in research activity and all 
anticipated risks to subjects. Make at least yearly reports on the progress of the study to the 
IRB/IEC, and issue a final report within 3 months of study completion.
7. Ensure that requirements for informed consent, as outlined in ICH and local regulations, are 
met.
8. Obtain valid informed consent from each subject who participates in the study, and document 
the date of consent in the subject’s medical chart. Valid informed consent is the most current 
version approved by the IRB/IEC. Each informed consent form should contain a subject 
authorization section that describes the uses and disclosures of a subject’s personal 
information (including personal health information) that will take place in connection with the 
study. If an informed consent form does not include such a subject authorization, then the 
investigator must obtain a separate subject authorization form from each subject or the 
subject’s legally acceptable representative.
9. Prepare and maintain adequate case histories of all persons entered into the study, including 
eCRFs, hospital records, laboratory results, etc, and maintain these data for a minimum of 
2 years following notification by the sponsor that all investigations have been discontinued or 
that the regulatory authority has approved the marketing application. The investigator should 
contact and receive written approval from the sponsor before disposing of any such 
documents.
10. Allow possible inspection and copying by the regulatory authority of GCP-specified essential 
documents.
11. Maintain current records of the receipt, administration, and disposition of sponsor-supplied 
drugs, and return all unused sponsor-supplied drugs to the sponsor.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 83 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
12. Report adverse reactions to the sponsor promptly. In the event of an SAE, notify the sponsor 
within 24 hours.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 84 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
Appendix C
Elements of the Subject Informed Consent 
In seeking informed consent, the following information shall be provided to each subject:
1. A statement that the study involves research.
2. An explanation of the purposes of the research.
3. The expected duration of the subject’s participation.
4. A description of the procedures to be followed, including invasive procedures.
5. The identification of any procedures that are experimental.
6. The estimated number of subjects involved in the study.
7. A description of the subject’s responsibilities.
8. A description of the conduct of the study.
9. A statement describing the treatment(s) and the probability for random assignment to each 
treatment.
10. A description of the possible side effects of the treatment that the subject may receive.
11. A description of any reasonably foreseeable risks or discomforts to the subject and, when 
applicable, to an embryo, fetus, or nursing infant.
12. A description of any benefits to the subject or to others that reasonably may be expected from 
the research. When there is no intended clinical benefit to the subject, the subject should be 
made aware of this.
13. Disclosures of appropriate alternative procedures or courses of treatment, if any, that might be 
advantageous to the subject and their important potential risks and benefits.
14. A statement describing the extent to which confidentiality of records identifying the subject 
will be maintained, and a note of the possibility that regulatory agencies, auditor(s), IRB/IEC, 
and the monitor may inspect the records. By signing a written informed consent form, the 
subject or the subject’s legally acceptable representative is authorizing such access.
15. For research involving more than minimal risk, an explanation as to whether any compensation 
and an explanation as to whether any medical treatments are available if injury occurs and, if 
so, what they consist of or where further information may be obtained.
16. The anticipated prorated payment(s), if any, to the subject for participating in the study.
17. The anticipated expenses, if any, to the subject for participating in the study.
18. An explanation of whom to contact for answers to pertinent questions about the research 
(investigator), subject’s rights, and IRB/IEC and whom to contact in the event of a 
research-related injury to the subject.
19. A statement that participation is voluntary, that refusal to participate will involve no penalty or 
loss of benefits to which the subject otherwise is entitled, and that the subject may discontinue 


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 85 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
participation at any time without penalty or loss of benefits to which the subject is otherwise 
entitled.
20. The consequences of a subject’s decision to withdraw from the research and procedures for 
orderly termination of participation by the subject.
21. A statement that the subject or the subject’s legally acceptable representative will be informed 
in a timely manner if information becomes available that may be relevant to the subject’s 
willingness to continue participation in the study.
22. A statement that results of pharmacogenomic analysis will not be disclosed to an individual, 
unless prevailing laws require the sponsor to do so.
23. The foreseeable circumstances or reasons under which the subject’s participation in the study 
may be terminated.
24. A written subject authorization (either contained within the informed consent form or provided 
as a separate document) describing to the subject the contemplated and permissible uses and 
disclosures of the subject’s personal information (including personal health information) for 
purposes of conducting the study. The subject authorization must contain the following 
statements regarding the uses and disclosures of the subject’s personal information:
a) that personal information (including personal health information) may be processed by or 
transferred to other parties in other countries for clinical research and safety reporting 
purposes, including, without limitation, to the following: (1) Takeda, its affiliates, and 
licensing partners; (2) business partners assisting Takeda, its affiliates, and licensing 
partners; (3) regulatory agencies and other health authorities; and (4) IRBs/IECs;
b) it is possible that personal information (including personal health information) may be 
processed and transferred to countries that do not have data protection laws that offer 
subjects the same level of protection as the data protection laws within this country; 
however, Takeda will make every effort to keep your personal information confidential, 
and your name will not be disclosed outside the clinic unless required by law;
c) that personal information (including personal health information) may be added to 
Takeda’s research databases for purposes of developing a better understanding of the 
safety and effectiveness of the study medication(s), studying other therapies for patients, 
developing a better understanding of disease, and improving the efficiency of future 
clinical studies;
d) that subjects agree not to restrict the use and disclosure of their personal information 
(including personal health information) upon withdrawal from the study to the extent that 
the restricted use or disclosure of such information may impact the scientific integrity of 
the research; and
e) that the subject’s identity will remain confidential in the event that study results are 
published.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 86 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
25. Women of childbearing potential (eg, nonsterilized, premenopausal women) who are sexually 
active must use adequate contraception (as defined in the informed consent) from Screening 
and throughout the duration of the study. Regular pregnancy tests will be performed 
throughout the study for all women of childbearing potential. If a subject is found to be 
pregnant during study, study medication will be discontinued and the investigator will offer the 
subject the choice to receive unblinded treatment information.
26. Men subjects must use adequate contraception (as defined in the informed consent) from 
Screening throughout the duration of the study. If the partner or wife of the subject is found to 
be pregnant during the study, the investigator will offer the subject the choice to receive 
unblinded treatment information.
27. A statement that clinical trial information from this trial will be publicly disclosed in a publicly 
accessible website, such as ClinicalTrials.gov.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 87 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
Appendix D
Investigator Consent to Use of Personal Information 
Takeda will collect and retain personal information of investigator, including his or her name, 
address, and other personally identifiable information. In addition, investigator’s personal 
information may be transferred to other parties located in countries throughout the world (eg, the 
United Kingdom, United States, and Japan), including the following:

Takeda, its affiliates, and licensing partners.

Business partners assisting Takeda, its affiliates, and licensing partners.

Regulatory agencies and other health authorities.

IRBs and IECs.
Investigator’s personal information may be retained, processed, and transferred by Takeda and 
these other parties for research purposes including the following:

Assessment of the suitability of investigator for the study and/or other clinical studies.

Management, monitoring, inspection, and audit of the study.

Analysis, review, and verification of the study results.

Safety reporting and pharmacovigilance relating to the study.

Preparation and submission of regulatory filings, correspondence, and communications to 
regulatory agencies relating to the study.

Preparation and submission of regulatory filings, correspondence, and communications to 
regulatory agencies relating to other medications used in other clinical studies that may contain 
the same chemical compound present in the study medication.

Inspections and investigations by regulatory authorities relating to the study.

Self-inspection and internal audit within Takeda, its affiliates, and licensing partners.

Archiving and audit of study records.

Posting investigator site contact information, study details and results on publicly accessible 
clinical trial registries, databases, and websites.
Investigator’s personal information may be transferred to other countries that do not have data 
protection laws that offer the same level of protection as data protection laws in investigator’s own 
country.
Investigator acknowledges and consents to the use of his or her personal information by Takeda 
and other parties for the purposes described above.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 88 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
Appendix E
LA Classification of Esophagitis Grading System
LA Classification of Esophagitis Grading System
Grade
Definition
O
No mucosal breaks
A
One (or more) mucosal break no longer than 5 mm that does not extend between the tops of 2 mucosal folds.
B
One (or more) mucosal break more than 5 mm long, that does not extend between the tops of 2 mucosal 
folds.
C
One (or more) mucosal break that is continuous between the tops of 2 or more mucosal folds, but which 
involves less than 75% of the circumference.
D
One (or more) mucosal break, which involves at least 75 % of the esophageal circumference.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 89 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
Appendix F
GERD Symptoms Investigator Assessments 
Definitions of GERD Symptoms Assessed by Investigator
Symptom
Definition
Heartburn
A burning feeling in the mid-epigastric area and/or chest area.
Acid Regurgitation
Flow of sour or bitter fluid into the mouth.
Dysphagia
Difficulty in swallowing.
Belching
The voiding of gas from the stomach through the mouth, which may have been associated 
with acid regurgitation.
Epigastric Pain
Central upper abdominal pain.
Definitions of GERD Symptoms Severity by Investigator
Severity
Definition
None
No symptoms.
Mild
Symptom did not last long and was easily tolerated.
Moderate
Symptom caused discomfort and/or interrupted usual activities (including sleep).
Severe
Symptom caused great interference with usual activities and may have been incapacitating 
(including sleep).
Very Severe
Symptom caused intense and constant discomfort and/or marked interference with usual 
activities (including sleep).


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 90 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
Appendix G
Definition of Heartburn Severity (Daytime/Nighttime) 
Definitions of Daytime Heartburn Severity (Daytime=Awake Time)
None
No heartburn.
Mild
Occasional heartburn, can be ignored, does not influence daily routine.
Moderate
Heartburn cannot be ignored and/or occasionally influences daily routine.
Severe
Heartburn present most of day and/or regularly influences daily routine.
Very Severe
Constant heartburn and/or markedly influences daily routine.
Definitions of Nighttime Heartburn Severity (Nighttime=Sleep Time)
None
No heartburn.
Mild
Occasional heartburn, can be ignored, does not influence sleep.
Moderate
Heartburn cannot be ignored and/or occasionally influences sleep.
Severe
Heartburn present most of night and/or regularly influences sleep.
Very Severe
Constant heartburn and/or markedly influences sleep.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 91 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
Appendix H
Diary
The following diary questions will be asked in the morning:
1. Did you have heartburn last night?
Yes 
No 
If yes, what was the maximum severity? Choose 1.

Mild

Moderate

Severe

Very Severe
2. Did you take any rescue medication last night? (such as Talcid chewable 
tablets, Gaviscon tablets and/or other antacids)
Yes 
No 
The following diary questions will be asked in the evening: 
1. Did you have heartburn today?
Yes 
No 
If yes, what was the maximum severity? Choose 1.

Mild

Moderate

Severe

Very Severe
2. Did you take any rescue medication today? (such as Talcid chewable 
tablets, Gaviscon tablets and/or other antacids)
Yes 
No 


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 92 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
Appendix I
Detailed Description of Amendments to Text
This appendix describes content changes in reference to Protocol Incorporating Amendment 
No. 03 dated 20 February 2017.
Change 1: Update contract research organization (CRO) contact information.
The change occurs in Section 1.1 Contacts:
Description of 
change:
Changed the contact for SAE, pregnancy, and special interest adverse event 
reporting from Mingfang Zhu to Jie Pan. The methods of contact were updated 
accordingly.
Rationale for Change: The contact was updated to reflect a change in responsibilities at the CRO.
Change 2: Change the appropriate contact for confirming available brands of rescue medication.
The change occurs in Section 8.1.1.2 Rescue Medication:
Initial 
wording:
If the listed rescue medications are not available, the subject should contact the 
contract research organization (CRO) or Takeda Medical Advisor for confirmation of 
available brand. 
Amended 
or new 
wording:
If the listed rescue medications are not available, the subject should contact the 
contract research organization (CRO) or Takeda Medical Advisor subject’s 
responsible investigator for confirmation of available brand. During the rescue 
medication administration, the following should be noted:
Rationale for Change: The subject does not need to contact the CRO or Takeda Medical Advisor, 
but can discuss available rescue medications with the investigator directly.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 93 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
Change 3: Gastrin levels will be blinded to both investigators and medical monitors during the 
study period.
The change occurs in Section 9.1.10 Procedures for Clinical Laboratory Samples, Table 9.a, 
footnote b:
Initial 
wording:
(b) Gastrin levels to be measured under fasting conditions. Gastrin levels above the 
upper limit of normal will be evaluated by the medical monitor and principal 
investigator on a case-by-case basis.
Amended 
or new 
wording:
(b) Gastrin levels to be measured under fasting conditions. Gastrin levels above the 
upper limit of normal will be evaluated by the medical monitor and principal 
investigator on a case-by-case basis. Gastrin levels will be blinded to both 
investigators and the medical monitor during the study period.
This change also appears in a later paragraph within the text of Section 9.1.10 Procedures for 
Clinical Laboratory Samples.
Rationale for Change: Because PPI treatments will be associated with increases in gastrin levels,
reviewing these data during the study may reveal the subject’s treatment assignment.
Change 4: Clarify acceptable windows for screening labs and endoscopy.
The primary change occurs in Section 9.3.1 Screening. 
Initial 
wording:
The screening clinical laboratory tests, hepatitis panel, and endoscopy must be 
performed within 7 days prior to randomization.
Amended 
or new 
wording:
The screening clinical laboratory tests, hepatitis panel, and endoscopy must be 
performed within 7 14 days prior to randomization.
Rationale for Change: The window for screening laboratory tests (including hepatitis panel) and 
endoscopy was extended to 14 days prior to randomization in order to allow greater flexibility for 
scheduling procedures for subjects who may be eligible for study entry, but without compromising 
their safety.
The following sections also contain this change:

Section 6.1 Study Design.

Section 9.1.10 Procedures for Clinical Laboratory Samples.

Section 9.1.16 Endoscopy.

Section 9.3.2 Study Randomization. 

Appendix A Schedule of Study Procedures.


Dexlansoprazole Capsules
Study No. TAK-390MR_301
Page 94 of 94
Protocol Incorporating Amendment No. 03
20 February 2017
CONFIDENTIAL
Change 5: Update one of the definitions of an SAE.
The change occurs in Section 10.1.4 SAEs:
Initial 
wording:
5. Leads to a CONGENITAL ANOMALY/BIRTH DEFECT. 
Amended 
or new 
wording:
5. Leads to Is a CONGENITAL ANOMALY/BIRTH DEFECT.
Rationale for Change: Updated to be the correct definition.




䢢
䢢
䢢
䢢
䢢
䢢
䢢
䢢
(/(&7521,&6,*1$785(6
Signed by 
Meaning of Signature 
Server Date 
(dd-MMM-yyyy HH:mm ‘UTC’) 



 
 



 
 



 
 



 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 





GG
䣃䣯䣧䣰䣦䣯䣧䣰䣶䢢䢵䢢䣶䣱䢢䣃䢢䣒䣪䣣䣵䣧䢢䢵䢢䣕䣶䣷䣦䣻䢢䣶䣱䢢䣇䣸䣣䣮䣷䣣䣶䣧䢢䣶䣪䣧䢢䣇䣨䣨䣫䣥䣣䣥䣻䢢䣣䣰䣦䢢䣕䣣䣨䣧䣶䣻䢢䣱䣨䢢䣆䣧䣺䣮䣣䣰䣵䣱䣲䣴䣣䣼䣱䣮䣧䢢䢪䢸䢲䢢䣯䣩䢢䣓䣆䢫䢢䣣䣰䣦䢢䣣䣰
䣃䣥䣶䣫䣸䣧䢢䣅䣱䣯䣲䣣䣴䣣䣶䣱䣴䢮䢢䣎䣣䣰䣵䣱䣲䣴䣣䣼䣱䣮䣧䢢䢪䢵䢲䢢䣯䣩䢢䣓䣆䢫䢢䣱䣰䢢䣊䣧䣣䣮䣫䣰䣩䢢䣱䣨䢢䣇䣴䣱䣵䣫䣸䣧䢢䣇䣵䣱䣲䣪䣣䣩䣫䣶䣫䣵䢮䢢䣣䣰䣦䢢䣏䣣䣫䣰䣶䣧䣰䣣䣰䣥䣧䢢䣱䣨䢢䣊䣧䣣䣮䣫䣰䣩䢢䣫䣰
䣕䣷䣤䣬䣧䣥䣶䣵䢢䣙䣫䣶䣪䢢䣊䣧䣣䣮䣧䣦䢢䣇䣴䣱䣵䣫䣸䣧䢢䣇䣵䣱䣲䣪䣣䣩䣫䣶䣫䣵䢢䣙䣫䣶䣪䢢䣆䣧䣺䣮䣣䣰䣵䣱䣲䣴䣣䣼䣱䣮䣧䢢䢪䢵䢲䣯䣩䢢䣓䣆䢫
%LRVWDWLVWLFV$SSURYDO
)HE87&
&OLQLFDO6FLHQFH$SSURYDO
)HE87&
&OLQLFDO6FLHQFH$SSURYDO
)HE87&
PPD

SAP_001.pdf: 
This may include, but is not limited to, redaction of the following: 


• Other information as needed to protect confidentiality of Takeda or partners, personal
information, or to otherwise protect the integrity of the clinical study.
Title:  A Phase 3 Study to Evaluate the Efficacy and Safety of Dexlansoprazole (60 mg QD) and 
an Active Comparator, Lansoprazole (30 mg QD) on Healing of Erosive Esophagitis, and 
Maintenance of Healing in Subjects With Healed Erosive Esophagitis With Dexlansoprazole (30 
mg QD) and Placebo
NCT Number: NCT02873702
SAP Approve Date: 14 February 2018
Certain information within this Statistical Analysis Plan has been redacted (ie, specific content 
is masked irreversibly from view with a black/blue bar) to protect either personally 
identifiable information or company confidential information. 
Named persons or organizations associated with the study.
Proprietary information, such as scales or coding systems, which are considered confidential 
information under prior agreements with license holder.


1.0
TITLE PAGE
TAKEDA DEVELOPMENT CENTER
STATISTICAL ANALYSIS PLAN
STUDY NUMBER: TAK-390MR_301
A Phase 3 Study to Evaluate the Efficacy and Safety of Dexlansoprazole (60 mg QD) and an 
Active Comparator, Lansoprazole (30 mg QD) on Healing of Erosive Esophagitis, and 
Maintenance of Healing in Subjects With Healed Erosive Esophagitis With 
Dexlansoprazole (30 mg QD) and Placebo
PHASE 3
Version: Final
Date: 14 February 2018
Prepared by:
CONFIDENTIAL PROPERTY OF TAKEDA
This document is a confidential communication of Takeda. Acceptance of this document 
constitutes the agreement by the recipient that no information contained herein will be published 
or disclosed without written authorization from Takeda.
PPD


PPD
PPD
PPD


TAK-390MR_301
Page 3 of 23
Statistical Analysis Plan Final
14 February 2018
CONFIDENTIAL
2.0
TABLE OF CONTENTS
1.0
TITLE PAGE ..................................................................................................................1
1.1
APPROVAL SIGNATURES.....................................................................................2
2.0
TABLE OF CONTENTS.................................................................................................3
3.0
LIST OF ABBREVIATIONS..........................................................................................5
4.0
OBJECTIVES .................................................................................................................6
4.1
Primary Objectives ....................................................................................................6
4.2
Secondary Objectives.................................................................................................6
4.3
Study Design .............................................................................................................6
5.0
ANALYSIS ENDPOINTS.............................................................................................10
5.1
Primary Endpoints ...................................................................................................10
5.2
Secondary Endpoints ...............................................................................................10
5.3
Additional Endpoints ...............................................................................................10
5.4
Safety Assessments..................................................................................................10
6.0
DETERMINATION OF SAMPLE SIZE.......................................................................11
7.0
METHODS OF ANALYSIS AND PRESENTATION...................................................12
7.1
General Considerations............................................................................................12
7.1.1
Definition of Study Days and Visit Window ......................................................12
7.2
Analysis Sets ...........................................................................................................13
7.3
Disposition of Subjects ............................................................................................14
7.4
Demographic and Baseline Characteristics...............................................................14
7.5
Medical History and Concurrent Medical Conditions...............................................14
7.6
Medication History and Concomitant Medications...................................................14
7.7
Study Drug Exposure and Compliance.....................................................................14
7.8
Efficacy Analysis.....................................................................................................15
7.8.1
Primary Efficacy Endpoint.................................................................................15
7.8.2
Secondary Efficacy Endpoints............................................................................15
7.8.3
Additional Efficacy Endpoints ...........................................................................15
7.9
Pharmacokinetic/Pharmacodynamic Analysis ..........................................................16
7.10
Other Outcomes.......................................................................................................16
7.11
Safety Analysis........................................................................................................16
7.11.1 Adverse Events ..................................................................................................16
7.11.2 Clinical Laboratory Evaluations .........................................................................17
7.11.3 Vital Signs .........................................................................................................18
7.11.4 12-Lead ECGs ...................................................................................................18


TAK-390MR_301
Page 4 of 23
Statistical Analysis Plan Final
14 February 2018
CONFIDENTIAL
7.11.5 Other Observations Related to Safety.................................................................18
7.12
Interim Analysis ......................................................................................................18
7.13
Changes in the Statistical Analysis Plan...................................................................18
8.0
REFERENCES..............................................................................................................19
LIST OF IN-TEXT TABLES
Table 7.a
Visit Windows for Healing Period......................................................................12
Table 7.b
Visit Windows for Maintenance Period..............................................................13
LIST OF IN-TEXT FIGURES
Figure 4.a
Schematic of Study Design ..................................................................................9
LIST OF APPENDICES
Appendix A
Criteria for Identification of Markedly Abnormal Laboratory Values .................20
Appendix B
Criteria for Identification of Markedly Abnormal Vital Sign Values...................21
Appendix C
Criteria for Markedly Abnormal Values for Electrocardiograms.........................22
Appendix D
Data Handling for Subject Daily Diary...............................................................23


TAK-390MR_301
Page 5 of 23
Statistical Analysis Plan Final
14 February 2018
CONFIDENTIAL
3.0
LIST OF ABBREVIATIONS
AE
adverse event
BMI
body mass index
CMH
Cochran-Mantel-Haenszel
ECG
electrocardiogram
EE
erosive esophagitis 
FAS-H
Full Analysis Set – Healing Period
FAS-M
Full Analysis Set – Maintenance Period
GERD
gastroesophageal reflux disease
HLT
high level term
MedDRA
Medical Dictionary for Regulatory Activities
MAV
markedly abnormal values
PT
preferred term
QD
once daily
SI
System International
SOC
system organ class
TEAE
treatment-emergent adverse event
TRAE
treatment-related adverse event
WHODrug
World Health Organization Drug Dictionary


TAK-390MR_301
Page 6 of 23
Statistical Analysis Plan Final
14 February 2018
CONFIDENTIAL
4.0
OBJECTIVES
4.1
Primary Objectives
The primary objective is to compare the efficacy of dexlansoprazole capsules (60 mg QD) and 
lansoprazole capsules (30 mg QD) in healing erosive esophagitis (EE) over 8 weeks of treatment 
in Chinese subjects with endoscopic evidence of EE; the primary comparison will be to 
determine whether dexlansoprazole is noninferior to lansoprazole.
4.2
Secondary Objectives
The secondary objective is to compare the efficacy of dexlansoprazole capsules (30 mg QD) and 
placebo in the maintenance of healing in Chinese subjects with healed EE; the primary 
comparison will be to determine whether dexlansoprazole is superior to placebo.
4.3
Study Design
This is a phase 3, randomized, double-blind, multicenter, active-controlled, 2-arm study with an 
initial 8-week healing period with noninferiority design, followed by a randomized, placebo-
controlled 6-month maintenance period. The study is designed to evaluate healing, maintenance 
of healed EE and the effect of therapy on relieving gastroesophageal reflux disease (GERD) 
related symptoms. Approximately 450 subjects will be enrolled at an estimated 25 sites across 
China. Further details can be found in the study protocol (Protocol Amendment 3, 20 February 
2017).
The study consists of 3 periods; a Screening Period (maximum 21 days), a Healing Period, which 
will last 8 weeks, and a Maintenance Period of up to 6 months. After signing an informed 
consent form subjects will undergo a screening evaluation within 21 days prior to the first dose 
of study drug (Study Day 1). Subjects will be instructed that lifestyle or behavior modifications 
designed to treat their symptoms of GERD should not be altered throughout the study. Subjects 
will be given a diary on the first day of the Screening Period. Throughout the Screening Period, 
subjects will record the presence and maximum severity of daytime and nighttime heartburn 
symptoms each day in their diary. 
During the Screening Period, subjects will undergo various procedures to determine eligibility 
for the Healing Period. Screening evaluations will include the following: demographics, medical 
and social history, physical examination including vital signs, height and weight, 
electrocardiogram (ECG), endoscopy, clinical laboratory evaluations including tests for serum 
and urine pregnancy (all women of childbearing potential) and hepatitis panel, and concomitant 
medication assessment. The screening clinical laboratory tests, hepatitis panel, and endoscopy 
must be performed within 14 days prior to randomization. Endoscopy data will be collected to 
identify subjects with EE, and only those subjects with endoscopically-confirmed EE 
Grades A-D as defined by the LA Classification Grading System, will be eligible for this study. 
Endoscopic pictures will be taken by the study site and kept in the site’s source document files 
according to the site’s practice.


TAK-390MR_301
Page 7 of 23
Statistical Analysis Plan Final
14 February 2018
CONFIDENTIAL
Subjects who satisfy the screening evaluation and selection criteria, and have EE confirmed by 
endoscopy, may be entered into the study. Subjects having an esophageal stricture will be 
excluded from the study. The endoscope must pass freely into the stomach during the endoscopy.
All subjects will return to the investigative site on Day -1 which will be deemed as the Baseline. 
Subjects who have completed all of the Screening procedures and met all eligibility requirements 
and none of the exclusion criteria will have routine fasting laboratory evaluations, including 
fasting serum gastrin, a urine pregnancy test (all women of childbearing potential), physical 
examination, and vital signs measurements to assure continued eligibility. Subjects will be 
dispensed study drug on Study Day -1 according to an interactive web response system and will 
begin taking study drug on the following day (Study Day 1). In addition, subjects will be 
assessed for GERD symptoms such as heartburn, acid regurgitation, dysphagia, belching, and 
epigastric pain by the investigator.

Subjects will be assigned in a 1:1 ratio to one of the following 2 treatment groups during the 
8-week Healing Period; the randomization will be stratified by baseline endoscopic findings 
(grades A/B or C/D).
–
Group I:
dexlansoprazole capsules (60 mg QD).
–
Group II:
lansoprazole capsules (30 mg QD).
During the 8-week Healing Period, study drug will be self-administered orally QD before 
breakfast in the morning. Subjects will document the presence and maximum severity of daytime 
and nighttime heartburn symptoms using a diary. Subjects will also record the use of rescue 
medication. Subject visits will be conducted at Weeks 4 and 8 of the Healing Period to collect 
and/or dispense study drug, assess GERD symptoms, review concomitant medication use, and 
assess adverse events (AEs). 
At the Week 4 Visit, the subject will undergo a physical examination including vital signs, 
laboratory evaluations, and urine pregnancy test (all women of childbearing potential). 
At the Week 8 Visit, all subjects will undergo a physical examination including vital signs, 
laboratory evaluations, fasting serum gastrin, serum and urine pregnancy test (all women of 
childbearing potential), ECG and an endoscopy. In addition, study drug will be collected, a 
review of concomitant medication use will be performed, and an assessment of AEs will be 
conducted. If the subject’s EE has healed completely as determined by endoscopy, the subject 
will have completed the Healing Period of the study, and will continue in the Maintenance 
Period. If the subject’s EE has not completely healed after 8 weeks of treatment, all Final Visit 
procedures will be performed and the subject will not be eligible to continue into the 
Maintenance Period. 
For subjects who prematurely discontinue during the Healing Period, efforts should be made to 
perform all procedures scheduled for the Week 8 / Early Termination Visit no later than 5 days 
after the last dose of study drug.


TAK-390MR_301
Page 8 of 23
Statistical Analysis Plan Final
14 February 2018
CONFIDENTIAL
At the start of the 6-Month Maintenance Period, subjects with healed EE will be randomized in a 
1:1 ratio to one of the following 2 groups; the randomization will be stratified by baseline 
endoscopic findings (grades A/B or C/D).

Group I:
dexlansoprazole capsules (30 mg QD)

Group II: placebo (QD)
During the 6-month Maintenance Period, study drug will be self-administered orally, QD in the 
morning before breakfast. Subjects will continue to document the presence and maximum 
severity of daytime and nighttime heartburn symptoms using a diary. Subjects will also record 
the use of rescue medication. Subject visits will be conducted at Months 1, 3 and 6, of the 
Maintenance Period to collect and/or dispense study drug, assess GERD symptoms, review 
concomitant medication use, and assess AEs. Endoscopies will be performed at Months 1 and 
6/Final Visit to evaluate maintenance of healed EE. Subjects with endoscopic evidence of 
relapsed EE will be discontinued from the study.
At the Month 1 Visit, the subject will undergo a physical examination including vital signs, 
laboratory evaluations, endoscopy, and urine pregnancy test (all women of childbearing 
potential). 
At the Month 3 Visit, the subject will undergo a physical examination including vital signs, 
laboratory evaluations and urine pregnancy test (all women of childbearing potential). An 
optional endoscopy may be performed based on investigator’s discretion if the subject presents 
with GERD symptoms at any time point during the Maintenance Period. 
At the Month 6 Visit, all subjects will undergo a physical examination including vital signs, 
laboratory evaluations, fasting serum gastrin, serum and urine pregnancy test (all women of 
childbearing potential), endoscopy, and ECG. In addition, study drug will be collected, a review 
of concomitant medication use will be performed, and an assessment of AEs will be conducted. 
For subjects who prematurely discontinue during the Maintenance Period, efforts should be 
made to perform all procedures (including endoscopy) scheduled for the Month 6 / Early 
Termination Visit no later than 5 days after the last dose of study drug.
A schematic of the study design is included as Figure 4.a.


TAK-390MR_301
Page 9 of 23
Statistical Analysis Plan Final
14 February 2018
CONFIDENTIAL
Figure 4.a
Schematic of Study Design
dexlansoprazole (60 mg QD)
dexlansoprazole (30 mg QD)
Screening Period 
OR
Randomization
OR
lansoprazole (30 mg QD)
placebo (QD)
Healing Period
Maintenance Period
Day -1
Day 1
Week 4
Week 8/Final Visit
Day 1
Mo 1
Mo 3
Mo 6/Final Visit
Randomize
1st Dose
Healing Period
Randomize
1st Dose
Maintenance 
Period
Mo=month.


TAK-390MR_301
Page 10 of 23
Statistical Analysis Plan Final
14 February 2018
CONFIDENTIAL
5.0
ANALYSIS ENDPOINTS
5.1
Primary Endpoints
The primary endpoint is the percentage of subjects who have complete healing of EE over 
8 weeks as assessed by endoscopy.
5.2
Secondary Endpoints
The secondary endpoint is the percentage of subjects who maintain complete healing of EE over 
6 months as assessed by endoscopy.
5.3
Additional Endpoints
Additional endpoints include:

The percentage of days with neither daytime nor nighttime heartburn over the 8 weeks of the 
Healing Period as assessed by the daily diary.

The percentage of days with neither daytime nor nighttime heartburn over the 6 months of 
the Maintenance Period as assessed by the daily diary among the subjects who were healed at 
Week 8.

The percentage of days without rescue medication use over the 8 weeks of the Healing 
Period as assessed by the daily diary.

The percentage of days without rescue medication use over the 6 months of the Maintenance 
Period as assessed by the daily diary among the subjects who were healed at Week 8.

The severity of GERD symptoms at Weeks 4 and 8 as assessed by the investigator during the 
Healing Period.

The severity of GERD symptoms at Months 1, 3, and 6 as assessed by the investigator during 
the Maintenance Period. 
5.4
Safety Assessments
Safety will be assessed by AEs, clinical laboratory evaluations (including gastrin), vital signs, 
physical examination, and ECGs.


TAK-390MR_301
Page 11 of 23
Statistical Analysis Plan Final
14 February 2018
CONFIDENTIAL
6.0
DETERMINATION OF SAMPLE SIZE
A total of 450 subjects with EE documented during Screening are planned to be enrolled into this 
study. Approximately 300 subjects are expected to enter the Maintenance treatment period. 
Assuming a 10% dropout rate during the Healing Period and an 85% healing rate at Week 8 for 
both lansoprazole and dexlansoprazole, 225 subjects per arm will provide at least 80% power at 
the 1-sided 0.025 level of significance to meet the noninferiority criteria between lansoprazole 
and dexlansoprazole. Noninferiority to lansoprazole will be declared if the lower bound of the 
confidence interval for the difference in healing rates is greater than -10%.
The fixed noninferiority margin of -10% is based on a double-blind, parallel-group, comparative 
study that evaluated EE healing rates after an 8-week treatment period with lansoprazole 30 mg 
QD or placebo. In this study, the difference in response rate between the lansoprazole 30 mg
dose group and the placebo group was 40.4%; the lower limit of the 2-sided 95% confidence 
interval was 25.9%. Hence, even with a conservative assumption of this lower bound as the 
treatment effect of lansoprazole 30 mg, a -10% noninferiority margin would assure that 
dexlansoprazole 30 mg retains more than 60% of the treatment effect of lansoprazole 30 mg. 
Assuming a 33% dropout rate during the Maintenance Period and that maintenance rates are 14% 
and 66% for placebo and dexlansoprazole 30 mg, respectively, 150 subjects per arm will have at 
least 99% power at the 2-sided 0.05 level of significance to detect a difference between the 
treatment groups.


TAK-390MR_301
Page 12 of 23
Statistical Analysis Plan Final
14 February 2018
CONFIDENTIAL
7.0
METHODS OF ANALYSIS AND PRESENTATION
7.1
General Considerations
Statistical analysis will be performed using the SAS System, Version 9.2 or higher.
All study-related raw data for enrolled subjects, including derived data, will be presented in data 
listings. Continuous data will be summarized using number of subjects, mean, standard 
deviation, median, minimum, and maximum. Categorical data will be summarized using the 
number and percentage of subjects for each category where appropriate.
7.1.1
Definition of Study Days and Visit Window
Study day will be calculated relative to the date of the first dose of study drug in the study. The 
study day prior to the first dose of study drug will be calculated as: 
Date of assessment/event – date of first dose of study drug.
The study day on or after the first dose of study drug will be calculated as: 
Date of assessment/event – date of first dose of study drug + 1.
Baseline is defined as the last non-missing measurement prior to or on Study Day 1 (prior to first 
dose). The baseline values for the Maintenance Period will be the assessment performed at the 
Week 8 visit of the Healing Period.The visit windows for each post baseline visit are defined in 
Table 7.a. If a subject has more than 1 measurement in the same visit window, the measurement 
closest to the scheduled visit will be used. If 2 measurements in the same window are of equal 
distance to the scheduled visit, the measurement that occurs after the scheduled visit will be 
used. If 2 or more measurements occur on the same day, the last value obtained will be used.
Table 7.a
Visit Windows for Healing Period
Visit
Scheduled 
Day
Safety Labs 
Serum 
Gastrin
Vital 
Signs
ECG
Endoscopy
GERD 
Symptoms 
Investigator 
Assessment
Baseline
Day -1
1
1
1
1
1
1
Week 4
Day 28
2-42
NA
2-42
NA
NA
2-42
Week 8
Day 56
43-70
2-70
43-70
NA
2-70
43-70
Note: Safety labs (including gastrin), vital signs, and ECG data obtained more than 7 days after the last day of study 
drug and efficacy data obtained more than 7 days after the last day of study drug will not be included in the analyses.
Additionally, for subjects with healed EE by Week 8 who are randomized and receive at least 
1 dose of maintenance study drug, the window selection for the Week 8 Visit will include only 
measurements assessed on or before the date of the first dose of maintenance period study drug; 
for visits during the Maintenance of Healed EE Period, the window selection will only include 
measurements assessed after the date of the first dose of maintenance period study drug.


TAK-390MR_301
Page 13 of 23
Statistical Analysis Plan Final
14 February 2018
CONFIDENTIAL
The summary of visits during the maintenance period will be relative to the start of maintenance 
treatment rather than relative to the start of the study. The table below summarizes the visit
windows for each visit during the Maintenance of Healed EE Period. 
For the purpose of the diary compliance calculation and derivation of diary-based endpoints, the 
last day of study drug in each period will not be included since the subject will not be expected
to have completed the diary entries for that day by the Week 8 or month 6 Final Visit. Therefore, 
summaries for the healing period weeks of treatment will include Study Day 1 through Study 
Day 70 or the day before the last dose of healing period study drug, or the day before the first 
dose of maintenance study drug, whichever occurs first; summaries for the Maintenance period
will include the day of the first dose of maintenance study drug through maintenance Study 
Day 180 or the day before the last dose of maintenance study drug, whichever occurs first.
Table 7.b
Visit Windows for Maintenance Period
Visit
Scheduled 
Day
Safety Labs 
and Vital 
Signs
Serum 
Gastrin
ECG
Endoscopy
GERD 
Symptoms 
Investigator 
Assessment
Maintenance 
Baseline
-1M
1M
1M
1M
1M
1M
Month 1
30M
2M-60M
2M-60M
NA
2M-60M
2M-60M
Month 3
90M
61M-135M
61M-135M
NA
61M-135M
61M-135M
Month 6
180M
136M-210M
136M-210M
2M-210M
136M-210M
136M-210M
Note: Safety laboratory (including gastrin), vital signs, and ECG data obtained more than 7 days after the last day of 
study drug of Maintenance period and efficacy data obtained more than 7 days after the last day of study drug of 
Maintenance period will not be included in the analyses.
M=Maintenance Period.
7.2
Analysis Sets
The full analysis set (FAS) will be defined separately for the Healing and Maintenance Periods. 
The full analysis set for the Healing Period (FAS – H) will include all randomized subjects who 
have documented EE at screening and receive at least 1 dose of study drug during the first 
8 weeks of treatment. The full analysis set for the Maintenance Period (FAS – M) will include all 
subjects with healed EE by week 8 who are randomized and receive at least 1 dose of study drug 
during 6 months of maintenance treatment.
The safety analysis set will be defined separately for the healing period and for the Maintenance 
Period. The safety analysis set for the Healing Period (Safety Set – H) will include all subjects 
who receive at least 1 dose of study drug during Healing Period. The safety analysis set for the 
Maintenance Period (Safety Set – M) will include all subjects with healed EE by Week 8 who 
are randomized and receive at least 1 dose of study drug during 6 months of maintenance 
treatment.


TAK-390MR_301
Page 14 of 23
Statistical Analysis Plan Final
14 February 2018
CONFIDENTIAL
7.3
Disposition of Subjects
Subjects’ study completion data, including reasons for premature termination, will be provided in 
listings and also summarized. Summaries of the reasons for premature termination will be 
presented separately for the healing period and for the maintenance of healed EE period. 
A summary of screening failures and listings of inclusion/exclusion criteria responses will be 
provided.
Significant protocol deviations captured on the electronic Case Report Form will be summarized.
7.4
Demographic and Baseline Characteristics
Demographic variables will be summarized for the FAS-H and the FAS-M. For continuous 
variables (age, weight, height and body mass index [BMI]), summary statistics will be generated. 
The number and percentage of subjects in each category will be presented (eg, gender, race). 
BMI (in kg/m2) will be calculated using the subject’s baseline height and weight measurement 
and summarized. 
7.5
Medical History and Concurrent Medical Conditions
Medical history and concurrent medical conditions will be coded using MedDRA. Medical 
history and concurrent medical conditions will be presented in a data listing.
7.6
Medication History and Concomitant Medications
All medication history and concomitant medications will be coded by therapeutic classification, 
subclassification, and medication using the World Health Organization Drug Dictionary (WHO 
Drug). A concomitant medication is defined as a medication that is ongoing as of Study Day 1, 
ends on or after Study Day 1, or starts on or after Study Day 1 and no more than 1 day after the 
last dose of study drug. Medication history and concomitant medications will be presented in a 
data listing.
7.7
Study Drug Exposure and Compliance
Overall study drug compliance (%) will be determined as (total count of capsules taken) / total 
number of days on study drug 100%, separately for the healing period and for the maintenance 
period. 
For the healing period, the total number of days on study drug (exposure) will be calculated as 
date of last dose of study drug - date of first dose of study drug + 1, assuming there is no gap in 
the dosing. If the last dose date is missing, then the duration of the treatment period will be 
imputed as 70 days or the day before first dose date in maintenance period, whichever is earlier.
For the maintenance period, the total number of days on study drug (exposure) will be calculated 
as date of last dose of maintenance study drug - date of first dose of maintenance study drug + 1, 
assuming there is no gap in the dosing. Any gaps in dosing will be ignored when calculating the 
total. If the last dose date of the maintenance period is missing, then the duration of the 
maintenance period will be imputed as 189 days. 


TAK-390MR_301
Page 15 of 23
Statistical Analysis Plan Final
14 February 2018
CONFIDENTIAL
Subjects with unreturned study drug will be assumed to have taken 1 capsule of study drug for 
each day of exposure for the calculation of overall compliance. Subjects with overall compliance 
100% will be set to 100% in the analysis.
In addition, diary compliance will be determined as the percentage of days during treatment with 
diary entries. 
Diary Compliance =
(Number of days with two diary entries collected during treatment period) / (Number of days
with two diary entries expected during treatment period) × 100%
Exposure and compliance data will be presented in a data listing.
7.8
Efficacy Analysis
The efficacy endpoints will be summarized using the FAS-H for the healing period and using the 
FAS-M for the maintenance period.
7.8.1
Primary Efficacy Endpoint
The primary efficacy variable will be the percentage of subjects who have complete healing of 
EE over 8 weeks as assessed by endoscopy Subjects who do not have endoscopically 
documented healing and who prematurely discontinue will be considered as not healed. The 
primary endpoint will be presented in a data listing and summarized for the Healing period for 
the FAS-H.
7.8.2
Secondary Efficacy Endpoints
The secondary efficacy variable will be the percentage of subjects who maintained complete 
healing of EE over 6 months as assessed by endoscopy. Subjects who do not have endoscopically 
documented maintenance of healing and who prematurely discontinue will be considered to have 
relapsed. The secondary endpoint will be presented in a data listing and summarized for the 
Maintenance period for the FAS-M.
If a subject’s final endoscopy was performed prior to the Month 6 Visit and indicated recurrence 
of EE, the subject will be considered to have recurrence of EE at the Month 6 Visit.
7.8.3
Additional Efficacy Endpoints
All additional efficacy variables will only be presented in data listings, no summary tables will 
be produced. The following are the additional efficacy variables to be listed:
The severity of GERD symptoms at Weeks 4 and 8 as assessed by the investigator during the 
Healing Period. 


TAK-390MR_301
Page 16 of 23
Statistical Analysis Plan Final
14 February 2018
CONFIDENTIAL
The percentage of days with neither daytime nor nighttime heartburn and the percentage of days 
without rescue medication use over the 8 weeks of the Healing Period and over the 6 months of 
the Maintenance Period as assessed by the daily diary.

The severity of daytime and nighttime heartburn over the 8 weeks of the Healing Period and 
over the 6 months of the Maintenance Period as assessed by daily Diary.

The severity of nighttime heartburn over the 8 weeks of the Healing Period and over the 
6 months of the Maintenance Period as assessed by daily Diary.

The severity of daytime heartburn over the 8 weeks of the Healing Period and over the 
6 months of the Maintenance Period as assessed by daily Diary.
7.9
Pharmacokinetic/Pharmacodynamic Analysis
Not applicable. 
7.10
Other Outcomes
Not Applicable.
7.11
Safety Analysis
All safety analyses will be performed using the Safety Analysis Set-H for the Healing Period, 
and using the Safety Analysis Set-M for the maintenance period. Results will be summarized by 
treatment group.
7.11.1 Adverse Events
All AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA). 
A Treatment Emergent Adverse Event (TEAE) will be defined as an AE that starts or worsens on 
or after Study Day 1, and no more than 30 days after the last dose of study drug. All TEAEs will 
be listed by subject number and MedDRA coding. A listing of all unique coded terms will also 
be provided.
The following summaries of TEAEs will be presented separately:

TEAEs for subjects who enter into the Healing Period, occurring during the 8 week healing 
period (ie, TEAE starts or worsens on or after the first dose of healing phase study drug and 
no more than 30 days after the last dose if a subject does not receive any maintenance study 
drug or before the first dose of maintenance study drug) will be summarized by treatment 
group using the Safety Analysis Set-H.

TEAEs for subjects who enter into Maintenance period, occurring during the 6 months
maintenance treatment period (ie, TEAE starts or worsens on or after the first dose of 
maintenance study drug and before 30 days after last dose of maintenance) will be 
summarized by treatment group using the Safety Analysis Set-M.


TAK-390MR_301
Page 17 of 23
Statistical Analysis Plan Final
14 February 2018
CONFIDENTIAL
The number and percentage of subjects with TEAEs will be summarized in several different 
tables:

All AEs by system organ class (SOC), high level term (HLT), and preferred term (PT).

Treatment-related AEs (TRAEs) by SOC, HLT, and PT.

Most frequent AEs by SOC and PT (sorted by frequency of PT occurring in 5% of 
subjects).

Most frequent TRAEs by SOC and PT (sorted by frequency of PT occurring in 2% of 
subjects).

Severity of all AEs by SOC and PT (mild, moderate, or severe).

Severity of TRAEs by SOC and PT (mild, moderate, or severe).

Relationship to study drug for all AEs by SOC and PT (not related, related).
A subject with 2 or more AEs within the same level of the MedDRA term will be counted only 
once in that level using the most extreme incident (most severe for the severity tables and related 
for the relationship to study drug tables). 
Additionally, treatment-emergent serious AEs, deaths and TEAEs resulting in premature 
discontinuation from study drug will be listed and summarized by SOC and PT. The most 
frequent treatment-emergent non-serious AEs will also be summarized by SOC and PT.
A pre-treatment event will be defined as an AE that starts before Study Day 1. A list of 
pre-treatment AEs by subject number and MedDRA coding will be presented separately. 
Pre-treatment AEs will be summarized by SOC, HLT and PT.
7.11.2 Clinical Laboratory Evaluations
Clinical laboratory variables (including serum gastrin) will be summarized using descriptive 
statistics for Baseline, postbaseline, and change from Baseline to postbaseline values using the 
safety analysis set-H for the healing period to summarize changes from Baseline and using the 
safety analysis set-M for the maintenance period to summarize changes from Week 8.
Individual results for serum fasting gastrin, clinical hematology and chemistry laboratory tests 
that are within the predefined “markedly abnormal laboratory value (MAV) criteria” will be 
summarized in tables. All clinical laboratory data will be presented in data listings.
The percentage of subjects with elevated gastrin values ≥200 pg/mL and ≥400 pg/mL will be 
summarized.
Elevated hepatic parameters will be summarized.
Summaries and listings of laboratory data will be presented in Systeme Internationale (SI) and 
conventional units. MAV tables and listings will be presented in the unit specified in the MAV 
criteria in Appendix A.


TAK-390MR_301
Page 18 of 23
Statistical Analysis Plan Final
14 February 2018
CONFIDENTIAL
7.11.3 Vital Signs
Vital signs will be summarized using descriptive statistics for Baseline, postbaseline, and change 
from Baseline to postbaseline values using the Safety Analysis Set-H for the Healing Period to 
summarize changes from Baseline, using the Safety Analysis Set-M for the Maintenance period 
to summarize changes from Week 8.
All individual vital signs that meet predefined criteria for MAV (Appendix B) will be 
summarized in tables. All vital sign data will be presented in data listings.
7.11.4 12-Lead ECGs
ECG results will be interpreted using 1 of the following categories: within normal limits,
abnormal but not clinically significant, or abnormal and clinically significant. Week 8 Visit ECG 
assessments will be cross-tabulated against the baseline assessment using the Safety Analysis 
Set-H. Month 6 ECG assessments will be cross-tabulated against the Week 8 assessment using 
the Safety Analysis Set-H.
All individual quantitative ECG values that meet predefined criteria for MAV (Appendix C) will 
be listed.
All ECG data will be presented in a data listing.
7.11.5 Other Observations Related to Safety
Physical examination results will be presented in a data listing and will not be summarized.
7.12
Interim Analysis
Not applicable. 
7.13
Changes in the Statistical Analysis Plan 
None.


TAK-390MR_301
Page 19 of 23
Statistical Analysis Plan Final
14 February 2018
CONFIDENTIAL
8.0
REFERENCES
None


TAK-390MR_301
Page 20 of 23
Statistical Analysis Plan Final
14 February 2018
CONFIDENTIAL
Appendix A
Criteria for Identification of Markedly Abnormal Laboratory Values
Hematology—Criteria for Markedly Abnormal Values
Parameter
Low Abnormal
High Abnormal
Hemoglobin
<0.8 × LLN,
>1.2 × ULN
Hematocrit
<0.8 × LLN,
>1.2 × ULN
RBC count 
<0.8 × LLN, 
>1.2 × ULN
WBC count 
<0.5 × LLN
>1.5 × ULN
Platelet count
<75 x 103/L
>600 x 103/L
RBC=red blood cell, WBC=white blood cell. LLN=lower limit of normal, ULN=upper limit of normal
Chemistry—Criteria for Markedly Abnormal Values
Parameter
Low Abnormal
High Abnormal
ALT
--
>3x ULN
AST
--
>3x ULN
GGT
--
>3x ULN
Alkaline phosphatase
--
>3x ULN
Total bilirubin
--
>2.0 mg/dL
Albumin
<2.5 g/dL
--
Total protein
<0.8x LLN
>1.2x ULN
Creatinine
--
>2.0 mg/dL
Blood Urea Nitrogen
--
>30 mg/dl
Sodium
<130 mEq/L
>150 mEq/L
Potassium
<3.0 mEq/L
>6.0 mEq/L
CPK
--
>5 x ULN
ALT=alanine aminotransferase, AST=aspartate aminotransferase, GGT=-glutamyl transferase, CPK=creatine 
phosphokinase, LLN=lower limit of normal, ULN=upper limit of normal.


TAK-390MR_301
Page 21 of 23
Statistical Analysis Plan Final
14 February 2018
CONFIDENTIAL
Appendix B
Criteria for Identification of Markedly Abnormal Vital Sign Values
Parameter
Unit
Lower Criteria
Upper Criteria
Pulse
bpm
<50 
>120
Systolic blood pressure
mm Hg
<85
>180 
Diastolic blood pressure
mm Hg
<50
>110
Body temperature
oC
<35.6
>37.7


TAK-390MR_301
Page 22 of 23
Statistical Analysis Plan Final
14 February 2018
CONFIDENTIAL
Appendix C
Criteria for Markedly Abnormal Values for Electrocardiograms
Parameter
Unit
Lower Criteria 
Upper Criteria
Heart Rate
bpm
<50
>120
QT Interval
msec
≤50
≥460
QTcB Interval
msec
≤50
≥500 
OR 
≥30 change from baseline and ≥450
QTcF Interval
msec
≤50
≥500 
OR 
≥30 change from baseline and ≥450


TAK-390MR_301
Page 23 of 23
Statistical Analysis Plan Final
14 February 2018
CONFIDENTIAL
Appendix D
Data Handling for Subject Daily Diary
Subjects will document the presence of daytime and nighttime heartburn(yes/no) and maximum 
severity (1=Mild, 2=Moderate, 3=Severe, or 4=Very Severe) and record their usage of rescue 
medication (yes/no) in their diary two times per day, once in the morning for nighttime heartburn 
and once in the evening for daytime heartburn. If a subject indicated that no heartburn was 
present during a diary entry, a heartburn severity of ‘0=None’ will be assumed in the database.
For analysis purposes, diary entries will be assigned to a study day based on the day the 
collection interval started for that entry. For example, the Study Day 1 diary entries will include 
the evening diary completed on Study Day 1 (the collection interval started when the subject 
awoke on Study Day 1) and the morning entry completed on Study Day 2 (the collection interval 
started when the subject went to bed on Study Day 1).
For each subject, the percentage of days with neither daytime nor nighttime heartburn during 
treatment will be calculated using all days with at least 1 morning or evening diary entry during
the Healing Period and during the Maintenance Period. For example, if a subject completed at 
least 1 diary entry on 52 of 56 days during the Healing Period, but missed both entries on 4 days, 
52 days will be used as the denominator in the analysis. All entries on that day will need to be 
heartburn-free (when only one entry collected, that entry will need to be heartburn-free) in order 
for the day to be counted as a day with neither daytime nor nighttime heartburn.
A similar approach will be used to determine the percentage of days without rescue medication
during treatment (the denominator would be total number of days with either a daytime or night 
time result marked during the Healing or Maintenance period).
The mean severity of daytime and nighttime heartburn during the Healing and Maintenance 
Periods for each subject will be calculated by taking the mean of the average severity on all days 
with at least one morning or evening diary entry. For each day, the average severity for the day 
will be determined by taking the mean of the morning and evening diary entries on that day. If 
one entry is missing, the average for the day will be the non-missing diary entry. These daily 
averages will then be averaged for all days with non-missing data to obtain the endpoint value 
for each subject.